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Abbreviations  
 
For all proteinogenic amino acids the standard IUPAC three- or one-code abbreviations were 
used.  For length, time and mass descriptions the standard IS units were used.  
 
aa   amino acid(s)  
a.dest.   aqua destillatum 
ATCC   American Type Culture Collection, USA 
bp   base pair 
C55P   undecaprenyl phosphate / lipid carrier 
°C degree Celsius 
Da Dalton  
Dha   didehydroalanine 
Dhb   didehydrobutyrine  
DMSO   dimethylsulfoxide  
DNA desoxy ribonucleic acid  
dNTPs deoxyribonucleotide triphosphates 
DSMZ German Research Centre for Microorganisms and Cell Cultures,  
Braunschweig, Germany 
EDTA ethylenediaminetetraacetic acid 
FMN riboflavin-5′-phosphate 
GlcNAc  N-acetylglucosamine  
HPLC   High Performance Liquid Chromatography 
IPTG isopropyl-β-D-thiogalactopyranoside 
kDa Kilo Dalton  
Lan   lanthionine  
lipid II   GlcNAc-MurNAc-pentapeptide-pyrophosphoryl-undecaprenol 
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MALDI-TOF Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight mass  
spectrometry 
MeLan   methyllanthionine  
MIC   minimal inhibitory concentration  
MilliQ   ultrapure water 
mRNA   messenger RNA  
msc multiple cloning site  
MurNAc  N-acetlymuramic acid 
MW   molecular weight  
NADH nicotinamide adenine dinucleotide 
NCS   German Reference Centre for Staphylococci, Werningerode, Germany 
NCTC    Health Protection Agency Culture Collections, Salisbury, UK 
ORF open reading frame  
ORI origin of replication  
PEG polyethylene glycol 
r resistant 
RNA ribonucleic acid  
RT room temperature  
SDS sodium dodecyl sulfate  
TFA trifluoroacetic acid 
Tris tris(hydroxymethyl)aminomethane 
U units  
v/v volume per volume  
w/v weight per volume  
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Introduction  
 
The discovery of the first antibiotic penicillin was one of the most important milestones in 
medicine and in the fight against infectious disease (Fleming, 1929). Before antibiotics were 
discovered bacterially caused infectious diseases had been the most frequent cause of 
human death. The beginning of industrialized production and widespread use of penicillin in 
the 1940ies heralded the dawn of the golden era of antimicrobials. In the past 70 years the 
successful therapeutic use of penicillin and its derivatives led to discovery and development 
of a multitude of antibiotics, many of which are of bacterial or fungal origin. Today, more 
than 80% of anti-infective drugs are natural compounds or derivatives thereof (Newman and 
Cragg, 2007; Li and Vederas, 2009).  
However, emergence and spread of antibiotic resistance among pathogens has been 
reported since antimicrobials were employed for medical purposes. In the past years, rapidly 
developing superbugs, i.e. human pathogens that are resistant to almost all commonly used 
antibiotics, have become an enormous problem. Among those are Gram-positive bacteria 
like methicillin-resistant Staphylococcus aureus strains (MRSA) and vancomycin-resistant 
Enterococcus faecium (VRE), as well as multiresistant Gram-negative pathogens such as 
Pseudomonas aeruginosa, Acinetobacter baumanii and Enterobacteriaceae. This 
necessitates further search for new antibiotic substances and sources, especially for 
compounds with new MoA and novel targets (van Heel et al., 2011). To this end, bacteria 
and their huge potential to produce antimicrobial substances represent an inexhaustible 
source for the discovery of new antibiotics and so far neglected antibiotic classes (Newman 
and Cragg, 2007; Davies, 2011), especially since metagenomic data indicate that less than 1% 
of all existing microbes have been identified so far (Singh and MacDonald, 2010).  
 
Bacterial peptide antibiotics 
Production of peptide antibiotics is a common feature of bacteria and antibiotic producers 
are found in every major lineage. These substances can be divided into two main groups, 
non-ribosomally and ribosomally expressed polypeptide antimicrobials.  
Non-ribosomal peptides are made by multi-modular enzyme complexes called non-
ribosomal-peptide synthases (NRPS). Frequently, extreme modifications of these peptides 
result in formation of unusual aa, cyclic or branched structures, in introduction of lipid based 
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side chains or sugar substitutions. More than 300 different modifications, introduced by 
isomerization, methylation, acetylation, glycosylation and heterocyclic ring formation are 
known (Marahiel, 2009; Hancock and Chapple, 1999). Clinically established members are the 
glycopeptide vancomycin and the cyclic lipopeptide daptomycin. 
Members of the class of ribosomally produced peptide antibiotics are structurally very 
heterogeneous and commonly are referred to as bacteriocins (Tagg et al., 1976). Since 1925 
bacteriocinogenic strains have been identified within the domain of Gram-negative and 
Gram-positive bacteria as well as within Archaea (archaeacins) (Gratia, 1925; Rodriguez-
Valera et al., 1982; O'Connor and Shand, 2002; Riley and Wertz, 2002).  
Generally, bacteriocins exhibit an antimicrobial activity at extremely low concentrations and 
their involvement in colonization and defense of ecological niches is suggested (Riley and 
Wertz, 2002; Cotter et al., 2005). Some bacteriocins, mostly those produced by Gram-
positives, were found to function as peptide pheromones in quorum-sensing and cell-cell 
communication resulting in a co-ordinative regulation of competence, sporulation, virulence 
and biofilm production (Turovskiy et al., 2007).  
Characteristically, bacteriocins are gene-encoded and synthesized as precursors consisting of 
an N-terminal leader and a C-terminal propeptide sequence. The following hypotheses for 
leader functions are currently discussed in literature: 1. the leader resembles a secretion 
signal and mediates the transport through the cytoplasmatic membrane; 2. it serves as 
recognition signal for recruitment of the modification machinery; 3. a function as an 
intramolecular chaperon; 4. the leader is part of the self-immunity as it keeps the modified 
prepeptide inactive previous to export; and 5. the leader peptide enhances stability against 
proteolytic degradation resulting in a prolonged half-life of the precursor (Jack et al., 1995).  
The propeptide is the inactive and unmodified precursor of the bacteriocin. In general, the 
propeptide undergoes several post-translational modifications during maturation, resulting 
in formation and introduction of unusual aa and intramolecular rings. These enzyme-
mediated alterations occur on aa side chains and, less frequently, on the peptide backbone. 
They often mediate enhanced stability and are essential for the 3-dimensional structure and 
consequently, for the bioactivity of bacteriocins.   
Accordingly to Klaenhammer (1988), nearly 99% of all existing bacteria at least make one 
bacteriocin and, indeed, a plethora of new bacteriocin classes and families has been 
identified by genome sequencing that led to an enormous progress in the field of 
ribosomally synthesized and post-translationally modified compounds. Interestingly, these 
novel bacteriocins are often widely distributed over all bacterial lineages (Schmidt, 2010).  
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A closer analysis of the previously falsely classified lantibiotic cypemycin revealed a new 
class, the linearidins (Claesen and Bibb, 2010). Members of this class are predicted to share 
a linear structure and a high amount of unusual aa, including didehydro-aa. Although 
didehydro-aa are also present in another bacteriocin class, lantibiotics, the respective 
modification enzymes share no significant sequence similarity and therefore, an alternative 
biosynthesis mechanism is discussed. Linearidins might rather be involved in extracellular 
signalling, since cypemycin only exhibits marginal antimicrobial activity. Bioinformatic 
analysis indicated a widespread occurrence of linearidins-like gene clusters within 
prokaryotic strains and even in certain Archaea.  
The classical bacteriocin classification scheme that divides bacteriocins into those produced 
by Gram-positives and Gram-negatives has been abolished recently. In this context, 
discovery of microcin B17-like peptides (figure 1.2), that had been thought to be unique to 
Gram-negatives, in the genomes of Gram-positive bacteria, led to the definition of a new 
class called TOMMs (thiazole/oxazole-modified microcins) (Lee et al., 2008; Haft et al., 
2010). Microcins have a MW below 10 kDa and members of this class are highly modified, 
hydrophobic peptides. They are characterized by class-specific modifications, the 
heterocyclic oxazoles/thiazoles. TOMMs are encoded by short structural genes that code for 
peptides of 50-70 aa and that tend to be rich in Cys, Ser, Thr and Gly residues. These aa are 
often found in repetitive motifs and serve as precursor aa for the class-specific thiazoles and 
oxazoles (Melby et al., 2011; Haft, 2009). They are introduced by the concerted action of a 
trimeric complex consisting of a cyclodehydratase (C), a dehydrogenase (B) and a docking 
scaffold protein (D) (Li et al., 1996).  
 
 
 
Figure 1.1: Formation of the heterocyclic aa thiazole and oxazole. Peptide backbone 
cyclodehydration of Cys, Ser or Thr results in thiazoline or (methyl)oxazoline rings. Subsequently, 
these are oxidized to thiazoles or (methyl)oxazoles.  
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The cyclodehydratase joins the Cys, Ser or Thr side chains to the carbonyl group (contributed 
by the peptide bond) of the most neighboring aa. This reaction results in elimination of a 
water molecule from the amide backbone and in formation of a heterocyclic structure 
named thiazoline (Cys) or oxazoline (hydroxy-aa) (figure 1.1). In general, these structures are 
immediately oxidized by a dehydrogenase to aromatic thiazole or oxazole residues (figure 
1.1). The scaffolding protein is apparently important for complex assembly and regulation of 
the cyclodehydrogenase. Often, the docking protein is present as a C-terminally fused 
domain of the corresponding cyclodehydrogenase (Melby, 2011; Haft et al., 2010). 
Genomic data mining revealed that homologous gene clusters are widespread among 
prokaryotes (Lee et al., 2008; Haft et al., 2010; Brown et al., 2009). Interestingly, these 
clusters contain additional biosynthetic enzymes, some of which possess significant similarity 
to modification enzymes of other bacteriocins, like the lantibiotic dehydrogenases (LanB, 
LanM). This fact might suggest that TOMMs undergo further, mainly peptide specific 
modifications. The cluster of the TOMM-peptide thiocillin IV (B. cereus) contains two LanB 
homologs which dehydrate Ser and Thr. These dehydrated aa are either involved in 
formation of the thiopeptide subclass-specific pyridine ring or remain as didehydro- aa in the 
active peptide (Brown et al., 2009). Unusual for bacteriocins, the structural gene of thiocillin 
IV is situated far from the genes coding for the biosynthetic enzymes (Lee et al., 2008). 
In 2009 Haft postulated, based on a bioinformatic approach, a new family of TOMMs, the 
heterocycloanthracins (Haft, 2009). Precursors of this family are characterized by the 
presence of Gly and Cys rich repeats consisting of CGG, GCG or RCG triplets. In 2010, the 
author identified two further subfamilies, whose structural genes share strong aa similarity 
either to the α-subunit of a nitrile hydratase (nitrile hydratase-related leader peptides; 
NHLP) or to the cyanobacterial nitrogen-fixing proteins containing a conserved Nif11 domain 
(Nif11-related leader peptides; N11P). NHLP-encoding clusters lack the dehydratase, but in 
their neighborhood a docking-protein-cyclodehydrogenase fusion protein is found. N11P 
precursors are often clustered with homologs of the lantibiotic modification system, rather 
than being surrounded by genes having sequence similarity to those of the TOMM 
machinery (Haft et al., 2010). 
Recently, it has been shown that introduction of the heterocyclic aa oxazoline and thiazoline 
or of their oxidized derivatives, oxazole and thiazole, into peptides of other bacteriocin 
classes is based on the same biosynthetic pathway, employing enzymes that are homologous 
to those of the TOMM biosynthesis machinery (Melby et al., 2011; Donia et al., 2008).  
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This suggests that these bacteriocins, e.g. the cyclic cyanobactins produced by 
cyanobacteria, the streptolysin-like toxins and the thiopeptides, also are members of 
TOMMs. 
 
 
 
Figure 1.2: Structure of the linear TOMM peptide microcin B17. The class-typical oxazole and 
thiazole rings are highlighted in green (Melby et al., 2011).  
 
The members of the TOMM subclasses comprise compounds with different bioactivities like 
antibacterial, antifungal, antimalarial, antitumor or multidrug reversing functions. Their MoA 
either depends on 1. membrane depolarization; 2. inhibition of the ribosome and protein 
biosynthesis; 3. degradation of nucleic acids by targeting enzymes involved in RNA/DNA 
structure maintenance and synthesis or 4. targeting biosynthetic enzymes (Melby et al., 
2011; Lee et al., 2008). Additionally, an effect on the fungal cell wall has been reported for 
the antifungal thiopeptide cyclothiazomycin (Mizuhara et al., 2011).  
 
A divers group of ribosomally produced bacterial peptide antibiotics:  
the lantibiotics  
The term lantibiotics, introduced in 1988 by Schnell et al., is an abbreviation for “lanthionine 
containing antibiotics” and highlights the importance of (methyl-)lanthionine to this group: 
all lantibiotics are structurally defined by the presence of these thioether-aa.  
 
The non-proteinogenic amino acid lanthionine  
In 1941, Horn et al. identified a non-proteinogenic aa in sodium carbonate treated wool 
consisting of two Ala residues linked by a thioether bridge and called this aa lanthionine 
(Lan). Lanthionine is widely distributed in nature, occurring not only in lantibiotics, but also 
in the cell wall of some Fusobacteria (Vasstrand et al., 1979; Fredriksen et al., 1990), in 
human hair and in feathers. Furthermore, lanthionine-containing compounds, like ketimines, 
appear to play a role in signal transduction of mammalian vascular and nervous systems 
(Fontana et al., 1990; Ricci et al., 1989; Hensly et al., 2010).  
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In lantibiotic and ketimine peptides, thioether formation is catalyzed by specific modification 
enzymes. The prokaryotic lantibiotic modifying enzymes and the eukaryotic ketimine 
biosynthesis machinery only share low aa sequence similarity, but have comparable overall 
folding structures including zinc ligand motifs and active sites (Zhang et al., 2009). Formation 
of thioether-aa results in introduction of covalent, intramolecular junctions that are essential 
for peptide stability and structure.  
 
The lantibiotic biosynthesis machinery and the current lantibiotic classification scheme 
In lantibiotic production, the rare aa are introduced by post-translational modifications. Like 
other bacteriocins, lantibiotics are ribosomally synthesized, resulting in the expression of a 
precursor containing an N-terminal leader and C-terminal propeptide (Ingram, 1970; 
Banerjee and Hansen 1988). Extensive post-translational modifications as well as proteolytic 
removal of the leader convert the inactive propeptide into its active form (van de Meer et 
al., 1993). In general, the active peptide has a length of 18 up to 35 aa and a high content 
(24-47%) of Cys, Thr and Ser residues (Lawton et al., 2007). 
The most important modification results in the introduction of the typical thioether-aa 
lanthionine (Lan) and methyllanthionine (MeLan). This modification is based on an 
enzymatically catalyzed two step reaction including a dehydratisation and a cyclization step 
(figure 1.3). Although spontaneous cyclization has been observed (Toogood, 1993), 
lanthionines of lantibiotics are cyclized by chemoselective and regioselective enzymes, that 
generate a specific bridging pattern and one favored isomer (Goto et al., 2010; Xie and v. d. 
Donk, 2004). 
Dehydration of Ser and Thr, respectively, leads to the formation of the didehydro-aa 
didehydroalanine (Dha) and didehydrobutyrine (Dhb). Based on their location within the 
propeptide sequence, few hydroxy-aa specifically escape dehydration and remain 
unmodified within the active peptide. These are mainly residues that are located within the 
lanthionine ring structures. The majority of the didehydro-aa is subsequently involved in 
formation of the thioether-aa. In a nucleophilic Michael addition a sulfhydryl-group of a 
neighboring Cys residue is linked to the unsaturated double bound of the didehydro-aa 
resulting in the generation of lanthionine (Dha + Cys) and methyllanthionine (Dhb + Cys) 
(Ingram, 1969; 1970). In class I lantibiotics, the Cys is located C-terminally to the didehydro-
aa, whereas this arrangement is not uniformly found in peptides of class II and III (Lawton et 
al., 2007; Rink et al., 2005). 
Today four different modification enzymes are known to play a role in lanthionine 
formation: the enzymes LanB, LanC, LanM and LanL. Based on the enzyme types involved, on 
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the proteins used for transport and processing and on the presence of conserved leader 
structures, the lantibiotics are currently classified into three main classes (Willey and v. d. 
Donk, 2006; Pag and Sahl, 2002). This new classification scheme focuses on the biosynthesis 
of the prepeptides in contrast to the previous structure- and MoA-based schemes from Jung 
et al. (1991) and de Vos et al. (1995). Based on aa similarity, the members are additionally 
divided into subclasses that are named after the respective prototype lantibiotic (table 1.2). 
 
 
Figure 1.3: Formation of the thioether-aa lanthionine. Hydroxy-aa are enzymatically dehydrated to 
the corresponding didehydro-aa. Subsequently, in a nucleophilic Michael addition, a Cys derived SH 
group is connected to the didehydro-aa resulting in the formation of (methyl-)lanthionine.   
 
Lantibiotics of the class I are modified by a membrane associated enzyme complex 
consisting of two individual enzymes, the dehydratase LanB and the cyclase LanC (Klein et 
al., 1992; Schnell et al., 1992; Engelke et al., 1994; Siegers et al., 1996), whereas peptides 
that are modified by the bifunctional enzyme LanM (Rincé et al., 1994) are classified as class 
II lantibiotics. LanM enzymes have an aa sequence similar to that of LanC, but are distinct 
from LanB (Sahl et al., 1995; Siezen et al., 1996). Up to now, little is known about the 
reaction pathway leading to lantibiotic dehydration. Paul et al. (2007) demonstrated in in 
vitro dehydration assays with the lacticin 481 modifying LanM enzyme that ATP hydrolysis is 
absolutely required for this reaction. The authors suggested that a.) the phosphate group is 
used to phosphorylate Ser/Thr residues, turning the hydroxyl-group into a good leaving 
group, and that b.) phosphate elimination finally leads to the generation of the didehydro-
aa. Interestingly, participation of ATP is usually not found in dehydratases that in general act 
via acid-base reactions and LanM enzymes miss typical ATP binding sites (Paul et al., 2007).  
LanM as well as LanC proteins contain three conserved motifs including characteristic zinc 
binding sites that are essential for their cyclase activity (Okeley et al., 2003). Here, zinc ions 
are involved in the activation of the Cys derived SH-group into an ethiolate which 
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subsequently reacts with the didehydro-aa to form the thioether-aa (methyl-)lanthionine (Li 
et al., 2006; Zhu et al., 2003).  
Additionally, class I and class II differ in the proteins involved in transport and processing, as 
well as in typical leader sequence motifs. Class I peptides are transported by an ABC 
transporter (LanT) and leader cleavage is catalyzed intracellularly or extracellularly by the 
protease LanP (v. d. Meer et al., 1993; Meyer et al., 1995) or another protease of the 
producer. Leaders of class I lantibiotics contain a common “F(N/D)L(E/N/D)” motif at 
position -20 to -15 to the cleavage site, as well as a conserved Pro at position -2, whose 
presence is not essential for the removal of the leader (v. d. Meer et al., 1994; Oman and v. 
d. Donk, 2010).  
In contrast, class II peptides usually possess a double glycine cleavage site (GG) that is 
altered in some of these peptides to GA or GS (Chatterjee et al., 2005) and a leader motif 
with the sequence ELXX(V/L/I)X (Patton et al., 2008). The leader cleavage occurs during the 
export of the modified prepeptide and is catalyzed by an N-terminal protease domain of the 
exporter (Pag and Sahl, 2002). Class II peptides are further divided into four subclasses based 
on the sequence similarity of the active lantibiotic. These subclasses are 1. the lacticin 481-
like peptides, 2. the mersacidin-like peptides, 3. the two-peptide lantibiotics and 4. the 
cinnamycin-like peptides. 
Members of the lacticin 481- and mersacidin-like peptide families share a common motif 
that consists of the following conserved aa sequence GxxxxTxs/tCd/eC(3-10)xC (Cotter et al., 
2006). Interestingly, an elongated version (SxxxGNxGxxCTxTxECmxxC) of this motif also is 
present in the α−peptides of the two-peptide lantibiotics (Cotter et al., 2006). These 
lantibiotics consists of two peptides, the α- and the β-peptide that are separately modified 
by two distinct LanM enzymes (McAuliffe et al., 2000). Moreover, the α- as well as the β-
peptides characteristically have related ring patterns and the β-peptides additionally harbor 
a conserved motif consisting of the aa sequence s/txxxxcps/tTxCs/TxxC (Cotter et al., 2006).  
A third class (class III) is formed by lanthionine containing peptides (lantipeptides) that are 
devoid of a significant antimicrobial activity (Willey and v. d. Donk, 2007). Instead, these 
peptides exert morphogenetic and signalling functions e.g. SapB serve as biosurfactant 
facilitating the emergence of newly formed aerial hyphae in streptomycetes (Kodani et al., 
2005). Generally, class III peptides are modified by LanM-like proteins, but these enzymes 
often do not possess zinc ligands indicating an alternative cyclization mechanism (Willey and 
v. d. Donk). The leaders often harbor GG protease sites and additionally, a conserved helical 
recognition region at their N-termini (Müller et al., 2011).  
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In 2010, a further lantibiotic family was identified, the labyrinthopeptins (Meindl et al., 2010, 
Müller et al., 2010). Peptides of this family are characterized by the presence of a novel 
carbacyclic aa called labionin that is assembled from two Dha and one Cys in two 
consecutive Michael additions. This unusual aa is introduced by post-translational 
modifications catalyzed by the biosynthetic enzyme LabKC which has a sequence similar to 
that of the class III peptide SapB modifying enzyme RamC. Therefore, labyrinthopeptins were 
assigned to the type-III lantibiotics (Müller et al., 2010). Interestingly, LabKC enzymes show 
only little sequence similarity to the LanC-like domain and important active sites, such as zinc 
binding motifs, are missing. In addition, also the N-terminus does not show sequence 
similarity to lantibiotic dehydrases. Instead, it exhibits similarity to eukaryotic Ser/Thr 
kinases. As for LanM enzymes, a phosphorylation of Thr and Ser residues, resulting in the 
formation of the didehydro-aa, is postulated, but in contrast to LanM enzymes, LabKC were 
shown to require GTP, instead of ATP, for this reaction (Müller et al., 2010).  
Also in 2010, another lantibiotic modification enzyme was discovered (Goto et al., 2010). The 
corresponding lantibiotic peptide (venezuelin) lacks antimicrobial activity and is modified by 
the bifunctional lantibiotic modification enzyme, LanL, via an alternative biosynthetic route. 
Similarly to the previously described enzymes of the LanM/C type, this enzyme contains a 
classical LanC-like domain in its C-terminal part, including all active and zinc binding sites. 
However, there is no dehydratase-like domain and, instead, two regions resembling a 
Ser/Thr kinase and lyase domain, like in the LabKC enzyme, are present at the N-terminus 
and these are essential for the dehydration. Based on sequence alignment analysis, Goto 
and co-workers (2010) postulated a new biosynthetic pathway for lanthionine formation by 
this enzyme including 1. phosphorylation of Thr/Ser residues by the kinase domain; 2. a β-
elimination of these phosphate groups that generates Dha and Dhb as a result of the lyase 
activity and 3. cyclization by the LanC-like domain resulting in the formation of the thioether-
aa by the same strategy as described for LanC and LanM enzymes.  
Although the domains responsible for the dehydration step have dissimilar aa sequences in 
LanB, LanM and LanL/LabKC, the underlying reaction chemistry appears to be quite similar, 
as phosphorylation and elimination of the phosphate is used to generate the didehydro-aa in 
all three dehydration reactions (Chatterjee et al., 2005; Paul et al., 2007; Goto et al., 2010). 
Lantibiotics are characterized by a high proportion of unusual aa. About one-third of the aa 
within the propeptide undergo structural changes of their side chains by post-translational 
modifications (Chatterjee et al., 2005). Introduction of the thioether rings converts the linear 
peptide chain into a polycyclic structure, which confers enhanced peptide rigidity, 
proteolytic resistance (Bierbaum et al., 1996), and resistance to thermal inactivation as well 
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as increased tolerance to oxidation (Sahl et al., 1995). Furthermore, since some of these ring 
structures are involved in target binding by forming specific binding pockets (Hsu et al., 
2004), a structure-function relationship becomes evident for several lantibiotics (Ross and 
Vanderas, 2011).  
Beside the typical lantibiotic modifications, some lantibiotics harbor additional less 
frequently encountered modifications that are often confined to a single lantibiotic or to 
related lantibiotics (Sahl and Bierbaum; 1998; Willey and v.d. Donk, 2006), but also 
contribute to activity and stability of peptides (McAuliffe et al., 2001). So far, a total of 20 
modifications have been described (table 1.1).  
 
 
 
Figure 1.4: Structures of (A) nisin (class I), (B) mersacidin (class II) und C) labyrinthopeptin A2 (class 
III). (Me)Lan and labionin rings are highlighted by colors, whereas residues of the same thioether-aa 
are marked in same colors. Didehydro-aa are designated in orange.  
 
As a consequence of various modifications, structure prediction of active lantibiotic peptides 
based on the primary sequence is almost impossible. Even the prediction of the typical 
lantibiotic aa lanthionine and didehydro-aa is difficult, since some hydroxy-aa, didehydro-aa 
and Cys prevent further modifications and remain unmodified in the active peptide. Based 
on an in silico analysis of all known lantibiotic peptides, Rink et al. suggested universal rules 
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Table 1.1: Overview over all post-translationally introduced aa modifications found in lantibiotic peptides. 
 
Name Description Enzymes Mechanism Example 
Didehydroalanine Dha unsaturated didehydro-aa LanM, LanB, 
LanL, LabKC 
Dehydration of Ser all lantibiotics 
  
Didehydrobutyrine Dhb Dehydration of Thr 
Lanthionine Lan thioether bridged di-carboxy-di-aa LanM, LanC, 
LanL 
Nucleophilic addition of Cys to Dha 
Methyllanthionine MeLan Nucleophilic addition of Cys to Dhb 
Lanthionine sulphoxide SO-Lan oxidized Lan  ? Oxidation of a C-terminal Lan  actagardine 
Labionin Lab carbacyclic tri-aa with a methylene 
and a thioether bridge 
LabKC Two consecutive nucleophilic Michael 
additions of two Dha and one Cys  
labyrintho-
peptins 
2-Aminovinyl-D-cysteine AviCys thioether cross-linked Ser-Cys 
derived di-aa  
LanD Oxidation and decarboxylation of a C-terminal 
Cys followed by an addition to Dha; 
elimination of the free COO-  
epidermin  
2-Aminovinyl-methyl-D-
cysteine 
AviMeCys thioether cross-linked Thr-Cys 
derived di-aa 
LanD Oxidation and decarboxylation of a C-terminal 
Cys followed by an addition to Dhb; 
elimination of the free COO-   
mersacidin  
Lysinoalanine LysN-Ala cross-linked Lys-Dha derived di-aa CinOrf7 Alcylation of a C-terminal Lys to Dha  cinnamycin 
Disulfide bridge  S-S cross-linkage of two Cys spontaneous Oxidation of two Cys derived sulfhydryl groups haloduracin α 
D-Alanine D-Ala D-isomer of Ala LanJ Hydrogenation of Dha   lacticin 3147 
2-Oxopropionate OPr α-ketoalkanate spontaneous  Hydratisation and desamination of N-terminal 
Dha; elimination of free NH3
+ 
lactocin S 
2-Oxobutyrate Obu α-ketoalkanate spontaneous  Hydratisation and desamination of N-terminal 
Dhb; elimination of free NH3
+ 
Pep5 
2-Hydroxypropionate HPr hydroxylated propionate ? Reduction of OPr epicidin 280 
Erythro-3-hydroxy-
aspartate  
HyAsp hydroxylated Asp CinX Hydroxylation of Asp cinnamycin 
Nα-Succinyl-tryptophan   Suc-Trp succinylated Trp ? Succinylation of a Trp  subtilin 
variant 
5-Chlorotryptophan ClTrp chlorinated Trp MibH Chloronation of Trp microbispori-
cines 4-Dihydroxyproline OH-OHPro two-fold hydoxylated Pro  MibO Di-Hydroxylation of Pro 
Hydroxyproline OHPro hydroxylated Pro MibO Hydroxylation of Pro 
D-Lactate D-Lac reduced and hydrolyzed Dha ElxB + ElxO Reduction of the pyruvate that is based on the 
hydrogenation of an N-terminal Dha to lactate; 
NADPH dependent  
epilancin 15X 
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for the occurrence of modifications in lantibiotic precursors (Rick et al., 2005; Moll et al., 
2010). According to these rules, the extent of dehydratisation is controlled by the aa context 
of flanking regions near to the dehydratable residues. Ser residues are predicted to escape 
dehydration more often than Thr. Hydroxy-aa that undergo dehydratisation more often are 
flanked by non-aromatic hydrophobic rather than by hydrophilic aa. Furthermore, the ring 
patterns differ in various lantibiotics, even in peptides of the same class. 
 
Mode of action of lantibiotic peptides (MoA) 
Except for class III peptides, the overwhelming majority of lantibiotics displays an 
antibacterial activity that mainly is restricted to Gram-positive bacteria. Although sometimes 
reported, Gram-negatives are generally not affected due to the protective effect of their 
outer membrane that prevents access to the main target. Consequently, treatment of 
bacterial cells with lantibiotics in concert with an outer membrane (OM) destroying agent 
like EDTA showed an antibiotic effect even against Gram-negatives e. g. Salmonella strains 
(Kordel and Sahl, 1986; Stevens et al., 1991). Some lantibiotics (e.g. nisin Z) can affect E. coli 
and other Gram-negatives like Helicobacter pylori or Neisseria at higher concentrations, 
probably due to either a self-promoted uptake or a lantibiotic-based destabilization of the 
OM by its binding to lipopolysaccharides (Nagao et al., 2009).  
Initial binding to the cell surface is driven by charge and based on the electrostatic attraction 
of the peptide to the membrane. Thereby, the cationic peptides interact with acidic 
polymers, such as the cell wall associated teichoic acids, as well as with acidic phospholipids 
e.g. phosphatidylglycerol and cardiolipin (Matsuzaki et al., 1999). This binding induces a 
conformational change that results in a rearrangement of hydrophilic and hydrophobic aa 
into an amphipathic helix and, thus in formation of a 3-dimensional structure that allows 
membrane insertion (Jung and Sahl, 1991).  
The antibacterial effect generally depends on the inhibition of cell wall biosynthesis or the 
disruption of membrane integrity by pore formation. Inhibition of cell wall biosynthesis is 
achieved by binding of active peptides to the membrane-bound cell wall precursors lipid I 
and lipid II. Lipid I is assembled on the cytoplasmic side of the membrane by transfer of the 
UDP-activated amino-sugar N-acetyl-muramic acid (MurNAc) that carries the pentapeptide 
side chain to the membrane-bound lipid carrier undecaprenyl-pyrophosphate (C55PP). 
Coupling of the second UDP-activated amino-sugar, N-acetyl-glucosamine (GlucNAc) to lipid I 
generates lipid II and is followed by transport of the hydrophilic cell wall building block 
through the hydrophobic environment of the membrane (Bouhhs et al., 2008). 
Subsequently, by transglycosylation and transpeptidation, the cell wall building blocks are 
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coupled to growing peptidoglycan chains of a nascent cell wall. The lipid carrier is recycled 
and returns to the cytosolic side where it is dephosphorylated to C55P (Bauer and Dicks, 
2005; Schneider and Sahl, 2010 a,b).  
Nisin, the most intensively studied lantibiotic, acts by a dual MoA including both 
mechanisms a) cell wall biosynthesis inhibition via complexing and dislocalization of lipid I 
and lipid II and b) disruption of the membrane integrity caused by the formation of short-
lived membrane spanning pores (Wiedemann et al., 2001 and 2004).  
Both MoA are assigned to specific regions of the active peptide. The N-terminal rings A and B 
form a binding pocket, called the pyrophosphate cage, that allows the specific interaction 
and binding of nisin to the pyrophosphate moiety of lipid I/ II. As demonstrated in NMR 
spectra, this binding depends on five hydrogen bonds between the backbone amides of nisin 
and the pyrophosphate linkage group of lipid II (Hsu et al., 2004). Since nisin is able to bind 
to both cell wall precursors, but not to C55P alone, the monosaccharide MurNAc-
pentapeptide is also involved in target binding. Binding and complexing of lipid I/II result in 
delocalization of the cell wall precursors and, hence, in their abduction from the sites of 
nascent cell wall biosynthesis. For nisin-treated cells an accumulation of delocalized lipid II 
molecules has been demonstrated (Brötz et al., 1998). This is most likely accompanied by 
delocalization of proteins involved in cell division. As a consequence of delocalization of the 
cell wall biosynthesis and cell division machinery, formation of the divisom might also be 
affected (Hyde et al., 2005; Errington et al., 2003; Henrichfreise et al., 2009). 
Moreover, nisin causes formation of short-lived (6 s) membrane spanning and potential-
dependent pores. In lipophilic environments, an amphipathic helix with a central and flexible 
hinge region is formed that enables the peptide to insert into the membrane. This 
subsequently results in temporary membrane perturbations and assembly of a membrane 
spanning pore (van Heusden et al., 2002). Within the pore, hydrophobic aa side chains are 
immersed into the core of the membrane, whereas hydrophilic groups, like the positively 
charged aa His and Lys, face the water-filled channel or interact with the phospholipid head 
groups (v. d. Hooven et al., 1996; van Heusden et al., 2002). Pore formation (2-2.5 nm in 
diameter) allows small molecules, like aa and ions (e.g. K+) to leak from the cell, resulting in 
disruption of the barrier function of the membrane and, consequently, in dissipation of the 
membrane potential. Finally, this results in the abrupt arrest of cellular biosynthesis 
processes and in cell death (Sahl and Brandis, 1982; Wiedemann et al., 2001). Although nisin 
mutants incapable to form pores retained considerable antimicrobial activity, the capacity 
for pore formation appears to be the primary effect of its antimicrobial activity. This is based 
on the fact that pore formation results in a rapid killing so that inhibition of peptidoglycan 
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biosynthesis does not come into effect (Brötz et al., 1998; Wiedemann et al., 2001). 
Nevertheless, lipid II binding is essential for nisin activity, as nisin had enhanced binding 
efficacy to lipid II-containing model membranes. This indicates that lipid II serves as docking 
molecule and mediates a ‘targeted’ pore formation (Brötz et al., 1998). Binding of lipid II 
appears to enable the peptide to integrate into the membrane by causing a conformational 
change resulting in a transmembrane orientation of the lantibiotic (van Heusden et al., 
2002). Furthermore, lipid II appears to stabilize the resulting pores (Wiedemann et al., 2004; 
Breukink et al., 1999). The essential function of lipid II in pore formation is underlined by the 
fact that nisin pores exist of eight nisin and four lipid II molecules (Hasper et al., 2004).  
Lantibiotics like mersacidin/epidermin/gallidermin and Pep5 only act by one of these two 
mechanisms. Due to its elongated structure Pep5 apparently binds the membrane and acts 
via dissipation of membrane integrity by pore formation (Sahl and Brandis, 1982; Pag, phD 
thesis, 1998). In contrast, epidermin and gallidermin preserve a nisin-like lipid II binding 
motif, but since they are shorter and lack the C-terminal amphiphilic tail of nisin, they are 
incapable to perform pore formation and solely act on lipid II and the cell wall biosynthesis 
(Bonelli et al., 2006). This also was shown for the globular lantibiotics of the mersacidin-like 
subgroup. In contrast to nisin, mersacidin has a lower affinity to lipid II and the N-acetyl-
glucosamine of the cell wall precursor takes part in the complex, since lipid I is not bound by 
those peptides. All mersacidin-like lantibiotics share a conserved TxS/TxEC motif (Böttiger et 
al., 2009; Cotter et al., 2006) within their essential C-ring which is involved in lipid II binding 
although it differs from the lipid II binding pocket of nisin. Interestingly, this essential C-ring 
is similar to the A-ring of lacticin 481 subfamily peptides (Szekat et al., 2003). Consequently, 
lipid II complexing here results in accumulation and dislocation of lipid II as well as in 
prevention of transglycosylation by steric hindrance (Brötz et al., 1997).  
Divalent ions like calcium increase the activity of some lantibiotics that contain the lipid II 
motif of mersacidin (Barrett et al., 1992). By NRM studies, Kärcher and coworkers observed 
that a negatively charged and conserved E residue is involved in Ca2+ binding of actagardine 
(Schneider et al., 2000). Depending on the net charge and presence and localization of 
positively charged aa within the lantibiotic peptide, Ca2+ ions appear to contribute to the 
antimicrobial activity of these peptide in many ways (Böttiger et al., 2009): 1. binding of 
calcium confers a positive net charge to neutral peptides like mersacidin, which might result 
in an enhanced membrane interaction and, consequently, in a deeper membrane insertion; 
2. for positively charged peptides, e.g. plantaricin C , calcium might stabilize a conformation 
that promotes membrane insertion. 
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An ion independent MoA was demonstrated for the uncharged lacticin 481. In contrast to 
other neutral peptides, it contains a positively charged aa on its N-terminus that might be 
sufficient for membrane interaction and formation of complexes with lipid II (Böttiger et al., 
2009). 
Two-peptide lantibiotics have a dual MoA like nisin, but here it depends on two 
synergistically acting peptides (Morgan et al., 2005). While lipid II binding is mediated by the 
α-peptides that show sequence similarity to mersacidin-like lantibiotics, the elongated β-
peptide acts on the membrane. The individual peptides are separately modified by two 
LanM enzymes (McAuliffe et al., 2000) and the peptides themselves are inactive or display 
only little activity (Holo et al., 2001; Navaratna et al., 1999).  
For lacticin 3147 it has been demonstrated that lipid II binding results in a conformational 
change within the α-peptide leading to enhanced complex formation with the second 
peptide (Wiedemann et al., 2006). A proline residue within the β-peptide motif is apparently 
involved in complex formation, since mutations in this site strongly affect the 
peptide:peptide synergism (Lawton et al., 2007). Complex formation itself enhances the 
affinity of the α-peptide to lipid II and, therefore, results in a deeper insertion of the 
complex into the membrane. This complex arrangement allows the β-peptide to adopt a 
transbilayer orientation and, thereby, results in pore formation. These pores were found to 
be significantly smaller (0.6 nm) than those formed by nisin (Bonelli et al., 2006). Since all 
members of the two-peptide lantibiotics are quite homologous, it is hypothesized that they, 
with exception of the cytotoxic cytolysin, share a similar MoA (Willey and v. d. Donk, 2006).  
Cinnamycin-like peptides display a different MoA and act by the disruption of enzymatic 
functions. These peptides indirectly inhibit the phospholipase A2 by forming a complex with 
its lipid substrate phosphatidylethanolamine (PE) in a 1:1 stoichiometry. Subsequently, this 
results in a transbilayer lipid movement and reorganization of the membrane (Hosoda et al., 
1996; Iwamoto et al., 2007; Makino et al., 2003). 
Class III lantibiotics like SapT and SapB exhibit a morphogenetic rather than an antibacterial 
effect. If at all, these peptides have low antimicrobial activities. Based on their amphiphilic 
structure, they serve as biosurfactants e.g. during the emergence of aerial hyphae of 
streptomyces strains (Kodani et al., 2005 and 2004).  
For some lantibiotics (e.g. subtilin) an inhibiting effect on the outgrowth of endospores is 
reported (Oman and v. d. Donk, 2009). A recent publication dealing with the molecular basis 
of the antisporal effect of nisin demonstrated that this effect also depends on the 
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membrane and lipid II binding activity of active peptides. By preventing the establishment of 
a membrane potential and cell wall biosynthesis, the spore outgrowth is inhibited at the 
stage of spore germination (Gut et al., 2011). 
 
 
 
Figure 1.5: Overview over the MoA of lantibiotics: Almost all lantibiotics act either by inhibition of 
cell wall biosynthesis by lipid II binding and or disruption of the membrane.  
 
Producer self-protection of lantibiotic producers 
Production of antimicrobials targeting classical and widely distributed cell structures, like 
lipid II or the prokaryotic membrane, necessitates development of a dedicated producer self-
protection machinery in order to avoid the risk of self-destruction. Lantibiotic producers are 
highly resistant against their own lantibiotic and this resistance is very specific and restricted 
to their own lantibiotics or very closely related variants thereof (Jack, Bierbaum and Sahl, 
1998; Heidrich et al., 1998).  
In general, two strategies have evolved. The most widely distributed mechanism relies on an 
ABC-transporter, LanEFG (Klein and Entian, 1993; Siegers and Entian, 1995), that removes 
the membrane-bound lantibiotic by pumping it back into the extracellular space without 
degradation (Peschel and Götz, 1996; Otto et al., 1998; Stein et al., 2003). Thereby, the 
amount of membrane-bound peptide is kept below a critical level. Energy for transport is 
provided by ATP hydrolysis (Okuda et al., 2010; Okuda and Sonomoto, 2011). These 
immunity-transporters consist of two heterodimeric membrane spanning proteins (LanEG) 
and two homodimeric ATP-binding proteins (LanF). The presence of an accessory factor 
(LanH) which acts as an ancillary protein of the transporter has been described for some 
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lantibiotic producers, e.g. epidermin, gallidermin (Hille et al., 2001; Peschel et al., 1997) and 
nukacin ISK-1 (Aso et al., 2008) producing strains. For the gallidermin producer, the presence 
of a LanH, which acts as an ancillary protein for the assembly of the LanFEG transporter, has 
been reported (Peschel et al., 1997). The NukH protein was shown to cooperatively 
contribute to immunity as a lantibiotic binding protein that inactivates membrane-bound 
nukacin prior its export by NukEFG (Okuda et al., 2005).  
The second mechanism is based on the expression of LanI immunity peptides or proteins, 
which belong to three classes, 1. the lipoproteins; 2. a group of small peptides and 3. 
transmembrane proteins. LanI are found, for example, in Pep5 and Epicidin 280 as well as in 
nisin and subtilin and lacticin 3147 producers.  
PepI and EciI peptides are very small (about 70 aa), share a highly hydrophobic N-terminus 
and a hydrophilic C-terminus (Reis et al., 1994). They are membrane-associated and localized 
at the interface between cell membrane and cell wall (Hoffmann et al., 2004). In contrast, 
NisI (245 a) and SpaI (165 aa) are larger and possess a consensus lipopeptide signal 
sequence. These proteins are attached to the outside of the cytoplasmic membrane via a 
lipid anchor (Klein and Entian, 1994). Transmembrane spanning LanI proteins contain at least 
three transmembrane domains and are found in the gene clusters of lacticin 3147 and 
cytolysin (McAuliffe et al., 2000; Coburn et al., 2009).  
LanI proteins and peptides act via 1. a direct interaction with the lantibiotic, resulting in its 
antagonization by sequestering the peptide (nisin) or 2. a membrane interaction generating 
an environment unsuitable for the function of the lantibiotic, or 3. a direct interaction with 
the target has been proposed (Pep5).  
Studies on nisin and lacticin 3147 indicate that their immunity peptides directly interact with 
the corresponding lantibiotic resulting in the formation of an insoluble complex (Stein et al., 
2003; Draper et al., 2009), whereas PepI appears to be located in the membrane cell wall 
interface (Hoffmann et al., 2004). An additional feature of LanI was discovered, when it was 
found, that secreted but lipid anchor-free NisI proteins aggregated nisin extracellularly 
(Koponen et al., 2004). In general, LanI proteins and peptides are highly specific and so they 
have no or only very little sequence similarity (Stein et al., 2002; Draper et al., 2008). 
Interestingly, some lantibiotic producers such as the producers of nisin, subtilin and lacticin 
3147, developed both strategies (Siegers and Entian, 1995; Klein and Entian, 1993; Draper et 
al., 2009) and in these cases, although both systems are required for the full immunity, the 
larger part is mediated by the LanI system (Pag et al., 1999; Stein et al., 2002; McAuliffe et 
al., 2000).  
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Lantibiotic gene clusters and their regulation 
Genes associated with lantibiotic biosynthesis are almost always located adjacent to the 
structural gene and together they form the lantibiotic gene cluster (Siezen et al., 1996). One 
exception, in the cyanobacterium Prochlorococcus, has been described so far. This 
lantipeptide producing strain harbors 29 putative lanA that are widely distributed within the 
genome. These prepeptides share quite similar aa sequences in their leaders and six of them 
were shown to be modified in vitro by the same LanM (Shi et al., 2010). 
In addition to the genetic information for the prepeptide (lanA), the gene clusters encode for 
proteins essential for lantibiotic modification (mainly lanB,C,M), regulation (lanR,K), export 
(lanT), processing (lanP) and immunity (lanEFG,H,I). In this nomenclature the generic symbol 
lan replaces a specific designation, that is derived from the name of the peptide (Jack et al., 
1995). Usually, at least parts of the cluster are organized in operons that allow the co-
expression of proteins that are involved in same functions. LanA often is clustered with 
genes of modification enzymes in a biosynthesis operon, in which it usually is the first ORF. 
Besides this, there is no uniform gene order in individual clusters (Siezen et al., 1996; Willey 
and v. d. Donk, 2006). 
Clusters are often found on plasmids (Pep5) or, as far as they are chromosomally encoded, 
associated with mobile elements like IS elements or transposons (Nisin; Schnell et al., 1988; 
Horn et al., 1991). This finding together with the fact that GC contents of many gene clusters 
differ from the overall GC content of the producer, indicates that clusters might be spread 
through horizontal gene transfer (Willey and v. d. Donk, 2006).  
Production of a lantibiotic is energy-intensive and therefore, this process has to be tightly 
regulated. For many clusters, a specific regulation was demonstrated, that is most 
frequently based on dedicated two-component response regulatory systems. This system 
consists of a membrane-bound histidine kinase (LanK) which responds to an external 
stimulus by autophosphorylation of a conserved His residue. As shown in detail for nisin 
(Kuipers et al., 1995) and mersacidin (Schmitz et al., 2006), triggering agents are the active 
peptides themselves. Nisin, that had been rendered antimicrobially inactive, still retained its 
induction capacity, indicating that induction is not based on pore formation and might be 
due to a direct interaction of the peptides with the kinase (Kuipers et al., 1995; Kleerebezem, 
2004). Subsequently, the phosphate group is transferred to an Asp residue of the 
appropriate response regulator (LanR) that often functions as a transcriptional activator 
(Kraaij et al., 1999). In the following, the response regulator undergoes a conformational 
change that enables it to bind to specific operator structures, thereby affecting transcription 
of the target genes (Willey and v. d. Donk, 2006; Yonezawa and Kuramitsu; 2005).  
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Certain gene clusters e.g. in mersacidin and cinnamycin producer strains, contain additional 
LanR proteins, indicating a more complex regulation. In the mersacidin cluster the two-
component system consists of MrsK2 and MrsR2 that control producer self-protection in an 
auto-regulated manner, whereas mersacidin production is under control of the MrsK2 
independent, orphan response regulator MrsR1 (Guder et al., 2002). Other lantibiotic gene 
clusters, like the lacticin 3147 cluster, are controlled by repressor proteins.  
Even uninduced cells produce a basal level of the bacteriocin, so that a subinhibitory 
concentration accumulates in the surrounding. These peptides serve as signal molecules 
and, once a threshold concentration is reached, induce their own biosynthesis (Kuipers et al., 
1995). Such auto-inducing mechanisms strongly underline the signalling function of 
lantibiotics and enable the producer to communicate with other cells in order to achieve 
high level production rates and a rapid build-up of the self-immunity in a concerted action 
(Kuipers et al., 1995).  
Furthermore, lantibiotic production and other cellular processes, such as competence and 
sporulation, usually are co-regulated and appear to be part of a complex stress response. For 
example, in B. subtilis, transcription of spaR and spaK is controlled by the alternative sigma 
factor σH (Stein et al., 2002). Additionally, production of the two-peptide lantibiotic Smb 
depends on induction by the competence stimulation peptide (CSP) (Yonezawa and 
Kuramitsu, 2005). As a consequence, lantibiotic production and competence development 
occur simultaneously and might provide a mechanism to ensure a pool of heterologous DNA 
for transformation and uptake (v. d. Ploeg, 2005; Yonezawa and Kuramitsu, 2005).  
 
Current and future applications of lantibiotics and associated proteins   
Nowadays, over 80 lantibiotics have been identified (table 1.2), several of which exhibit high 
potential to inhibit clinically significant pathogens. In consideration of the fact that the 
potential to act as antimicrobials is combined with a low tendency to generate resistance, 
makes lantibiotics highly attractive for medical applications (v. Heel et al., 2011; Wilson-
Standford and Smith, 2011). The majority of lantibiotics acts on targets (e.g. lipid II) that are 
known from other clinically used antibiotics, but in contrast to these, they are orders of 
magnitude more potent and bind to different target sites. Thus, they might overcome the 
problem of pre-existing resistance mechanisms.  
In general, lantibiotics have many characteristics, like their low MW, lack of toxicity, broad 
range of activity and low immunogenicity which make them suitable for applications in many 
areas, mainly in food industry. Nevertheless, particularly for medical applications, some 
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hurdles have to be overcome. For nisin, these are the low solubility, lack of stability and 
activity at higher pH as well as their tendency to interact with blood components.  
The first and only lantibiotic in commercial use is nisin. Since it exhibits an antimicrobial 
activity against Gram-positives, including spoilage causing bacteria like Listeria 
monocytogenes, it has been adopted as a food preservative (E234) in processed dairy 
products, canned fruits and vegetables (Cotter et al., 2005, McAuliffe et al., 2001). 
Importantly, development of significant resistance levels has rarely been observed. Nisin also 
exhibits a high efficacy against clinically relevant human pathogens, like Helicobacter pylori, 
making it a putative agent for treatment of peptic ulcers (Nascimento et al., 2006). Another 
application in veterinary medicine for treatment of bovine mastitis also has been reported 
(Broadbent et al., 1989). 
Besides nisin, other lantibiotics have been investigated regarding their potential application 
as antimicrobials (Des Field et al., 2010). Many lantibiotics were demonstrated to be efficient 
in vitro and in vivo against multiresistant superbugs. Regarding this, mersacidin emerged as 
an effective agent to treat MRSA infections in a murine model (Limbert et al., 1991; 
Kruszewska et al., 2004).  
Besides the classical antibiotic use, lantibiotics could find application in further medical 
settings and might serve as additives and probiotics in order to prevent infections or 
bacterial colonization. Epidermin and lacticin 3147 are active against the acne causing 
bacterium Propionibacterium acnes, thus providing the opportunity to use these substances 
as additives in cosmetics and personal-care products (Kellner et al., 1988; Lawton et al., 
2007). In an in vitro colonization experiment, Pep5 and epidermin prevented adhesion of 
coagulase-negative staphylococci, specifically of S. epidermidis, to siliconisated catheters 
(Fontana et al., 2006). The coating of medical devices would be an elegant strategy to reduce 
catheter-related infections.  
Lacticin 3147 exerts an antimicrobial effect on different cariogenic Streptococcus mutant 
strains and, therefore, its use as additive in dental applications is discussed (Suda et al., 
2011). Salivaricins have interesting effects against Streptococcus pyogenes strains. 
Therefore, the salivaricin A producer was supplemented as a probiotic to milk drinks and was 
demonstrated to persist in the oral cavity. Thus, S. pyogenes infections were prevented by a 
probiotic bacterial replacement strategy using a strain of the indigenous oral tongue 
microbiotia that is known for lantibiotic production (Dierksen et al., 2007). Moreover, 
chewing gums and lozenges, that include salivaricin-producing strains, have been developed 
(BLIS Technologies). Some lantibiotics have additional properties that are interesting for 
medical applications other than the use as antimicrobials. A contraceptive effect due to 
spermicidal activities has been reported for nisin in vitro and in vivo. After intravaginal 
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application, nisin appears to completely impede sperm motility and, hence, block 
conception. The exact underlying mechanism has not been elucidated yet. Like bacterial 
membranes, the membrane of the sperms carries negatively charged phospholipids on its 
outside suggesting that a membrane-damaging effect could be responsible for sperm 
immobilization. As a consequence of its spermicidal activity, nisin could be employed as a 
safe and potent vaginal contraceptive. As a side effect, based on its antimicrobial activity, 
nisin would further inhibit growth of bacteria causing sexually transmitted diseases (Aranha 
et al., 2004; Reddy et al., 2004 a, b).  
Furthermore, potential protein chemistry applications are discussed for lantibiotic 
biosynthesis enzymes. Usage of the biosynthesis machinery in in vivo and in vitro 
bioengineering approaches is a promising technology to design novel antimicrobial 
compounds. Novel antibiotics could be designed on the basis of either the generation of 
improved lantibiotic analogs or the introduction of thioether rings into existing therapeutics 
(Rink et al., 2005; Kluskens et al., 2005). Since lantibiotics are ribosomally synthesized these 
peptides are amenable to rational drug design. Here, known lantibiotics structures serve as 
blueprints for the expression of mutated peptides. In this context, an in vitro mutasynthesis 
approach has been established by Leevengood et al. (2009) as a method to improve the class 
II lantibiotic lacticin 481 by introduction of unnatural aa side chain substitutions.  
The promiscuity of the lantibiotic modification enzymes and their ability to display activity in 
vitro, allow introduction of lantibiotic modifications even into synthetic analogs (Chatterjee 
et al., 2006). Introduction of additional non-usual aa might be useful to enhance peptide 
efficacy, solubility and stability as well as to improve their pharmacodynamics properties. 
Successful improvement of therapeutically used peptide variants of enkephalin and 
somatostatin by chemical introduction of thioether bridges has been previously reported 
(Ösapay et al., 1997; Rew et al., 2002). To this end, Kuipers and coworkers established an in 
vivo system that is based on the nisin biosynthesis and transport machinery (Kuipers et al., 
2005; Bosma et al., 2011) and introduces didehydro- as well as thioether-aa into non-
lantibiotic peptides. Using this system they successfully produced lanthionine-bridged 
variants of vasopressin, enkephalin and angiotensin.  
In conclusion, lantibiotics hold a considerable promise as alternatives for traditional 
therapeutics, as probiotics, preservatives and additives in agro-food- or cosmetic-industry 
and veterinary and human medicine. Even the enzymes of the lantibiotic biosynthesis 
apparatus have a high potential for biotechnological use because of their ability to modify 
non-lantibiotic therapeutics and pharmaceuticals.  
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Table 1.2: Overview of all lantibiotics (01/2012). Classification according to Willey and v. d. Donk (2006). Residues involved in (Me)Lan bridges are 
highlighted in colored boxes, whereas subsidiary residues of one thioether aa are marked in same colors. The positions (x) of additional modifications are 
marked by black, bold letters. Ser and Thr residues that are found to be dehydrated to Dha and Dhb are designated in orange. Conserved leader structures 
are underlined. The overall net charge of the peptides was calculated at pH7.  
 
Name Producer MW 
[Da] 
aa Cha
rge 
Amino acid sequence References 
Leader sequence Prepeptide sequence 
Class I lantibiotics (LanBC modified, elongated peptides) 
Nisin-like lantibiotics  
Nisin A Lactococcus lactis 
ATCC 11454 
3353 34 +3 MSTKDFNLDLVSVSKKDSGASPR   ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK Gross and Morell, 
1971 
Nisin Q Lactococcus lactis 
61-14 
3327 34 +3 MSTKDFNLDLVSVSKTDSGASTR ITSISLCTPGCKTGVLMGCNLKTATCNCSVHVSK Zendo et al., 2003 
Nisin Z Lactococcus lactis 
N8, NIZO22186 
3330 34 +3 MSTKDFNLDLVSVSKKDSGASPR   ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK Mulders et al., 1991 
Nisin F Lactococcus lactis 
F10 
3457 34 +3 MSTKDFNLDLVSVSKKDSGASPR ITSISLCTPGCKTGALMGCNMKTATCNCSVHVSK De Kwaadsteniet et 
al., 2008 
Nisin U Streptococcus 
uberis 42 
3029 31 +3 MNNEDFNLDLIKISKENNSGASPR ITSKSLCTPGCKTGILMTCPLKTATCGCHFG 
three variants (U, U2, U3), differ in 1-2 aa, sequences of 
nisin U2 and U3 haven’t been published, yet.  
Wirawan et al., 
2006 and 2007  
Subtilin Bacillus subtilis 3317 32 +2 MSKFDDFDLDVVKVSKQDSKITPQ WKSESLCTPGCVTGALQTCFLQTLTCNCKISK Gross et al., 1973 
Entianin Bacillus subtilis 
DSM 15029T 
3348 32 +2 not annotated WKSESVCTPGCVTGLLQTCFLQTITCNCKISK Fuchs et al., 2011 
Ericin S Bacillus subtilis 
A1/3 
3442 32 +1 MSKFDDFDLDVVKVSKQDSKITPQ WKSESVCTPGCVTGVLQTCFLQTITCNCHISK Stein et al., 2002 
 
Ericin A Bacillus subtilis 
A1/3 
2986 29 +2 MTNMSKFDDFDLDVVKVSKQDSKITPQ VLSKSLCTPGCITGPLQTCYLCFPTFAKC 
Planosporicin 
(LAB97518) 
Planomonospora 
spec. 
2194 24 -1 not annotated  ITSVSWCTPGCTSEGGGSGCSHCC 
 
Maffioli et al., 2009; 
Castiglione et al., 
2007  
Streptin 1 Streptococcus 
pyogenes M25 
2424 23 +3 MNNTIKDFDLDLKTNKKDTATPY    VGSRYLCTPGSCWKLVCFTTTVK 
   VGSRYLCTPGSCWKLVCFTTTVK 
two putative structures predicted  
Karaya et al., 2001 
Streptin 2 2821 26 +3 MNNTIKDFDLDLKTNKKDTA TPYVGSRYLCTPGSCWKLVCFTTTVK 
TPYVGSRYLCTPGSCWKLVCFTTTVK 
two structures predicted (elongated Streptin 1)  
Wescombe and 
Tagg, 2003 
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Salivaricin D Streptococcus 
salivarius 5M6c 
3475 34 +1 MSTKDFNLDVEVSKSNTGASA FTSHSLCTPGCITGVLMGCHIQSIGCNVHIHISK 
structure predicted  
Birri et al., 2012 
Epidermin-like lantibiotics 
Epidermin 
 
Staphylococcus 
epidermidis 
2164 22 +3 MEAVKEKNDLFNLDVKVNAKESNDSGAEP
R 
   IASKFICTPGCAKTGSFNSYCC  
AviCys (19 + 22) 
Allgaier et al., 1986 
[Val1,Leu6] 
Epidermin 
Staphylococcus 
epidermidis 
2151 22 +3 MEAVKEKNDLFNLDVKVNAKESNDSGAEP
R 
VASKFLCTPGCAKTGSFNSYCC  
AviCys (19 + 22) 
Israil et al., 1996 
Gallidermin Staphylococcus 
gallinarum 
Tü3928 
2165 22 +3 MEAVKEKNELFDLDVKVNAKESNDSGAEP
R 
IASKFLCTPGCAKTGSFNSYCC 
AviCys (19 + 22) 
Kellner et al., 1988 
Staphylo-
coccin T 
Staphylococcus 
cohnii 
MEAVKGKNELFDLDVKVNAKESNDSGAEP
R 
Furmanek et al., 
1999 
BsaA2, 
Staphylo-
coccin Au-26 
community-
acquired MRSA 
2089 22 +2 MEKVLDLDVQVKANNNSNDSAGDER ITSHSLCTPGCAKTGSFNSFCC 
AviCys (19 + 22); predicted structure, slightly different lanA 
variants identified, additional non-expressed lanA  
Daly et al., 2010 
Mutacin  
B-Ny266 
Streptococcus 
mutans 
2270 22 +3 not annotated  FKSWSFCTPGCAKTGSFNSYCC 
AviCys (19 + 22); structure predicted (on Edman sequenc-
ing results); additional non-expressed lanA 
Mota-Meira et al., 
1997 
Mutacin 1140 
Mutacin III 
Streptococcus 
mutans 
2263 22 +3 MSNTQLLEVLGTETFDVQEDLFAFDTTDT
TIVASNDDPDTR 
FKSWSLCTPGCARTGSFNSYCC 
AviCys (19 + 22), additional non-expressed lanA 
Hillman et al., 1998 
Qi et al., 1999 
Clausin Bacillus clausii OC ? 22 0 not annotated FTSVSFCTPGCGETGSFNSFCC 
AviCys (19 + 22) 
Bouhss et al., 2009 
Mutacin I Steptococcus 
mutans 
2364 24 +2 MSNTQLLEVLGTETFDVQEDLFAFDTTDT
TIVASNDDPDTR  
FSSLSLCSLGCTGVKNPSFNSYCC 
AviCys (19 + 22); predicted structure, additional non-
expressed lanA 
Qi et al., 2000 
Microbi-
sporicin  
(different 
variants) 
Microbiospora 
spec. (corallina) 
2246 24 +1 MPADILETRTSETEDLLDLDLSIGVEEIT
AGPA  
 VTSWSLCTPGCTSPGGGSNCSFCC 
AviMeCys (21-24); Variant 107891 A1: Chlorotryptophan 
(4), Dihydroxy-proline (14)  
Castiglione et al., 
2008 
2230 24 +1 Variant 107891 A2: Chlorotryptophan (4), Hydroxyproline 
(14) 
Pep5-like lantibiotics 
Pep5 Staphyloccoccus 
epidermidis 
3488 34 +7 MKNNKNLFDLEIKKETSQNTDELEPQ TAGPAIRASVKQCQKTLKATRLFTVSCKGKNGCK 
2-Oxobutyryl (1) 
Kaletta et al., 1989 
Epilancin K7 Streptococcus 
epidermidis K7 
3032 31 +5 MNNSLFDLNLNKGVETQKSDLSPQ SASVLKTSIKVSKKYCKGVTLTCGCNITGGK 
2-Hydroxypropionyl (1) 
Van de Kamp et al., 
1995 
Epicidin 280 Streptococcus 
epidermidis  
3133 30 +4 MENKKDLFDLEIKKDNMENNNELEAQ    SLGPAIKATRQVCPKATRFVTVSCKKSDCQ 
2-Hydroxypropionyl (1); predicted structure 
Heidrich et al., 1998 
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Epilancin 15X Streptococcus  
epidermidis 
3173 30 +7 not annotated  ASIVKTTIKASKKLCRGFTLTCGCHFTGKK 
Lactate (1)  
Ekkelenkamp et al., 
2005 
Class II lantibiotics (LanM modified, globular peptides)  
Lacticin 481-like lantibiotics 
Lacticin 481 Lactococcus lactis 
CNRZ 481 
2901 27 0 MKEQNSFNLLQEVTESELDLILGA  KGGSGVIHTISHECNMNSWQFVFTCCS 
 
Piard et al., 1993 
Nukacin  
ISK-1 
Staphylococcus 
warneri 
2960 27 +3 MENSKVMKDIEVANLLEEVQEDENEVLGA    KKKSGVIPTVSHDCHMNSFQFVFTCCS 
predicted structure 
Sashihara et al., 
2000 
Nukacin 
KQU131 
Staphylococcus 
hominis KQU-131 
3004 27 +3 MENSKIMKDIEVANLLEEVQEDELNEVLG
A 
 KKKSGVIPTVSHDCHMNSFQFMFTCCS 
predicted structure 
Wilaipun et al., 
2008 
Mutacin II, JT-
8, H-29B 
Streptococcus 
mutans T8 
3245 27 +1 MNKLNSNAVVSLNEVSDSELDTILGG NRWWQGVVPTVSYECRMNSWQHVFTCC Novák et al., 1994 
Mutacin K8 Streptococcus 
mutans K8 
~ 
2734 
? +1 4 lanA (MukA1/MukA3 fit to the mass of an antimicrobial peptide produced by this strain; two additional 
non-expressed lanA); unknown/predicted structures (similarity to lacticin 481)  
Robson et al., 2007 
MKNTTNEMLELIQEVSLDELDQVIGG    MGKGAVGTISHECRYNSWAFLATCCS 
 
+2 MKQSDEMLELIQEVSLDELDQVIGG AGNGVIRTITQGCRMPNNMQVLFTC 
+1 MKQSNEMLELIQEVSLDELDQVIGG   MGKGAVGTISHECRYNSWAFLATCCS 
 
+1 MKKGTQLYLEALEALQEIKVEELDTFIGG    GGRASNTISSDCRWNSLQAIFSCC 
Streptococcin 
 SA-FF22 
Streptococcus 
pyogenes SA-FF22 
2795 26 +2 MEKNNEVINSIQEVSLEELDQIIGA    GKNGVFKTISHECHLNTWAFLATCCS 
structure not fully confirmed, additional non-expressed 
lanA 
Jack et al., 1994 
Streptococcin 
AM49 
Streptococcus 
pyogenes 
MTKEHEIINSIQEVSLEELDQIIGA Hynes et al., 1994 
Macedocin Streptococcus 
macedonicus 
ACA-DC198 
MEKETTIIESIQEVSLEELDQIIGA Georgalaki et al., 
2002 
Macedocin A1 ? 23 0 MKNNNKICQDALESLQELKLEEVDELLGG     GHGVNTISAECRWNSLQAIFSCC 
putative lanA; structure predicted (based on similarity to 
lacticin 481)   
Papadelli et al., 
2007 
Variacin Kocuria varians 2658 25 -1 MTNAFQALDEVTDAELDAILGG    GSGVIPTISHECHMNSFQFVFTCCS 
structure predicted (similarity to lacticin 481) 
Pridmore et al., 
1996 
Plantaricin C Lactobacillus 
plantarum 
2880 27 +1 not annotated  KKTKKNSSGDICTLTSECDHLATWVCC 
structure partially elucidated, predicted 
González et al., 
1994 
Ruminococcin 
A 
Ruminococcus 
gnavus 
2675 24 0 MRNDVLTLTNPMEEKELEQILGG GNGVLKTISHECNMNTWQFLFTCC 
structure predicted, additional non-expressed lanA  
Dabard et al., 2001 
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Butyrivibrio-
cin OR79A 
Butyrivibrio 
fibrisolvens 
2910 25 0 MNKELNALTNPIDEKELEQILGG    GNGVIKTISHECHMNTWQFIFTCCS 
structure not fully elucidated/predicted based on similarity 
to lacticin 481 
Kalmokoff et al . 
1999 
Butyrivibrio-
cin OR36 
? 25 0 MNKDLNALTNPIDEKELEQILGG    GDGVFRTISHECHMNTWMFIFTCCS 
putative lanA, structure predicted based on similarity to 
lacticin 481 
Whitford et al., 
2001; Dufour et al., 
2007 
 Butyrivibrio-
cin OB247 
? 25 0    GDGVFRTISHECAMNTWMFIFTCCS 
putative lanA, structure predicted (similarity to lacticin)  
Salivaricin A 
 
Streptococcus 
salivarius 20P3 
2315 22 0 MKNSKDILNNAIEEVSEKELMEVAGG    KRGSGWIATITDDCPNSVFVCC 
structure not fully elucidated 
Ross et al., 1993 
Salivaricin B Streptococcus 
salivarius K12 
2740 25 0 MAKQQMNLVEIEAMNSLQELTLEELDNVL
GA 
   GGGVIQTISHECRMNSWQFLFTCCS 
putative lanA; structure predicted  based on similarity to 
lacticin 481   
Hyink et al., 2007 
Variacin Kocuria varians 2658 25 -1 MTNAFQALDEVTDAELDAILGG    GSGVIPTISHECHMNSFQFVFTCCS 
structure predicted (similarity to lacticin 481) 
Pridmore et al., 
1996 
Plantaricin C Lactobacillus 
plantarum 
2880 27 +1 not annotated  KKTKKNSSGDICTLTSECDHLATWVCC 
structure partially elucidated, predicted 
González et al., 
1994 
Bovicin HJ50 
Thermophilin 
1277 
Streptococcus 
bovis HJ50; 
thermophilus 
3428 33 +2 MMNATENQIFVETVSDQELEMLIGG    ADRGWIKTLTKDCPNVISSICAGTIITACKNCA 
  ADRGWIKTLTKDCPNVISSICAGTIITACKNCA 
Disulfide bridge (21+29); structure predicted 
Xiao et al., 2004  
Kabuki et al., 2007 
Salivaricin A1 Streptococcus 
agalactiae 120 
2321 22 0 MKNSKDVLNNAIEEVSEKELMEVAGG KKGSGWFATITDDCPNSVFVCC 
unknown structure  
 
Nakagawa et al., 
2003 
 Streptococcus 
pyogenes 
MGAS315 
MKNSKDILTNAIEEVSEKELMEVAGG 
S. pyogenes M1  MSFMKNSKDILTNAIEEVSEKELMEVAGG 
S. pyogenes 
MGAS10394 
MERRMSFMKNSKDILTNVIEEVSEKELME
VAGG 
Banks et al., 2004 
Salivaricin A2 Streptococcus 
salivarius 
? 22 0 MKNSKDILNNAIEEVSEKELMEVAGG KRGTGWFATITDDCPNSVFVCC 
unknown structure (lanA identified) 
Wescombe et al., 
2006 
 Salivaricin A3 ? 22 0 MKNSKDVLNNAIEEVSEKELMEVAGG 
 
KKGPGWIATITDDCPNSIFVCC 
unknown structure (lanA identified) 
Salivaricin A4 ? 22 0 MKNSKDILNNAIEEVSEKELMEVAGG KRGPGWIATITDDCPNSIFVCC 
unknown structure (lanA identified) 
Salivaricin A5 ? 22 0 MKNSKDILNNAIEEVSEKELMEVAGG KRGPGWIATITDDCPNSVFVCC 
unknown structure (lanA identified) 
Salivaricin 9 Streptococcus 
salivarius strain 9 
2560 24 +2 MKSTNNQSIAEIAAVNSLQEVSMEELDQI
IGA  
   GNGVVLTLTHECNLATWTKKLKCC 
structure predicted (similarity to lacticin 481)  
Wescombe et al., 
2011 
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Mersacidin-like lantibiotics 
Mersacidin Bacillus amylo-
liquefaciens  
1825 20 0 MSQEAIIRSWKDPFSRENSTQNPAGNPFS
ELKEAQMDKLVGAGDMEAA 
CTFTLPGGGGVCTLTSECIC 
AviMeCys (15+20)  
Chatterjee et al., 
1992 
Actagardine Actinoplanes 
liguriae 
1890 19 0 MSALAIEKSWKDVDLRDGATSHPAGLGFG
ELTFEDLREDRTIYAA  
 SSGWVCTLTIECGTVICAC 
Lanthionine sulphoxide (14+19) 
 
Zimmermann et al., 
1995 
Ala(O)-
Actagardine 
Actinoplanes 
liguriae 
1961 20 0 MSALAIEKSWKDVDLRDGATSHPAGLGFG
ELTFEDLREDRTIYA 
ASSGWVCTLTIECGTVICAC 
Lanthionine sulphoxide (14+19) 
 
Vertesy et al., 1999 
Deoxy-
actagardine B 
(DAB) 
Actinoplanes 
liguriae NCIMB 
41362 
 19 0 MSAITVETTWKNTDLREDLTAHPAGLGFG
ELSFEDLREDRTIYAA 
 SSGWVCTLTIECGTLVCAC 
Lanthionine sulphoxide (14+19) 
 
Boakes et al., 2010  
Nai-802 Actinoplanes, sp 
104802/104771 
? 20 +1 ?  SSGWVCTLTIECGTVICACR 
structure predicted based on similarity to Actagardine  
Matteo, VAAM 
Poster, 2011 
Michiganin A Clavibacter 
michiganesis  
2145 21 0 MNDILETETPVMVSPRWDMLLDAGEDTSP
SVQTQIDAEFRRVVSPYM  
SSSGWLCTLTIECGTIICACR 
predicted structure  
Holtsmark et al., 
2006 
Cinnamycin-like lantibiotics 
Cinnamycin; 
lantibiotic Ro 
09-198 
Streptomyces 
cinnamoneus/ 
griseoverticillatus  
2042 19 1 MTASILQQSVVDADFRAALLENPAAFGAS
AAALPTPVEAQDQASLDFWTKDIAATEAF
A 
CRQSCSFGPFTFVCDGNTK 
Lysinoalanine (19+6); Hydroxyaspartate (15) 
Marki et al., 1991 
Fredenhagen et 
al., 1990 
 
 
 
 
Duramycin Streptomyces 
cinnamoneus 
2014 19 0 not annotated CKQSCSFGPFTFVCDGNTK 
Lysinoalanine (19+6); Hydroxyaspartate (15) 
Duramycin B Strepto-
verticillium spec. 
1951 19 0 not annotated CRQSCSFGPLTFVCDGNTK 
Lysinoalanine (19+6); Hydroxyaspartate (15) 
Duramycin C Streptomyces 
griseoluteus 
2008 19 -1 not annotated CANSCSYGPLTWSCDGNTK 
Lysinoalanine (19+6); Hydroxyaspartate (15) 
Ancovenin Streptomyces 
spec. 
1959 19 0 not annotated CVQSCSFGPLTWSCDGNTK 
Lysinoalanine (19+6) 
Kido et al., 1983 
Two-peptide lantibiotics (synergistic action) 
Lacticin 3147 Lactococcus lactis 
subsp. lactis 
DPC3147 
3322 30 0 MNKNEIETQPVTWLEEVSDQNFDEDVFGA   CSTNTFSLSDYWGNNGAWCTLTHECMAWCK 
D-Ala (7) 
Ryan et al., 1996 
2847 29 +1 MKEKNMKKNDTIELQLGKYLEDDMIELAE
GDESHGG 
   TTPATPAISILSAYISTNTCPTTKCTRAC 
2-Oxobuturyl (1); D-Ala (9;12) 
Staphylo-
coccin C55 
 
Staphylococcus 
aureus C55 
3339 30 0 MKSSFLEKDIEEQVTWFEEVSEQEFDDDI
FGA 
  CSTNTFSLSDYWGNKGNWCTATHECMSWCK 
D-Ala (7); structure predicted  
Navaratna et al., 
1998 
2993 37 -1 MKNELGKFLEENELELGKFSESDMLEITD
DEVYAA  
GTPLALLGGAATGVIGYISNQTCPTTACTRAC  
structure predicted 
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Plantaricin W Lactobacillus 
plantarum 
3223  29 0 MKISKIEAQARKDFFKKIDTNSNLLNVNG
A 
      KCKWWNISCDLGNNGHVCTLSHECQVSCN 
Disulfide brigde (2 + 9); structure predicted  
Holo et al., 2001 
3099 32 +6 MTKTSRRKNAIANYLEPVDEKSINESFGA
↓GDPEAR 
     SGIPCTIGAAVAASIAVCPTTKCSKRCGKRKK 
structure predicted 
Haloduracin Bacillus 
halodurans C-125 
3043 28 +1 MTNLLKEWKMPLERTHNNSNPAGDIFQEL
EDQDILAGVNGA 
    CAWYNISCRLGNKGAYCTLTVECMPSCN 
Disulfide bridge (1-8) 
McClerren et al., 
2006 
Bacillus 
halodurans C-125 
2330 24 +1 MVNSKDLRNPEFRKAQGLQFVDEVNEKEL
SSLAGS↓GDVHAQ 
         TTWPCATVGVSVALCPTTKCTSQC McClerren et al., 
2006 
Smb Streptococcus 
mutans GS5 
? 30 +2 MKSNLLKINNVTEMEKNMVTLIKDEDMLA
GG  
IGTTVVNSTFSIVLGNKGYICTVTVECMRNCSK  
predicted structure 
Yonezawa et al., 
2005 
? 32 +2 MKEIQKAGLQEELSILMDDANNLEQLTAG        STPACAIGVVGITVAVTGISTACTSRCINK 
BHT Streptococcus 
ratti BHT 
3375 32 +1 MKEIQKAGLQEELSILMDDANNLEQLTAG IGTTVVNSTFSIVLGNKGYICTVTVECMRNCQ 
structure predicted  
Hyink et al., 2005 
2802 30 +2 MKSNLLKINNVTEVEKDMVTLIKDEDMEL
AGG 
     STPACAIGVVGITVAVTGISTACTSRCINK 
predicted structure 
Lichenicidin Bacillus licheni-
formis DSM13/ 
VK21/ ATCC14580 
3250 32 +1 MSKKEMILSWKNPMYRTESSYHPAGNILK
ELQEEEQHSIAGG  
TITLSTCAILSKPLGNNGYLCTVTKECMPSCN 
2-Oxobuturyl (1) 
Begley et al., 2009; 
Dischinger et al., 
2009; Shenkarev et 
al., 2010, Caetano 
et al., 2011 
3021 32 +2 MKTMKNSAAREAFKGANHPAGMVSEEELK
ALVGG↓NDVNPE  
TTPATTSSWTCITAGVTVSASLCPTTKCTSRC 
2-Oxobuturyl (1) 
Cytolysin Enterococcus 
faecalis V583 
4164  21 +1 MLNKENQENYYSNKLELVGPSFEELSLEE
MEAIQGS↓GDVQAE  
TTPACFTIGLGVGALFSAKFC 
structure predicted (2 thioether bridges confirmed) 
Booth et al., 1996 
2631 38 +1 MENLSVVPSFEELSVEEMEAIQGS↓GDVQ
AE 
TTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHC 
unknown structure (1 thioether bridge confirmed)  
Pneumo-
coccin 
Streptococcus 
pneumonia R6 
? 38 +1 MTNFNSNEKFCGKSLKSLSADEMSLIYGA
SDGAEPR 
WTPTPIILKSAAASSKVCISAAVSGIGGLVSYNNDCLG 
structure not fully elucidated (two thioether bridges 
confirmed of a NisBC modified chimeric peptide) 
Majchrzykiewicz et 
al., 2010 
 
 ? 30 +4 MKNDFVIGKSLKELSLEEMQLVYGGTDGA
DPR 
STIICSATLSFIASYLGSAQTRCGKDNKKK 
structure not fully elucidated (two thioether bridges 
confirmed of a NisBC modified chimeric peptide) 
Enterocin W Enterococcus 
faecalis NKR-4-1 
3256 30 0 MKKEELVGMAKEDFLNVICENDNKLENSG
A 
KCPWWNLSCHLGNDGKICTYSHECTAGCNA 
structure predicted 
disulfide bridge (2; 9) 
Sawa et al., 2012 
2728 29 +2 MTELNKRLQLKRDVSTENSLKKISNTDET
HGG 
VTTSIPCTVMVSAAVCPTLVCSNKCGGRG 
structure predicted 
Class III lantibiotics / lantipeptides  (lack antibiotic activity, but exhibit different functions such as morphogenetic ones) 
SapB Streptomyces 
coelicolor 
2026 21 0 MNLFDLQSMETPKEEAMGDVET TGSRASLLLCGDSSLSITTCN 
structure predicted 
Kodani et al., 2004 
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SapT Streptomyces 
tendae 
2032 21 0 not annotated  YTQGCSGLCTIVICATVVICG Kodani et al., 2005 
AmfS   Streptomyces 
griseus 
? 19 -1 MALLDLQAMDTPAEDSFGELRTGS QVSLLVCEYSSLSVVLCTP 
unknown structure 
Ueda et al., 2002 
Prochlorosin Prochlorococcus 
MIT9313 
- 17 
32 
- in total 29 putative LanA genes with homologous leaders; modified by one LanM enzyme (experimentally 
shown for 6 peptides; different Lan ring structures)  
Li et al., 2010 
Labyrinthopeptins (labionin containing peptides; LabKC modified) 
Labyrintho-
peptin A1 
Actinomadura 
namibiensis DSM 
6313 
? 20 -1 MASILELQDLEVERASSAA DSNASVWECCSTGSWVPFTCC 
Labionin (2+5+9; 11+14+19); Disulfide bridge (10+20) 
Müller et al., 2010 
Labyrintho-
peptin A3 
Actinomadura 
namibiensis DSM 
6313 
? 21 -1 MASILELQDLEVERASSAA  SNASVWECCSTGSWVPFTCC 
Labionin (1+4+8; 10+13+18); Disulfide bridge (9+19) 
Müller et al., 2010 
Labyrintho-
peptin A2 
1923 18 -1 MASILELQNLDVEHARGENR    SDWSLWECCSTGSLFACC 
Labionin (1+4+8; 10+13+17); Disulfide bridge (9+18) 
Lantibiotic peptides without classification/unknown structure and biosynthesis  
Lactocin S Lactobacillus sake 
L-45 
3764 37 +1 MKTEKKVLDELSLHASAKMGARDVESSMN
AD 
STPVLASVAVSMELLPTASVLYSDVAGCFKYSAKHHC 
D-Ala (7;11;19)  
Mortvedt and Nes, 
1990; Skaugen and 
Nes, 1994 
Pediocin PD-1 Pediococcus 
damnosus  
2866 27 ? unknown  KKIKKSXSGDIXXLXXEXDHLAXXXXX 
only partially identified, no structure  
Bauer et al., 2005 
Carnocin  
UI 49 
Carnobacterium 
pisciola 
4635 35
37 
? unknown  GSEIQPR  
only partially identified (N-terminus), no structure  
Stoffels et al., 1992 
Paenibacillin Paenibacillus 
spec. 
2983 30 +4 not annotated  ASIIKTTIKVSKAVCKTLTCICTGSCSNCK 
predicted structure; N-Acetylalanine (1)  
He et al., 2007 
unnamed Bifidobacterium 
longum DJO10A 
? ? ? MSINEKSIVGESFEDLSAADMAMLTDRNDDGVAPASLSFAVSVLSVSFSACSVTVVTRLASCGNCK  
gene cluster identified, predicted: LanD  AviCys or AviMeCys, unknown structure  
Lee et al., 2008 / 
2011 
Venezuelin Streptomyces 
venezuelae 
? ? ? MENHDIELLAHLHALPETDPVGVDGAPFAA TCECVGLLTLLNTVCIGISCA  
LanA identified, different variants in vitro modified, three putative cleavage sites (GA; AA; PFA) predicted, 
structure partially elucidated 
Goto et al., 2010 
Lantibiotic related peptides (formerly falsely classified as lantibiotics)  
Cypemycin Streptomyces 
spec. 
2094 22 +1 MRSEMTLTSTNSAEALAAQDFANTVLSAA
APGFHADCETPAM 
ATPATPTVAQFVIQGSTICLVC  
AviCys (19+22); Linearidin 
Komiyama et al., 
1993; Claesen and 
Bibb, 2010 
Sublancin 168 Bacillus subtilis 
168 
3876 37 +3 MEKLFKEVKLEELENQKGS  GLGKAQCAALWLQCASGGTIGCGGGAVACQNYRQFCR  
Disulfide bridge (7+36; 14+29); Glycosylation (22);  
S-linked glycopeptide 
Paik et al., 1998 
Oman et al., 2011 
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Material and Methods  
 
Microbiological methods  
Bacterial strains, culture media and growth conditions  
All bacterial strains are listed in table 2.1. For long time storage glycerol stocks were 
prepared. To this end, cells were cultivated overnight, mixed with sterile glycerol to a final 
concentration of 50% (v/v) and stored at −75°C. Strains were recovered from frozen samples 
by streaking out on appropriate solid agar plates. If not mentioned otherwise, cultures were 
maintained at 37°C. Fluid cultures were incubated in a shaking water bath (JULABO 
Labortechnik, Seelbach, Germany; 200 rpm for Bacillus strains, 100-160 rpm for all other 
strains) or on an orbital shaker (170 rpm, Infors, Bottmingen, Switzerland). For preparation 
of solid culture media, 14 g agar (Oxoid, Wesel, Germany) were added to 1 l of fluid medium 
prior autoclaving. Agar plates were cultivated in incubators (Heraeus, Langenselbold, 
Germany). Bacillus strains were grown in tryptic soy broth (TSB, Oxoid) or on tryptic soy agar 
(TSA, Oxoid). For lantibiotic production, producers and their mutants were cultured in 
synthetic two-fold Bacillus production medium (2xBPM; Bierbaum et al., 1995). For aerobic 
cultivation, Erlenmeyer flasks were maximally filled with 1/100 of the total volume and were 
closed by a silicon vent containing an ultra-fine glass microfiber filter (BugStopper™, 
Whatman/GE Healthcare, USA). Streptococci, enterococci and staphylococci were grown on 
Columbia blood agar plates (Becton and Dickinson, Heidelberg, Germany). For antimicrobial 
activity testing, indicator strains were maintained in Mueller Hinton (MH) broth (Difco, 
Detroit, USA) and on MH agar plates (Difco). Escherichia coli strains were cultivated in 
lysogeny broth (LB; Bertani, 1951).  
Nostoc punctiforme cells were stored in 1 ml stocks containing 5% DMSO and were 
recovered by inoculation of 5 ml media with 500 µl totally thawed stock culture (Soule et al., 
2007). In order to remove DMSO, cells were harvested (8,000g, 10 min, RT) and resuspended 
in 2 ml fresh medium (ATCC 619). This cell suspension was used for inoculation of 10 ml, 20 
ml or 50 ml cultures which were incubated under light (16 h per day) with slow shaking (80 
rpm) at 25°C for up to two weeks.  
For genetically manipulated strains, antibiotics were added to selection media in the 
following concentrations: ampicillin [40 µg/ml; AMP]; erythromycin [25 µg/ml; EM]; 
chloramphenicol [20 µg/ml; CM] and kanamycin [20 µg/ml; KANA].  
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Table 2.1: Bacterial strains used in this study. 
 
Strain/DNA Relevant characteristics Source/references 
Microbial strains involved in lantibiotic production 
Bacillus licheniformis DSM 13 lichenicidin producer  DSMZ 
B. licheniformis MW3 transformable variant of DSM 13  Waschkau et al., 2008 
B. licheniformis MW3 LicM1INT licM1 insertion mutant  this study 
B. licheniformis MW3 LicM2INT licM2 insertion mutant  this study 
Bacillus sp. HIL Y-85,54728 mersacidin producer Sanofi-Aventis, 
Frankfurt, Germany 
Bacillus amyloliquefaciens FZB42 harbors the 5’ part of the mersacidin 
gene cluster (mrsKR2FGE) 
Prof. Borriss, Berlin, 
Germany 
B. amyloliquefaciens mrs1 mutant carrying the mersacidin gene 
cluster; mrsA is replaced by ermB 
(mrsKR2FGEermBR1DMT) 
A.M. Herzner, 2008 
B. amyloliquefaciens mrs1  
+ pOPAR1 
mersacidin producing mutant: mrs1 
strain harboring the in trans (pOPAR1) 
completed mersacidin gene cluster 
this study 
B. amyloliquefaciens mrs1  
+ pPAR1/1 
mersacidin producing mutant: mrs1 
mutant harboring the in trans 
(pPAR1/1) completed mersacidin gene 
cluster  
this study 
Nostoc punctiforme ATCC 29133 putative lantibiotic producer:  
predicted gene cluster of puncticin 
ATCC 
Caldicellulosiruptor bescii DSM 
6725 
putative lantibitiotic producer: 
predicted gene cluster of besciin 
genomic DNA ( DSMZ) 
Intermediate cloning hosts 
E. coli SCS110 intermediate cloning host for plasmids 
previous to transformation into 
Bacillus; dcm- and dam- 
Yanisch-Perron et al., 
1985 
E. coli JM109 / E. coli JM83 intermediate cloning host for 
recombinant plasmid construction  
Yanisch-Perron et al., 
1985 
Strains involved in heterologous expression of lantibiotic biosynthesis genes   
E. coli Bl21 strain for recombinant protein 
expression; λDE3-lysogen, T7 RNA 
polymerase under control of the 
lacUV promotor 
Studier and Moffatt, 
1986 
E. coli C43/C41 Bl21(DE3) derivatives for expression of 
toxic proteins  
Miroux and Walker, 
1996 
 
For antimicrobial susceptibility testing the following indicator strains were used: Bacillus 
cereus DSM 31 (DSMZ), B. halodurans DSM 18197 (producer of the two-peptide lantibiotic 
haloduracin; DSMZ), B. megaterium ATCC 13632 (KM; ATCC), B. subtilis 168 (DSM 402; 
DSMZ), Enterococcus faecium BM 4147–1 (Leclercq et al., 1988), E. faecium L4001 (clinical 
isolate), Lactobacillus sake 790 E2 (laboratory stock), Lactococcus lactis NCTC 497 (NCTC), 
Micrococcus luteus DSM 1790 (lantibiotic susceptible control strain; DSMZ), M. luteus ATCC 
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4698 (lantibiotic susceptible control strain; ATCC), Staphylococcus aureus ATCC 33592 
(MRSA; ATCC), S. aureus ATCC 29213 (MSSA; ATCC), S. aureus 1450/94 (northern German 
epidemic strain; NCS), S. aureus Cowan ATCC 12598 (ATCC), S. aureus Newman NCTC 8178 
(NCTC), S. aureus SG511 (lantibiotic susceptible control strain; Sass and Bierbaum, 2008), S. 
aureus Wood 46 (ATCC 10832; ATCC), Staphylococcus carnosus TM300 (Rosenstein et al., 
2009), Staphylococcus gallinarum Tü 3928 (producer of the lantibiotic gallidermin; Kellner et 
al., 1988), Staphylococcus saprophyticus DSM 20229 (DSMZ), Staphylococcus simulans 22 
(Bierbaum and Sahl, 1987), S. aureus LT440/09 (community acquired MRSA; clinical isolate), 
S. aureus LT420/09 (MRSA; clinical isolate), S. aureus LT819/09 (MRSA; Rhine-Hessen 
epidemic strain; clinical isolate), Enterococcus faecalis BM4147_1 (clinical isolate) and 
Streptococcus pyogenes O-19310 (clinical isolate). 
 
Chemicals, antibiotics and solvents  
If not mentioned otherwise, all chemicals and solvents used in this work were of analytical 
grade and were obtained from the following suppliers: AppliChem (Darmstadt, Germany), 
Sigma-Aldrich (Taufkirchen, Germany) or Merck (Darmstadt, Germany). For Maldi-TOF 
analysis and HPLC purification MilliQ water (MilliQ Biocel System A10; Millipore GmbH, 
Schwalbach, Germany) was used for preparation of solutions and sample dilutions.  
For commercially used antibiotics, 100 mg/ml stock solutions were prepared and stored at 
-20°C. Ampicillin and kanamycin were dissolved in sterile MilliQ water whereas 
chloramphenicol and erythromycin were solved in ethanol (99%). Mersacidin was kindly 
provided by Sanofi-Aventis and stock solutions (8 mg/ml) were prepared in 80% ethanol. 
Nisin and Pep5 stocks (AG Sahl, University Bonn) of 8 mg/ml were generated in 0.1 M HCl or 
MilliQ water, respectively.  
 
Sterilization of media, equipment and bacterial cultures  
Plastic labware, media and chemical solutions were sterilized by autoclaving at 121°C for 20 
min (Varioklav 75S, H+P Labortechnik AG, Oberschleißheim, Germany). Solutions that 
contained heat instable substances were sterilized by filtration using sterile syringe filters 
with 0.2 or 0.4 µm pore size (Supor®Membrane; Pall Life Science Corporation, Ann Arbor, 
USA). Glass and metallic labware were heat sterilized for 4 h at 200°C (Kelvitron®, Heraeus). 
Bacterial cultures and contaminated labware were autoclaved at 134°C for 30 min.  
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Determination of the optical density of a bacterial culture   
The optical density of bacterial cultures was determined at a wavelength of 600 nm (OD600) 
using an UV-160 spectral photometer (Shimadzu, Duisburg, Germany). Cultures with an 
optical density higher than 0.3 were diluted in appropriate media. OD 1 was assumed to 
reflect a cell density of 2x108 cells/ml for Bacillus strains and a cell density of 2x109 for S. 
aureus and M. luteus (Heike Brötz, phD thesis, 1998). 
 
Methods in Molecular Genetics  
Purification of nucleic acids  
Genomic DNA of Bacillus strains was prepared using the PrestoSpinD Bug Kit according to 
the recommendations of the supplier (Molzym, Bremen, Germany) with following 
exceptions: 1. for lysis, cells were incubated at 37°C for 30 min in buffer 1 that had been 
supplemented with 10 µl lysozyme (100 mg/ml); 2. DNA was eluted in 100 µl pre-heated 
(70°C) MilliQ water and was stored at -20°C.  
Chromosomal DNA of N. punctiforme was isolated using the GENOMICTip20 Kit (Qiagen, 
Hilden, Germany). Cells were grown for 2-3 weeks and harvested by centrifugation (8,000 g, 
RT, 10 min). In order to remove cell surface polysaccharides that might block cell lysis, cells 
were washed in 1/10 of total culture volume with 5 M NaCl, 1 M sodium iodate and MilliQ 
water. Each washing step was repeated twice. Cells were aliquoted (250 µl), lyophilized and 
stored at -20°C until further processing. Cell pellets were thawed on ice and pestled using a 
metal eppi pistil. For cell lysis, cells were resuspended in 1 ml buffer 1 containing 200 mg/ml 
lysozyme and were incubated at 37°C for 2 hours. Genomic DNA was further purified 
following the manufacturer's instructions.  
Plasmids were isolated using the Gene-JetTM Plasmid Miniprep Kit (Fermentas) according to 
the protocol of the supplier. Cell lysis of Bacillus strains was performed by adding 10 µl 
lysozyme [100 mg/ml] to the resuspension buffer and incubation at 37°C for 30 min. Plasmid 
DNA was eluted in 40 µl MilliQ water. For elution of plasmids larger than 5 kb, MilliQ water 
was pre-heated up to 80°C. All plasmids used in this study are listed in table 2.2. Quality and 
quantity of nucleic acids were analyzed by agarose gel electrophoresis and 
spectrophotometry.  
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Overview over plasmids used in this study 
All plasmids used in this study are listed in table 2.2. Gene inactivation in Bacillus strains was 
performed by plasmid integration and homologous recombination using recombinant 
derivatives of the thermo-sensitive shuttle vector pMAD (Arnaud et al., 2004; figure 2.1). 
Recombinant vectors that contain up to 500 bp of the N- and C-terminal sequences of target 
genes were introduced into the corresponding restrictions sites of the mcs. Resulting vectors 
were introduced in E. coli SCS110 as intermediate cloning host and selected on LB agar 
plates containing ampicillin at 37°C. Finally, these vectors were transformed into Bacillus 
strains and selected on TSA agar plates containing the selection marker erythromycin (5 
mg/l) at 30°C. Homologous recombination and insertion of the vectors into target genes was 
performed by overnight cultivation at the non- permissive temperature (45°C) in TSB (25 
mg/l EM) and, subsequent, plating onto TSA agar plates (25 mg/l EM).  
 
 
 
Figure 2.1: Physical map of pMAD (Arnaud et al., 2004). The shuttle vector pMAD contains a 
thermo-sensitive origin of replication and confers resistance to ampicillin (bla) and erythromycin 
(ermC). Blue-white screening of recombinants is facilitated by a constitutively expressed β-
galactosidase (bgaB). 
 
Vectors of the pET expression system (Merck-Novagen, Darmstadt, Germany) were 
employed for heterologous expression of recombinant, HIS-tagged proteins in E. coli. In this 
system, proteins of interest are expressed under control of a strong bacteriophage T7lac 
promoter and are repressed by the LacI repressor protein. Expression hosts are lysogenic for 
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bacteriophage DE3 and, therefore, carry a chromosomal copy of the T7 RNA polymerase 
gene under control of a lacUV5 promoter, which is also repressed by LacI. By addition of 
isopropyl-β-D-thiogalactopyranoside (IPTG) to bacterial cultures, LacI is inactivated which 
results in the expression of T7 polymerases and, consequently, in expression of target genes.  
In pET22b, the coding sequence of six histidine residues is located downstream of the 
multiple cloning site (mcs) and enables a C-terminal fusion of the HIS-TAG to target proteins 
(figure 2.2). pET28b harbors two putative HIS-TAG sequences for expression of C- or N-
terminally HIS-tagged proteins (figure 2.2).  
 
    
 
Figure 2.2: Physical map of expression vectors pET22b and pET28a (Novagen/Merck chemicals). 
Plasmids confer resistance against ampicillin (Ap) or kanamycin (Kan). HIS-TAG coding sequences are 
located next to the mcs and allow cloning of N- or C-terminal HIS-tagged proteins.  
 
Photometric determination of nucleic acid concentration and purity 
UV-light based photometric determination of nucleic acid concentrations was performed 
using a Nanodrop spectrometer (Nanodrop Technologies, Wilmington, USA) at 260 nm. 
Purity was determined by the quotient of extinction at 260 nm over 280 nm. A quotient 
below 1.8 indicated contamination with proteins.  
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Table 2.2: Plasmids used in this study. 
Plasmid Information Aim Source 
pMAD shuttle vector harboring a 
temperature sensitive ORI, AMPr, 
EMr 
homologous recombi-
nation in Bacillus  
Arnaud et 
al., 2006 
pMADLicM1AC pMAD derivative carrying an approx. 
500 bp C- and N-terminal fragment 
of bli4126  
knock out of LicM1 this study 
pMADLicM1AC pMAD derivative carrying an approx. 
500 bp C- and N-terminal fragment 
of bli4128 
knock out of LicM2 this study 
pET22b HIS-TAG expression vector, AMPr heterologous expres-
sion of C-terminally 
HIS-tagged proteins in 
E. coli 
Novagen 
pET22PunM pET22 derivative harboring the C-
terminally HIS-tagged punM  
heterologous expres-
sion of PunM  
this study 
pET22AnaM pET22 derivative harboring the C-
terminally HIS-tagged anaM  
heterologous expres-
sion of AnaM 
this study 
pET28b HIS-TAG expression vector, KANAr heterologous expres-
sion of N-terminally 
HIS-tagged proteins in 
E. coli 
Novagen 
pET28PunA1 pET22 derivative harboring the N-
terminally HIS-tagged punA1 
heterologous expres-
sion of the PunA1 pre-
peptide  
this study 
pET28PunA1_XA pET22 derivative harboring the N-
terminally HIS-tagged punA1 
including a XA-factor cleavage site 
heterologous expres-
sion of the PunA1 pre-
peptide 
this study 
pET28AnaA pET22 derivative harboring the N-
terminally HIS-tagged gene anaA 
heterologous expres-
sion of the AnaA pre-
peptide  
this study 
pET28AnaA_XA pET22 derivative harboring the N-
terminally HIS-tagged besciin 
including XA-factor cleavage site 
heterologous expres-
sion of the AnaA pre-
peptide 
this study 
pUC19 shuttle vector; AMPr, CMr intermediate cloning 
vector for lantibiotic 
precursors 
Yanisch-
Perron et 
al., 1985 
pUC19AnaA pUC19 derivative harboring the 
structural gene anaA 
templates for site 
directed mutagenesis 
of protease cleavage 
sites 
this study 
pUC19PunA1 pUC19 derivative harboring the 
structural gene punA1 
this study 
pOPAR1 pCU1 derivative harboring mrsR1 and 
mrsA including its operator structure  expression of the lanti-biotic mersacidin in  
B. amyloliquefaciens  
Schmitz et 
al., 2006 
pPAR1/1 pCU1 derivative harboring mrsR1 and 
mrsA  
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DNA sequencing 
DNA sequencing was performed by Sequiserve (Vaterstetten, Germany) or Seqlab 
(Göttingen, Germany) employing the Sanger chain determination method (Sanger et al., 
1977). For sequencing, recombinant plasmids and PCR products were dissolved in sterile 
MilliQ water. Integrity of recombinant plasmids was confirmed by sequencing of inserts with 
vector-specific primers supplied by Sequiserve, if available.  
 
Agarose gel electrophoresis  
Standard agarose gel electrophoresis was used to analyze and separate DNA fragments 
employing 0.8-2% agarose gels (Top VisionTM LE GQ agarose, Fermentas) in a horizontal 
electrophoresis apparatus (Peqlab, Erlangen, Germany) according to Sambrook et al., 1989. 
DNA was stained with ethidium-bromide and visualized using ImageMaster VDS (GE 
Healthcare/Pharmacia).  
 
Polymerase chain reaction (PCR)  
Amplification of DNA was performed by the polymerase chain reaction in accordance with 
Mullis et al., 1986. DreamTaq Polymerase (Fermentas) was used for standard PCR batches. 
For cloning or subsequent sequencing DNA was amplified using PhusionTMHF DNA 
Polymerase (NEB, Frankfurt/Main, Germany) as detailed in the manual. Desoxynucleotides 
were ordered as premixed solutions (25 mM each; Fermentas). PCRs were performed in 50 
µl batches on the PCR express Thermal Cycler (Hybaid, ThermoLifeScience, Engelsbach, 
Germany) or the SensoQuest Labcycler (SensoQuest, Göttingen, Germany).  
All primers were synthesized by Metabion (Martinsried, Germany) or Microsynth (Balgach, 
Switzerland) and are listed in table 2.3. Sequencing and standard cloning primers were 
designed using the Primer3 tool: http://biotools.umassmed.edu/bioapps/primer3_www.cgi.  
 
Enzymatic modification of DNA  
Plasmids and PCR products were digested using restriction enzymes (FastDigestTM) from 
Fermentas. Digestion was performed as detailed in the manual. For cloning of large inserts (> 
2000 bp), vector backbones were dephosphorylated using alkaline dephosphatase 
(Fermentas) during digestion. After heat inactivation (10 min, 65°C) digested nucleic acids 
were stored at -20°C until further use.  
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Purification of DNA fragments and gel extraction from agarose gels  
PCR fragments were purified using the GeneJetTM PCR Purification Kit (Fermentas). For gel 
extraction, bands of interests were cut from a 0.6% agarose gel with a scalpel and DNA 
extraction was performed with the GeneJetTM Gel Extraction Kit (Fermentas). Both kits were 
used according to the manufacturer’s instructions with following changes: for cloning DNA 
was eluted in 35 µl pre-heated (50°C) MilliQ water. 
 
DNA ligation  
Recombinant vectors were ligated either for 1 h using T4 DNA Ligase (5u/µl) from Fermentas 
(20 µl total volume) or overnight using T4 DNA Ligase (10 u/µl) from Roche (10 µl total batch 
volume). For sticky end ligations a molar ratio of 3:1 (insert to vector) was calculated. For 
ligation of large inserts, a ratio of 5:1 was chosen and an additional incubation step was 
performed prior ligation: insert and vector fragments were mixed and subsequently 
incubated for up to 10 min at 45°C. For blunt end ligation a molar ratio of 1:2 was used and 
PEG (poly-ethylen-glycol, NEB) was supplemented. Ligations were performed according to 
the protocol of the manufactures. Ligation batches were used in transformation experiments 
without prior storage. 
 
Site directed mutagenesis  
For introduction of single point mutations, standard cloning PCRs were performed using 
primers containing the desired base exchange.  
In order to introduce up to seven point mutations, inserts of interest were cloned into 
pUC19. The resulting recombinant vectors were used as templates for a PCR based site 
directed mutagenesis employing the QuickChangeTM Site-Directed-Mutagenesis Kit (Agilent 
technologies, Waldbronn, Germany) and two primers, comprising the desired mutations. 
Both mutagenic primers, each complementary to opposite strands of the vector, were 
extended employing PfuUltra HF DNA polymerase (Agilent) without primer displacement. 
Parental plasmids, that lacked the desired mutations, were digested by DpnI which is specific 
for (hemi)methylated DNA. Subsequently, batches were transformed into super-competent 
E. coli XL-1 Blue cells (Agilent).  
Mutagenesis was performed following the suppliers’ instructions. Primers containing the 
desired exchanges were designed by the following tool: http://www.genomics.agilent.com/ 
CollectionSubpage.aspx?PageType=Tool&SubPageType=ToolQCPD&PageID=2296.  
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Table 2.3: Oligonucleotides used in this study.  
Name of the primer Template  Restriction 
sites 
Sequence (5’ - 3’)  TM 
B. licheniformis  
for∆LicM1FragmentA licM1: bp 4-486  BamH1 GATGGATCCAATGAAAAATCCGCCG  60 
rev∆LicM1FragmentA Mlu1 TCGACGCGTTCGCCCTTCAATTGATCTTC 60 
for∆LicM1FragmentC licM1: bp 2636-3156  Mlu1 TTCACGCGTCCTGGCATTTGAAAAGCAGC 62 
rev∆LicM1FragmentC  BglII TTGAGATCTAAACACGTTTTCTCTTTTAAAAGC 62 
forDelLicM2A licM2: bp 4-488  Mlu1 ATTACGCGTTGTGATAAGTGTTCTCGTCGC 62 
revDelLicM2A Nco1 GCACCATGGGTTTTCTTCGCCAAAGGGATG 62 
forDelLicM2C  licM2: bp 2596-3108  BamH1 ATCGGATCCGCCCGTCGGAATATCGAGA 62 
revDelLicM2C Mlu1 CGGACGCGTTGATACACGATGACAGCTGC 62 
forhomRecLicM1 B. licheniformis:  
bp 3949702-3949722  
- TGAATCTTCTTATCATCCAGC 58 
revhomRecLicM2 B. licheniformis:  
bp 3953148-3953168  
- GCATTTGGATGAAGGTCTTTC 60 
pMADmcs1 pMAD: sequencing  - CTAGCTAATGTTACGTTACAC 58 
pMADmcs2neu  GAAGCGAGAAGAATCATAATG 58 
Heterologous expression of lantibiotic biosynthesis genes 
forAnaApuc19 C. bescii:  
bp 1199426-1199805 
HindIII GACAAGCTTGTGCGCACAAAGGGTTATG 62 
revAnaApuc19 EcoR1 CACCTTAAGTGATACGGCGAGAAGACTCG 62 
AnaA_XA_Muta_sense pUC19AnaA - AAAGAAATTCAAGAGCAGAATTTGCCAGAAATAGAAGGTA
GAGGTACTCCAACTGTAGTTGTTGGTGTG 
60 
AnaA_XA_Muta_antisense - CACACCAACAACTACAGTTGGAGTACCTCTACCTTCTATTTC
TGGCAAATTCTGCTCTTGAATTTCTTT 
60 
forAnaApET28 pUC19AnaA 
pUC19AnaA_XA 
Nde1 ATACATATGAAAGAGTCTACTATCATTAAAAATC 62 
revAnaApET28 Xho1 AAA CTCGAG TTACCTCATTCTGCAGCTTCTA 62 
forAtheMHISpET22 anaM  Nde1 GAACATATGATGAAACAAGATAATAATTGGCT 62 
revAtheMHISpET22 Xho1 TTTCTCGAGTTCCAAACATAATATTTCTGGC 62 
revAnaM1EcoR1 EcoR1 TTGAGAATTCTTAAAACCTCTGT 62 
forAnaM1EcoR1 EcoR1 TAAGAATTCTCAACAACTCAGTT 62 
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Table 2.3 - continued  
Name of the primer Template  Restriction 
sites 
Sequence (5’ - 3’)  TM 
SeqpET22AnaMAB1 internal anaM primer for 
sequencing pET22AnaM:  
bp 1908-1929 
- TTCCCTTTCATTATCGGATTG 59 
SeqpET22AnaMAB2 internal anaM primer for 
sequencing pET22AnaM:  
bp 943-962 
- TCCCAATTTTGCCATAAACA 60 
forPunA1pUC19 N. punctiforme:  
bp 6250388-6250756  
EcoR1 AGAGAATTCAACACCGCACAAAACAAGTG 60 
revPunA1pUC19 HindIII TGGAAGCTTCCTGGCTCGTGCTTCTCTAA 60 
PunA1_XA_Muta_sense pUC19PunA - AAAGAAATTCAAGAGCAGAATTTGCCAGAAATAGAAGGT
AGAGGTACTCCAACTGTAGTTGTTGGTGTG 
60 
PunA1_XA_Muta_antisense - CACACCAACAACTACAGTTGGAGTACCTCTACCTTCTATTT
CTGGCAAATTCTGCTCTTGAATTTCTTT 
60 
forPunA1pET28 pUC19PunA1 
pUC19PunA1_XA 
Nde1  AGACATATGTTACACCAAATCAAAGAATTA 64 
revPunA1pET28 Xho1 CTACTCGAGTTATCTCGTTGGACAGTCG 64 
forpET22bHISPunM punM Nde1 TCACATATGTCTCAACTATTTGTTCAATC 62 
revPunMBamHIMut BamH1 ATCAGGATCCAGAATCGCTGTC  62 
forPunMBamHIMut BamH1 TTCTGGATCCTGATGGTAGTATC 62 
revpET22bHISPunM Xho1 TTGCCTCGAGTTCCCATAACAGCACCGA 62 
seqPunM1 internal punM primer for 
sequencing pET22PunM 
- CTGAGGAGCTTGCTGAGG 58 
B. amyloliquefaciens FZB42 
GyrA_F gyrA: 41-1066 bp - CAGTCAGGAAATGCGTACGTCCTT 58 
GyrA_R - CAAGGTAATGCTCCAGGCATTGCT 58 
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Transformation of Escherichia coli strains  
Preparation of electro-competent E. coli strains (Dower et al., 1988) 
For generation of electro-competent E. coli strains, a main culture of 500 ml LB, inoculated 
with 500 µl of an overnight grown pre-culture, was grown to an optical density of 0.5. After 
incubation on ice for 30 min, cells were harvested by centrifugation (5,000g, 4°C, 10 min) 
followed by three washing steps with 500 ml and 250 ml pre-chilled MilliQ water and with 20 
ml pre-chilled 10% glycerol solution. Finally, cells were resuspended in 0.8 ml glycerol (10%) 
and frozen for long time storage at -75°C in 50 µl aliquots.  
 
Transformation of electro-competent E. coli strains  
Frozen cells were thawed on ice, immediately mixed with 2 µl of ligation batches or 100 ng 
plasmid DNA, followed by electroporation employing a pre-chilled electro cuvette (1 mm) in 
a Biorad gene pulser (program EC2, Biorad, Munich, Germany). Cells were resuspended in 1 
ml LB and, for regeneration, incubated under shaking at 37°C for up to 1 h. Finally, 
transformants were plated onto appropriate selection media (undiluted, 1:10, 1:100 diluted 
and concentrated samples).  
 
Preparation of chemo-competent (CaCl2) E. coli strains 
For preparation of super-competent cells (Morrison, 1977), E. coli strains were freshly 
streaked out onto LB agar plates. Cultures (50 ml TYM media) were inoculated with 100 µl of 
an overnight grown LB pre-culture and cells were aerobically grown to a cell density of 0.6. 
Cells were harvested (5,000 g, 4°C, 5 min, Acc. 9, Br. 7) and the resulting cell pellets were 
resuspended in 5 ml of pre-chilled and filter-sterilized TFBI. After centrifugation cells were 
resuspended in 2.5 ml pre-chilled TFBII medium and aliquoted into 100 µl samples. Cells 
were shock-frozen in liquid nitrogen and stored at -75°C until further use.  
 
Table 2.4. Media for preparation of chemo-competent E. coli strains.   
 
Medium Volume Chemical ingredients  
TYM broth 50 ml 1 g Bacto-Trypton (Difco); 0.25 g yeast extract (Difco); 292 mg NaCl; 123 
mg MgSO4 
TFBI 50 ml  5 M potassium acetat (0.3 ml); MnCl2 (495 mg); 2 M KCl (2.5 ml); 1 M CaCl2 
(0.5 ml) and glycerol (7.5 ml)  
TFBII 50 ml 2 M MOPS pH7 adjusted with 5 M KOH (2.5 ml); 2 M KCl (0.25 ml); 1 M 
CaCl2 (3.7 ml) and glycerol (7.5 ml) 
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Transformation of chemo-competent (CaCl2) E. coli strains (Morrison, 1977) 
Frozen chemo-competent E. coli cells were thawed on ice immediately before use. 50 µl cell 
suspension were mixed with DNA (10-20 µl of a ligation batch or 100-200 ng plasmid DNA) 
and incubated on ice for 30 min. For transformation, cells were exposed to a heat shock 
treatment at 42°C for 30 seconds followed incubation on ice for 3 min. Transformed cells 
were resuspended in 500 µl pre-warmed LB. After regeneration for 45-60 min at 37°C with 
shaking, 100 µl of cell suspension were plated onto appropriate agar plates in 10- and 100-
fold dilutions, and as undiluted and concentrated samples.  
 
Transformation of Bacillus strains  
Natural competence transformation of B. amyloliquefaciens FZB42 and its mutants  
B. amyloliquefaciens FZB42 is a naturally competent Bacillus strain. It harbors a competence 
mediating signal cascade system consisting of kinases, transporters and transcription factors 
that allow uptake of heterogeneous DNA fragments resulting in integration of these 
fragments into its chromosomal DNA by homologous recombination.  
In order to generate genetically manipulated B. amyloliquefaciens strains, a modified 
protocol according to Anagnostopoulos and Spizizen (1961) was employed. Cells were 
aerobically grown at 37°C in 20 ml HS medium to an OD600 of 1.5 to 2. Cells were harvested 
(5,000 g, 5 min, RT) and resuspended in 20 ml LS medium. After 45 min incubation, EDTA 
was added followed by an additional incubation for 45 min. In successful transformation 
batches, 1 ml culture was mixed with 8 µg of linearized plasmid DNA followed by incubation 
for additional 2 h. 300 µl transformants were plated onto appropriate selective agar plates.  
 
Table 2.5: Solutions and media for competence transformation of Bacillus strains.  
 
Solution Volume Chemical ingredients 
10fold- 
S-Base 
100 ml 2.0 g (NH4)2SO4; 14.0 g K2HPO4; 6.0 g KH2PO4; 1.0 g NaCitrate x 2 H20; ad 
100 ml aqua dest.; after autoclaving 1 M MgSO4 (0.1 ml) was added.  
LS medium 
(low sulfate) 
20 ml sterile aqua dest. (16.5 ml); 10fold-S-Base (2.0 ml); 20% glucose (0.5 ml); 
1 mg/ml L-Trp (0.1 ml); 1% caseine hydrolysate (0.1 ml); 0.5 M spermine 
(0.2 ml); 0.1 M MgCl2 (0.5 ml); 0.1 M CaCl2 (0.1 ml) 
HS medium 
(high sulfate) 
20 ml sterile aqua dest. (13.4 ml); 10fold S-Base (2 ml); 20% glucose (0.5 ml); 1 
mg/ml L-Trp (1 ml); 1% caseine hydrolysate (0.2 ml); 2% yeast extract (1 
ml); 8% L-Arg 0.4% L-His (2 ml) 
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Protoplast transformation of natural competence deficient B. licheniformis DSM 13 
B. licheniformis DSM 13 harbors an insertion of an IS element in the competence gene comP 
and therefore this organism cannot be transformed by natural competence transformation. 
Transformation was performed according to the protoplast transformation protocol 
published by Waschkau et al. (2008) and use of the transformable mutant Bacillus 
licheniformis MW3.  
 
Moleculargenetic bioinformatic tools and accession numbers  
For bioinformatic analysis of DNA sequences, the tools listed below were used. Accession 
numbers of genomes and genes (NBCI data base) that were employed in sequence 
alignments are shown in table 2.6.  
Blasts were performed at the NCBI nucleotide website:  
 http://blast.ncbi.nlm.nih.gov/Blast.cgi  
Multi sequence alignments were done by Clustal W2; LALIGN or the PC tool DNAman: 
 http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
 http://www.ch.embnet.org/software/LALIGN_form.html 
Phylogenetic trees were calculated employing: 
 http://mobyle.pasteur.fr/cgi-bin/portal.py#forms::clustalw-multialign 
Bacillus transcription factor binding motifs were predicted by the DBTBS database: 
 http://dbtbs.hgc.jp/ 
Restriction analyses were performed using the NEBcutter: 
 http://tools.neb.com/NEBcutter2/index.php 
GC content of DNA sequences was determined with the GEMS launcher (Genomatix): 
 http://www.genomatix.de/cgi-bin/tools/tools.pl 
A subcellular localization of proteins was predicted using the online tool CELLO v.2.5: 
 http://cello.life.nctu.edu.tw/ 
Vector cards were created by the use of the PlasMapper 2.0: 
 http://wishart.biology.ualberta.ca/PlasMapper/index.html 
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Table 2.6: Accession numbers of genomes and genes.  
 
Strain/DNA Accession No. 
(NCBI data base; GeneBank) 
B. amyloliquefaciens FZB42 CP000560 
B. licheniformis DSM 13 AE017333 
B. licheniformis ATCC 14580 CP000002.3 
N. punctiforme ATCC 29133 CP001037.1 
C. bescii DSM 6725 CP001393 
gyrA JF519633 
mersacidin gene cluster AJ250862 
 
Protein- and biochemical methods  
Preparation of lantibiotic peptides 
(a) Production of lichenicidin 
For production of lantibiotics B. licheniformis DSM 13 and MW3 were cultured in 50 ml 
2×BPM at 37°C for up to 48 h. Production experiments with the B. licheniformis MW3 
insertion mutants LicM1INT and LicM2INT were performed at 45°C. After 48 h of incubation, 
the cells were pelleted by centrifugation at 10,000 g and 4°C for 30 min. For further analysis 
culture supernatant was sterilized by filtration and stored at −20°C. Cell pellets were 
immediately washed with 35 ml 70% isopropanol (adjusted to pH2 with HCl) and incubated 
at 4°C for 4 h. Cells were removed by centrifugation and the supernatant was sterilized by 
filtration. For the following analysis of the cell wash extract, isopropanol was removed by 
rotary evaporation (Rotavapor RE11, Essen, Germany) and the resulting protein solution was 
stored at −20°C. Antimicrobial activity was determined in agar well diffusion assays against 
different indicator strains, mainly against M. luteus.  
 
(b) Production of mersacidin by B. amyloliquefaciens  
Production of mersacidin by B. amyloliquefaciens mrs1 harboring pPAR1/1 or pOPAR1 was 
assayed in 50 ml synthetic medium (2x BPM). Cells were grown for 24 h at 37°C with 
agitation (180 rpm). For further analyses, culture supernatants were sterilized by filtration 
and stored at -20°C. Detection of an antimicrobial activity was performed by agar well 
diffusion assays against M. luteus, S. aureus SG511 und B. megaterium using 50 µl culture 
supernatant. 
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Table 2.7: Preparation of 2xBPM (Bierbaum et al., 1995).  
 
Medium Chemical ingredients 
Wolfe’s mineral 
salts 
Titriplex I (500 mg/l); ZnSO4·7 H2O (180 mg/l); CuSO4·5 H2O (50 mg/l); 
CoCl2·6 H2O (170 mg/l); CaCl2·2 H2O (130 mg/l); NaMoO4·1 H20 (11 mg/l); 
Al2(SO4)3 (26 mg/l); H3BO3 (10 mg/l); 1 M NaOH (5 ml/l) 
Mineral salts 10 mM CaCl2; 2 mM FeSo4; 1 mM MnSO4 
2xBPM 0.25 M (NH4)2SO4 (20 ml); 0.1 M MgSO4 (2 ml); 2 M K-P-buffer pH 7.0 (2 
ml); 0.5 M Tris-maleate pH 7.0 (20 ml); Wolfe’s mineral salts (2 ml); aqua 
dest. (27.5 ml); after autoclaving 2.5 M glucose (16 ml); mineral salts (10 
ml) were added to a total volume of 100 ml. 
 
HPLC purification of lantibiotics  
(a) Purification of lichenicidin  
2 ml cell wash extracts containing 0.1% TFA were applied to a POROS II RP-HPLC-column 
(10R2, 100×4.6 mm, Perseptive Biosystems, Freiburg, Germany) and eluted in a gradient of 
20-55% acetonitrile or isopropanol (containing 0.1% TFA). Peaks were detected by 
measuring absorbance at 210, 220 and 266 nm. Fractions were collected, assayed for their 
antimicrobial activity against the indicator strainM. luteus in agar well diffusion assays and 
analyzed by MALDI-TOF spectrometry.  
 
(b) Purification of mersacidin  
For purification of mersacidin produced by B. amyloliquefaciens FZB42 mutant strains, 5 ml 
culture supernatants containing 0.1% TFA were applied to a POROS II RP-HPLC-column and 
eluted in a gradient of 30-42% acetonitrile (containing 0.1% TFA). Peaks were detected 
measuring absorbance at 210 or 220 and 266 nm. Fractions were collected and assayed for 
an antimicrobial activity against M. luteus in agar well diffusion assays. All active fractions 
were combined and lyophilized. Resulting lyophilisates were resuspended in 15 ml 5% 
acetonitrile supplemented with 0.1% TFA and further purified using a RP C-18 column 
(Nucleosil-100-C18, 250 x 4.5 mm; Schambeck SFD GmbH, Bad Honnef, Germany). Active 
fractions were eluted in a gradient of 50-65% acetonitrile (containing 0.1% TFA).  
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Antimicrobial susceptibility testing  
(a) Determination of the minimal inhibitory concentration (MIC)  
Minimal inhibitory concentrations (MIC) of antimicrobial substances were determined by the 
geometric broth microdilution method. Serial two-fold dilutions of antimicrobials were 
prepared in 96 well polystyrene round bottom microtiter plates (Greiner, Frickenhausen, 
Germany) using half-concentrated MH broth. For M. luteus, MIC determinations were 
performed in fully concentrated MH broth. Cells were grown to an OD600 of 1. An inoculum 
of 5×105 CFU/ml was employed in a final volume of 200 µl. For MIC determination of 
antimicrobials that were further assayed in cell lysis experiments, an inoculum of 107 CFU/ml 
was used. Prior to incubation, the inoculated plates were shaken at RT for 10 min (4,000 
rpm; Titertek Flow Laboratories,). MICs were calculated from the lowest concentration 
resulting in the complete inhibition of visible bacterial growth after 16 h and 24 h of 
incubation. MIC determinations were performed three times. For antimicrobial activity 
testing of lantibiotics, CaCl2 was added to a final concentration of 1 mM. 
(b) Agar well diffusion assay 
Antimicrobial activity of culture supernatants, cell wash extracts and HPLC fractions was 
determined by the agar well diffusion method. One colony of the indicator strain was 
resuspended in 5 ml MH medium. 1 ml of this diluted cell suspension was used for 
inoculation of a second 5 ml MH culture and this dilution was used for seeding MH agar 
plates with indicator strains. Therefore, the surface of agar plates was overlaid with cell 
suspensions that immediately were removed by pipetting followed by incubation for 15 min 
at RT in order to air-dry the plates. Wells (diameter of 7 mm) were introduced into the 
surface using a sterile cork borer. 50 µl of each sample were added to a well, unless 
indicated otherwise, and dried for 15 min at RT. After incubation at 37°C overnight, activity 
was determined by the diameter (in cm) of inhibition zones around the wells. 
For determination of active HPLC fractions, each fraction was either directly pipetted onto 
the surface of indicator seeded agar plates (5 - 15 µl) or 50 µl were tested in prepared wells. 
Since M. luteus is known to be one of the most sensitive indicator strains for lantibiotics, all 
fraction activity testings were performed with M. luteus as a standard indicator organisms.  
(c) Determination of arbitrary units of antimicrobially active samples 
In order to compare the antibacterial efficacy of lichenicidin to other lantibiotics the 
arbitrary units of the cell wash extract containing lichenicidin in comparison to other 
lantibiotics e.g. Pep5, nisin and mersacidin were determined. Serial dilutions (each 
representing a 1:2 dilution) of the lantibiotics and the cell wash extract were prepared in 
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half-concentrated MH broth. Fresh colonies of indicator organisms were used to prepare cell 
suspensions of about 5×106 CFU/ml which were employed to inoculate MH agar plates. 10 µl 
of lantibiotic solutions were spotted onto plates that had been seeded with the indicator. 
The highest dilution yielding a clear inhibition zone on the lawn was detected by visual 
inspection after incubation overnight. 
(d) Stability assays 
Thermal stability of antimicrobial compounds was analyzed by incubating 2 ml culture 
supernatants and cell wash extract at 37°C, 45°C, 65°C, 80°C and 100°C for up to 240 min. 
Stability of antimicrobial activities against treatment with proteases was determined by 
adding 10 mg/ml of proteinase K, pronase E, α-chymotrypsin and trypsin (Serva, 
Feinbiochemica, Heidelberg) to cell-free supernatant and cell wash extract and incubating at 
37°C for up to 240 min. Influence of different pH on the activity was examined by adjusting 
the pH to 1.5, 3, 9 and 13 and incubating for 30 min at RT. Residual antimicrobial activities 
were then determined in agar well diffusion assays against M. luteus. 
(e) Growth assays in presence of antimicrobial agents  
Growth assays in presence of antimicrobial agents were performed against M. luteus in 96 
well polystyrene round bottom microtiter plates in a total volume of 200 µl. 25 ml MH broth 
were inoculated with 500 µl pre-culture and were grown to an optical density of 0.2. 100 µl 
of this cell suspension was used for inoculation. Peptides were added in concentrations 
corresponding to 5 times the MIC and in 1:2 dilutions. Growth curves were recorded by 
measuring the optical density over the time (12 h) in a microtiter plate absorbance reader 
(SunriseTM, Tecan Group, Switzerland).  
(f) Whole-cell biosensor assay  
By use of a β-galactosidase-based promotor-induction assay (Burkhard and Stein, 2005; 
Starón et al., 2011) antibiotic solutions were analyzed for their capacity to cause cell 
envelope stress. B. subtilis reporter strains express a chromosomally encoded β-
galactosidase under control of promotors of the antibiotic sensing and detoxification 
modules BceRC-AB (TMB279), YxdJK-LM (TMB299), PsdRS-AB (TMB588) and LiaRS (TMB016). 
Cell envelope stress caused by antibiotic samples was assayed by the agar well diffusion 
method. To this end, reporter strains were seeded onto MH agar plates containing X-Gal (5-
bromo-4-chloro-indolyl-galactopyranoside; Fermentas) in a final concentration of 400 µg/ml. 
50 µl of peptide solution were applied to each well (7 mm). In a qualitative β-galactosidase 
assay, plates were scored for the appearance of blue rings at or near to the edges of 
inhibition zones after incubation at 37°C for 24 h.  
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Detection of protease activity 
Protease activity in cell-free culture supernatants was detected on skim milk agar plates  
(3 g/l yeast extract, 5 g/l peptone, 2.5 g/l skim milk powder, 15 g/l agar, pH 7.2 (M. Nagel, 
diploma thesis 2007)). 50 µl of fresh and filter-sterilized supernatant were added into wells 
that had been introduced into agar surfaces with a sterile cork borer. Protease activity was 
determined by the appearance of clear zones around the wells after incubation at 37°C 
overnight. 
 
Heterologous protein expression of HIS-tagged proteins by E. coli Bl21 and E. coli C43 
For heterologous expression of HIS-tagged lantibiotic modification enzymes and precursors, 
expression strains were grown in 0,5-1 l LB main cultures containing ampicillin (pET22 
derivatives) or kanamycin (pET28 derivatives). 10 ml overnight pre-cultures were used for 
inoculation of main cultures that were grown to an OD600 of 0.5-0.6 at 30°C. Heterologous 
expression was induced with a final concentration of 1mM IPTG. Cells were pelleted by 
centrifugation (10 min, 6,000 rpm, 4°C, Sorvall, Heraeus). Cell pellets were resuspended in 
20 ml lysis buffer and stored at -20°C.  
Cells were lysed by addition of 15 µl of lysozyme (10 mg/ml; 30 min incubation on ice) 
followed by sonification (8x15 sec intervals at 60% including 15 sec of cooling on ice; Sonifier 
TM W250; Branson). Lysates were incubated for 15 min on ice after addition of 10 µl RNAse 
and DNAse [10 mg/ml]. Cell debris and intact cells were removed by centrifugation (6,500 g, 
10 min, 4°C). Purification of HIS-tagged proteins and peptides was performed using the 
Nickel-NTA purification system following the manual of the supplier (Qiagen) and was 
attempted accordingly to protein purification protocols published by McClerren et al., (2006) 
and Türck & Bierbaum (2011) with several variations and combinations thereof. Proteins 
were eluted in 500 µl aliquots, mixed with 100% glycerol to a final concentration of 50% and 
stored at -20°C. 
 
Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and the NuPAGE 
system (Invitrogen)  
Purified proteins and peptides were analyzed via standard SDS-PAGE (Laemmli, 1970) and in 
a Mini Protean III vertical electrophoresis apparatus (BioRad). For small peptides, 20-24% 
SDS-gels were prepared or 4-12% gradient Novex Bis-Tris gels were used in the NuPAGE 
electrophoresis system (MES-buffer, XCell SureLock® Mini-Cell, Invitrogen) according to the 
supplier’s instruction. LanM proteins were analyzed on 10% SDS-gels. 10xLDS sample buffer 
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(Invitrogen) was added to each sample. Samples were heated (70°C) for 10 min prior to 
electrophoresis. Gels were stained with PageBlue™ Protein Stain (Fermentas) or silver stain 
according to Heukeshoven and Dernick (1988).  
 
Table 2.8: Buffers for SDS-gel-electrophoresis.  
 
Buffer Chemical ingredients  
Solution A 3 M Tris-HCl; pH 8.5 
Solution D 0.96 M Tris; 0.8% (w/v) SDS 
Running Buffer 25 mM Tris; 192 mM glycine; 0.1 (w/v) SDS; pH 8.5 
10% separating gel 40% (19:1) acrylamide/bisacrylamide (2.25 ml); solution A (2.25 ml); 0.21% 
APS (1.2 ml); aqua dest. (3.126 ml); 20% SDS (0.06 ml); TEMED (6 µl) 
20% separating gel 40% (19:1) acrylamide/bisacrylamide (4.5 ml); solution A (2.25 ml); 0.21% 
APS (1.2 ml); aqua dest. (0.876 ml); 20% SDS (0.06 ml); TEMED (6 µl) 
4% stocking gel  40% (19:1) acrylamide/bisacrylamide (0.238 ml); solution D (0.3 ml); 0.21% 
APS (0.8 ml); aqua dest. (1.03 ml); TEMED (5 µl) 
 
Mass spectrometry by MALDI-TOF  
Mass spectrometry of peptide preparations was performed using a MALDI-TOF mass 
spectrometer (Bruker Biflex, Bruker Daltonics, Bremen, Germany). 1 µl of cell wash extracts 
or culture supernatants were mixed with 2 µl matrix (α-cyano-4-hydroxycinnamic acid in 
acetonitrile: 0.1% TFA in MilliQ water, 1:3). For MALDI-TOF analysis of active HPLC fractions, 
20 µl of each fraction were concentrated 1:10 using a rotational vacuum concentrator (RVC 
2–18, Christ, Osterode, Germany). Samples were spotted onto the MALDI target and air-
dried. Mass spectra were measured in the positive ion mode and analyzed by FlexAnalysis 
2.0 (Bruker Daltonics). 
 
Protein biochemical bioinformatic tools 
Potential protease cleavage sites were observed using the ExPasy PeptideCutter Tool:  
 http://www.expasy.ch/tools/peptidecutter/  
Transmembrane sequences were identified using the TMHMM web server v. 2.0.: 
 http://www.cbs.dtu.dk/services/TMHMM/ 
Blasts were performed at the NCBI nucleotide website:  
 http://blast.ncbi.nlm.nih.gov/Blast.cgi  
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Molecular weight and charges were predicted by the PC tool DNAman or by PROTEIN 
CALCULATOR v3.3: 
 http://www.scripps.edu/~cdputnam/protcalc.htm 
Multi sequence alignments were done by Clustal W2 or the PC tool DNAman: 
 http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
 Protein sequences that were chosen for blast and alignment analysis of putative 
lantibiotic and TOMM modification enzymes are listed in table 2.9. 
 
Table 2.9: Overview of biosynthetic enzymes that were used for alignments and blasts of putative 
lantibiotic and TOMM biosynthesis enzymes (*according to Haft 2009 and Haft et al., 2010).  
 
Query for Protein Substance Protein ID (NCBI) 
Standard LanM 
One-peptide lantibiotics MrsM Mersacidin CAB60261 
LctM Lacticin 481 AAC72258 
Two-peptide lantibiotics HalM1  
HalM2 
Haloduracin BH0452 
BH0455 
Lantipeptides ProcM Prochlorosin PMT0250 
Standard TOMM dehydrogenase (TIGR03605)* 
Microcin B17  MccC Microcin B17 P23185 
Streptolysin S  SagB Streptolysin S AAC25178  
Thiopeptides TpaE 
TpaF 
Thiopeptide TP-1161 ZP_06427466 
ZP_06427458.1 
Heterocycloanthracins predicted in B. cereus (Haft, 2008) BA_1266 
Plantazolicin  PznB Plantazolicin RBAM007480 
Standard TOMM cyclodehydratase (TIGR03603)* 
Microcin B17  MccB Microcin B17  P23184 
Streptolysin S  SagC Streptolysin S AAC25179  
Thiopeptides TpaC 
TpaD 
Thiopeptide TP-1161 ACR48336 
YP_055576.1 
Standard TOMM cyclodehydratase (TIGR03603)* 
Heterocycloanthracins predicted in B. cereus (Haft, 2008) BA_1268 
Plantazolicin  PznC Plantazolicin RBAM007460 
Standard TOMM scaffold protein (TIGR03604)* 
Microcin B17  MccD Microcin B17 P23186 
Streptolysin S  SagD Streptolysin S YP_002285592  
Heterocycloanthracins predicted in B. cereus (Haft, 2008) BA_1267 
Plantazolicin  PznD Plantazolicin RBAM007470 
TOMM scaffold-cyclodehydratase fusion proteins (TIGR03882)* 
Cyanobactins TruD Trunkamide ACA04490  
 
 
 
 
 
| 58 | 
 
 
 
 
| 59 | 
 
 
Results  
 
PART 1: Novel lantibiotic gene clusters and producers  
 
Aim of this project  
This project aimed at the identification of novel lantibiotic gene clusters that are encoded in 
publicly available sequenced bacterial genomes, but have not been characterized yet. 
Identification of novel lantibiotics and producers, especially in bacterial taxa not considered 
to comprise potential lantibiotic producers might enlarge the potential of therapeutical use 
of lantibiotics by discovery of new features and actions.   
Biosynthetic enzymes, which are involved in post-translational modifications of lantibiotic 
precursors share conserved structures and sequences. To this end, they are useful blueprints 
for the bioinformatical identification of homologous proteins and, thus, for predicting novel 
lantibiotic gene clusters.  
The lantibiotic mersacidin shows promising antimicrobial activities even against MRSA 
strains. Therefore, in this study, the aa sequence of its modification enzyme (MrsM) was 
chosen for a BlastP search in the NCBI genome database. As a result, various new putative 
lantibiotic-like gene clusters were identified. In this thesis, three putative lantibiotic 
producers, Bacillus licheniformis DSM 13, Nostoc punctiforme ATCC 29133 and 
Caldicellulosiruptor bescii DSM 6725, were chosen for a closer analysis. To this end, the 
predicted producers were either 1. analyzed for production of an antimicrobial activity that 
was subsequently demonstrated to be based on the predicted cluster by plasmid integration 
mutagenesis targeting the putative lantibiotic modification enzymes; or 2. heterologous 
expression of the biosynthetic enzymes and lantibiotic precursors of predicted gene clusters 
for subsequent in vitro modification experiments was aimed in this thesis.     
 
A: The novel lantibiotic gene cluster of Bacillus licheniformis DSM 13 
Genomic data mining based searches identified a putative two-peptide lantibiotic gene 
cluster in two isogenic Bacillus strains, B. licheniformis DSM 13 and ATCC 14580. As B. 
licheniformis strains are known for production of proteases, their lantibiotics were predicted 
to exhibit enhanced stability against bacterial proteases, an interesting feature that might 
also confer peptide stability in therapeutic enteral applications.  
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In this thesis, homologous expression of the new lantibiotic was achieved, followed by its 
partial purification and characterization. B. licheniformis DSM 13 was assayed for production 
of an antimicrobial activity that could be attributed, by MALDI-TOF analysis and plasmid 
integration mutagenesis, to production of a lantibiotic encoded by the predicted gene 
cluster. Additionally, a detailed bioinformatic analysis of the gene cluster was performed.  
 
Description and bioinformatic analysis of the novel two-peptide lantibiotic gene cluster of 
B. licheniformis DSM 13 / ATCC 14580  
Annotation of the sequenced chromosomes of B. licheniformis DSM 13 and ATCC 14580 
revealed two putative lantibiotic modification enzymes of the LanM-type (BLi04126/BL00928 
and BLi04128/BL00928; Veith et al., 2004; Rey et al., 2004). For following descriptions of the 
predicted lantibiotic gene cluster, locus tags of the DSM 13 strain were used.  
Both LanM-coding ORFs were recognized in data base searches, since both display significant 
aa identity to MrsM (33%) and to LanM enzymes of known two-peptide lantibiotics, like 
haloduracin (38%). Interestingly, these lanM-like genes are encoded on both DNA strands 
and are separated by a putative lantibiotic structural gene (BLi04127, licA1). This predicted 
lantibiotic precursor is located upstream of the putative modification enzyme (LicM1) 
encoded by bli04126 and was previously annotated as lichenicidin (Veith et al., 2004). It 
exhibits a high sequence similarity to other LanA peptides, like mersacidin (36%) and to the 
LanA1 peptide of haloduracin (40%).  
Presence of two LanM-coding genes, their arrangement within the cluster and their aa 
similarity to two-peptide lantibiotic modification enzymes, suggested a second precursor 
that might have been overlooked during annotation. This has also been postulated in a 
recent publication dealing with the two-peptide lantibiotic haloduracin (McClerren et al., 
2006). Lantibiotic structural genes can be identified by cumulative occurrence of Cys, Ser, 
Thr residues in the C-terminus of prepeptides and their conserved cleavage sites. Indeed, a 
closer analysis of the intergenic region upstream of licA1 revealed a second precursor (licA2; 
bp 3949269-3949514) in front of the second LanM homolog (licM2; bli04128). Eight bp 
downstream of a conserved AGGAGG Shine-Dalgarno sequence, this ORF encodes a peptide 
with 72 aa, consisting of a leader (34 aa) and a propeptide (38 aa) that are separated by a GG 
cleavage site. Like the above mentioned genes, this peptide also displays the highest 
similarity to corresponding gene of the hal gene cluster, e.g. to the β-peptide HalA2 (52%).  
Further downstream of licA1, additional ORFs are present that show sequence similarity to 
proteins involved in lantibiotic production. BLi04125 constitutes a transporter with a 
peptidase domain and 49% similarity to HalT(P). BLi4124 encodes a protein with an N-
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terminal signal domain, which is similar to the peptidase involved in processing of the 
lantibiotic cytolysin (CylA, 37%) and to a peptidase encoded in the genome of B. halodurans 
C-125 (BH1491, 49%) that, so far, has not been described to be part of the hal gene cluster. 
Based on these results, a role in transport and processing of the lichenicidin peptides was 
postulated and they were named LicT(P) and LicP, respectively.  
BLi04122 is a helix-turn-helix regulator protein, which showed 60% similarity to a protein 
that is encoded near the haloduracin gene cluster (BH0460) and might be involved in gene 
regulation by acting as transcriptional regulator. BLi04121 is a small protein with similarity 
(61%) to a protein encoded downstream of the haloduracin gene cluster (BH0459) and it 
harbors three transmembrane helices. BLi04123 is a small hypothetical protein, which 
showed no significant sequence similarity to known proteins.  
Following ORFs might be involved in producer self-protection: BLi04120 is the ATP binding 
domain of an ABC transporter; BLi04119 did not show any sequence similarity to known 
proteins, however, six transmembrane domains were predicted for this protein; BLi04118 
showed low similarity to MrsE, an ABC transporter subunit of the mersacidin gene cluster 
(21%) and likewise, a computer analysis showed six membrane-spanning regions. The N-
terminal two thirds of BLi04117 appeared to be homologous to 1. the bacitracin transporter 
of B. licheniformis, a protein that is able to prevent binding of bacitracin to the 
undecaprenyl-pyrophosphat of its target lipid II, 2. to the ATPase component of the CcmA 
multidrug resistance system and 3. to the ATPase subunit of the haloduracin gene cluster 
(HalF1, 35.8%). BLi04116 again is a transmembrane protein with six membrane-spanning 
helices and had similarity to the BcrB subunit of the bacitracin transporter (52%). The gene 
downstream to BLi04116 encodes a protein with similarity to the ferrochelatase HemH, 
indicating that the gene cluster ends here. Upstream, the cluster is bordered by BLi04129, 
encoding a pectate lyase. 
In conclusion, the novel gene cluster, spanning bp 3938843 to 3953096, comprises fourteen 
ORFs including two lantibiotic structural genes, two modification enzymes, a peptidase, an 
exporter, one regulator and, probably, two different immunity systems (an ABC transporter 
BLi04120-18 and a transporter with homology to the bacitracin transporter BLi4117/16) 
(figure 3.1.1) 
The GC content (45.1%) of the cluster is quite similar to the average GC content of the whole 
genome (46.2%) and the gene cluster does not seem to be associated with any mobile 
element. After searching both annotated sequences for “free” gene designations, according 
to established lantibiotic gene nomenclature and predicted functions, following gene 
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designations for the ORFs involved in biosynthesis of lichenicidin were proposed: licA1 
(BLi04127, structural gene of the mature α-peptide Licα), licA2 (structural gene of the 
mature β-peptide Licβ); licM1 (BLi04128 encoding the LanM that modifies LicA1), licM2 
(BLi04126 encoding the LanM modifying LicA2), licT(P) (BLi04125 encoding the processing 
transporter) and licP (BLi04124 encoding the peptidase). 
 
 
 
Figure 3.1.1: Gene cluster of lichenicidin. The gene cluster of the novel lantibiotic lichenicidin is 
located at the far end of the chromosome of B. licheniformis DSM 13 and covers bp 3938843-
3953096 (locus tags BLi04116 to BLi04128 and an additional, not yet annotated ORF). Genes of 
prepeptides are light blue; genes of modification enzymes are dark blue. Other genes are marked as 
follows: processing transporter, peptidase, regulator, genes that might be involved in immunity and 
encode proteins that have similarity to transporters. Numbers give the last two digits of DSM 13 
annotations. For small grey ORFs, no functions could be assigned up to now, however, similar ORFs 
are encoded in vicinity of the haloduracin gene cluster.  
 
Detailed bioinformatical analysis of the lantibiotic prepeptides LicA1 and LicA2 
AA sequences of the predicted lantibiotic precursors LicA1 and LicA2 were compared to 
sequences of previously described two-peptide lantibiotics (figure 3.1.2) e.g. haloduracin, 
lacticin 3741, SMB, BHT, plantaricin W, staphylococcin C55 and to mersacidin.  
Lantibiotic prepeptides of the two-peptide lantibiotic subgroup are characterized by typical 
LanA1 and LanA2 motifs. Such motifs were identified in both predicted lichenicidin peptides 
as shown in figure 3.1.2. Since these motifs include conserved Ser,Thr and Cys, the lantibiotic 
peptides harbor at least partial conserved lanthionine ring patterns. Based on this sequence 
similarity, bridging patterns were predicted for both lichenicidin peptides, that correspond 
to those of the closely related haloduracin peptides. Since the LicA1 propeptide contains a 
further Cys as well as four hydroxy-aa in its N-terminal part, an additional, fourth ring was 
predicted for this peptide. Moreover, similarity to the Lanα-peptides of haloduracin and 
plantaricin W suggested, that the serine (30) within the C-terminal ring most probably is not  
 
16  17      18    19   20 21 23         24              25                               26               27            28
22 licA1 
licP             licT(P)                   licM2               licA2         licM1
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 (A) 
LicA1: 
MSKKEMILSWKNPMYRTESSYHPAGNILKELQEEEQHSIAGGTITLSTCAILSKPLGNNGYLCTVTKECMPSCN 
 
 
 
 (B) 
LicA2: 
MKTMKNSAAREAFKGANHPAGMVSEEELKALVGGNDVNPETTPATTSSWTCITAGVTVSASLCPTTKCTSRC 
HalA2: 
LicA2: 
PlwA2: 
SmbA2: 
BhtA2: 
LtnA2: 
C55A2: 
Motif: 
GDVHAQ......TTWPC.ATVGV..S.VALCPTTKCTSQC 
NDVNPETTPATTSSWTC.ITAGVTVS.ASLCPTTKCTSRC 
GDPEAR......SGIPCTIGAAVAAS.IAVCPTTKCSKRCGKRKK 
            STPACAIGGVVGITVAVTGISTACTSRCINK 
            STPACAIG.VVGITVAVTGISTACTSRCINK 
      TTPAT....PAISILSAYIS.TNTCPTTKCTRAC 
GTPLAL...LG...GAATG.VIGYIS.NQTCPTTACTRAC 
                         sxxxxcpsTxCsxxC 
                         t      t   t 
30 
38 
37 
31 
30 
29 
32 
 
 
 
Figure 3.1.2: AA alignment of two-peptide lantibiotics and lichenicidin. AA sequence alignment of 
LicA1 and LicA2 propeptides with Lanα (A) and LanA2 propeptides (B) of the two-peptide lantibiotics 
plantaricin (PlwA1, AAG02567; PLWA2, AAG02566), staphylococcin C55 (SacA1, BAB78438; SACA2, 
BAB78439), lacticin 3147 (LtnA1, O87236; LtnA2, O87237), haloduracin (HalA1, BAB04173; HALA2, 
BAB04172), BHT (BhtA1, AAZ76603; BhtA2, AAZ76602) and SMB (SmbA1, BAD72777; SmbA2, 
BAD72776) and mersacidin (MrsA, Z47559). AA identities are highlighted in blue (100%), red (75%) 
and green (35%). AA that are removed by additional proteolysis are denoted in violet. AA, which are 
thought to be involved in additional modifications are marked in red (proteolysis) and yellow 
((Me)Lan ring). The thioether bridging pattern represent that of the Hal and Plw peptides. 
 
MrsA:    GDMEAACTFTLPGGGGVCTLTSECIC  
HalA1:       
LicA1: 
PlwA1: 
LtnA1: 
SacA1: 
SmbA1: 
BhtA1: 
Motif:  
  CAWYNISCRLGNKGAYCTLTVECMPSCN 
TITLSTCAILSKPLGNNGYLCTVTKECMPSCN 
   KCKWWNISCDLGNNGHVCTLSHECQVSCN 
  CSTNTFSLSDYWGNNGAWCTLTHECMAWCK 
  CSTNTFSLSDYWGNKGNWCTATHECMSWCK 
IGTTVVNSTFSIVLGNKGYICTVTVECMRNCSK 
IGTTVVNSTFSIVLGNKGYICTVTVECMRNCQ 
          SxxxGNxGxxCTxTxECmxxC        
28 
32 
29 
30 
30 
32 
32 
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dehydrated as it had been previously described for the corresponding Ser in these peptides 
(McClerren et al., 2006 and Holo et al., 2004). 
For LicA2, an additional processing step resulting in removal of six N-terminal residues was 
postulated. As this includes loss of two negatively charged aa, the active β-peptide gains a 
positive net charge. Such a second processing step has been demonstrated for other β-
peptides as well. This prediction was based on the presence of a protease within the Lic gene 
cluster, that has aa sequence similarity to proteases involved in second processing of 
plantaricin W and haloduracin β-peptides.  
 
Antimicrobial activity testing of the culture supernatant and an isopropanol cell wash 
extract of B. licheniformis DSM 13  
In order to test, if B. licheniformis DSM 13 produces an antimicrobial substance, cells were 
cultivated in synthetic medium (2xBPM), TSB, LB and MH broth at 37°C for up to 48 h. In agar 
well diffusion assays of the culture supernatant against different Gram-positive indicator 
strains (Bacillus subtilis, Micrococcus luteus, Staphylococcus aureus, Streptococcus pyogenes, 
Staphylococcus simulans and enterococci), the highest production was observed for 
incubation in 2xBPM. Neither hemolysis nor growth-inhibition of Gram-negative bacteria was 
observed. For detailed analysis, cells were grown in 50 ml 2xBPM for 24 h. Cells were 
harvested by centrifugation, culture supernatant was removed and resulting cell pellets were 
resuspended in 15 ml 70% isopropanol (pH2). 
These cell wash extracts and crude culture supernatants were assayed for antimicrobial 
activity in agar well diffusion assays against different indicator strains. Both samples 
exhibited an antibacterial activity against Gram-positive bacteria, including several MRSA 
strains. However, they had a slightly different spectrum of activity, indicating that culture 
supernatant and isopropanol cell wash extract might contain different substances (figure 
3.1.3). Gram-negative bacteria and eukaryotic cells were not affected (data not shown). As 
previously determined for culture supernatant, isopropanol extracts also showed no 
hemolytic activity on Columbia blood agar plates.   
Additionally, cross resistance of Bacillus halodurans C-125, which produces the closely 
related two-peptide lantibiotic haloduracin, was also tested; B. halodurans C-125 was 
sensitive to both fractions. Similar results were obtained with the mersacidin producer 
Bacillus spec. HIL Y-85.54728.  
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Figure 3.1.3: In agar well diffusion assays. B. licheniformis DSM 13 culture supernatant and 
isopropanol cell extract were active against Gram-positive bacteria, but showed slightly different 
spectra of activity, indicating that they contained different antibacterial compounds. 
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Stability testing of the antimicrobial activities produced by B. licheniformis DSM 13 
For further characterization of both active fractions, heat stability, resistance against 
protease treatment and pH stability were determined. In all stability testings, the cell wash 
extract was tested after evaporation of isopropanol. After incubation the samples were 
tested in agar well diffusion assays in order to analyze and compare inhibiting effects on the 
antimicrobial activity. 
The supernatant contained a substance that displayed only limited heat stability and was 
inactivated within 2 h at 80°C and within 30 min by boiling, whereas the activity of the cell 
wash extract was heat stable and even withstood 4 h at 100°C without any loss (figure 3.1.4).  
Both active fractions inhibited growth of the indicator strain M. luteus in a deferred 
antagonism test at pH 1.5. 3 and 9; however, the supernatant did not show any antibacterial 
activity at pH 13. In contrast, the cell extract was initially active, but inactivated after 
incubation for 4 h at pH 13 at RT (figure 3.1.5).  
Additionally, resistance of both substances against treatment with different proteases was 
tested. Incubation in presence of proteolytic enzymes (pronase E, proteinase K, trypsin, 
chymotrypsin) did not affect the antibacterial activity present in the supernatant. The 
activity of the isopropanol-extract was stable in the presence of trypsin and chymotrypsin, 
but, addition of proteinase K and pronase E led to inactivation within 4 h of incubation, 
indicating the proteinaceous nature of this substance (figure 3.1.6). 
 
 
Figure 3.1.4: Stability assay: heat treatment of culture supernatant and cell wash extract. The 
substance present in the cell wash extract was not affected, whereas the substance in culture 
supernatant was inactivated by heat.  
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Figure 3.1.5: Stability assay: In antagonism tests at different pH supernatant and cell wash extract 
were only slightly affected by pH 1.5 to 9, but inactivated at pH 13.   
 
 
 
 
Figure 3.1.6: Stability assay: Treatment with proteases. No loss of activity was detected after 
treatment with trypsin and chymotrypsin. The substance in the cell wash extract was inactivated by 
proteinase K and pronase E, while the antimicrobial activity in the supernatant was unaffected.  
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Preliminary characterization of the antimicrobial effects of both antimicrobial substances 
produced by B. licheniformis  
First indications that the action of the antibiotic substances might target the cell envelope 
were obtained from a test of four different B. subtilis reporter strains for a cell envelope 
stress antibiotic screening in a qualitative β-galactosidase based agar well diffusion assay 
(Burkhardt and Stein, 2008; Starón et al,. 2011). Here, the cell wash extract and supernatant 
were screened for their capacity to induce expression of LacZ-promotor fusions of the 
detoxification systems BceAB (TMB294) PsdA (TMB299), YxdL (TMB588) and LiaI (TMB016) 
that are involved in peptide sensing and detoxification of cell wall active antibiotics in 
Bacillus strains.  
 
 
 
Figure 3.1.7: Qualitative β-galactosidase based agar well diffusion assay against the reporter strain 
B. subtilis TMB016 indicated presence of a cell envelope stressing antibiotic in the culture 
supernatant (A), whereas the antibacterial substance within the cell extract is not recognized by the 
pLIAI reporter system (B).  
 
All four reporter strains were affected by culture supernatant and cell extract of B. 
licheniformis in agar well diffusion assays (1.3 cm), but a positive lipid II interaction was only 
detected in the pLiaI based whole cell biosensor as indicated by occurrence of a blue ring 
around the inhibition zone against the reporter strain B. subtilis TMB016 on MH agar plates 
containing X-Gal (figure 3.1.7 A). In contrast, the cell wash extract showed no lipid II 
interaction (figure 3.1.7 B).  
 
In a growth assay, the growth of the indicator M. luteus was inhibited in presence of 4xMIC 
culture supernatant (10 µl in 200 µl) and cell wash extract (7.5 µl in 200 µl) of B. licheniformis 
(figure 3.1.8). The antimicrobial compound of the cell wash extract completely inhibited 
growth of the indicator strain. In contrast, growth of M. luteus was observed in presence of 
antimicrobially active culture supernatant for 200 min and only then lysis started. These 
results also indicated production of two distinct antimicrobial substances with different 
modes of action by B. licheniformis DSM 13.  
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Figure 3.1.8: Cell growth assay of culture supernatant and isopropanol cell wash extract.  
The indicator strain M. luteus was grown in presence of 4xMIC of the culture supernatant and the cell 
wash extract. Both inhibited growth of the indicator, but apparently differed in their MoA.  
 
MALDI-TOF analyses of culture supernatant, whole cells and isopropanol cell extract of  
B. licheniformis DSM 13 
For the two-peptide lantibiotics haloduracin and lacticin 3147 an accumulation of lantibiotic 
peptides on the surface of producer cells has been demonstrated and MALDI-TOF analysis of 
whole cells (colony mass spectrometry; CMS) identified these peptides. For the putative 
lichenicidin producer, B. licheniformis DSM 13, mass signals (3021 Da, 3038 Da, 3054 Da, 
3071 Da, 3268 Da, 3284 Da, 3305 Da) within the relevant range of 1600 to 5000 Da were 
detected in mass spectra of whole cells and corresponding masses were additionally found 
in the analyses of the cell wash extract (figure 3.1.8 A and C). These signals clearly matched 
the calculated masses of both peptides encoded by LicA1 and LicA2, whereas the masses 
3268 Da, 3284 Da and 3305 Da might probably denote the LicA1 propeptide containing 4-6 
of 8 putative dehydrations (table 3.1.1). Masses of 3021 Da, 3038 Da, 3054 Da and 3071 Da 
were predicted to represent different Licβ-peptides that have lost the 6 N-terminal aa by 
proteolytic processing and harbor 9-12 dehydrated residues. These masses were not 
detected in mass spectra of the culture supernatant (figure 3.1.9 C), thus indicating a cell 
surface accumulation of the lichenicidin peptides, too. Five signals (2622 Da, 3199 Da, 3520 
Da, 3710 Da, 4762 Da) were identified within the spectra of the culture supernatant.  
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Figure 3.1.9: MALDI-TOF analyses of whole cells (CMS, A), culture supernatant (B) and cell wash extract (C) of B. licheniformis DSM 13. Two predominant 
mass signals (3038 Da; 3284 Da) were detected in mass spectra of whole cells and isopropanol extract, but were not observed in mass spectra of the culture 
supernatant.  
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Table 3.1.1: Calculation of putative MWs of Licα and Licβ peptides depending on the dehydration state of active peptides. Masses. that were predicted to 
represent the MW of active peptides. as suggested by MALDI TOF analysis, are highlighted in blue (present in CMS; isopropanol extract) or green (present in 
supernatant). AA, that might be dehydrated are shown in blue and Cys residues are marked in violet. 
 
putative aa sequence of Licα 
calculated MW [Da] of the Licα-peptide 
depending on the dehydration state  
8 7 6 5 4 3 
TITLSTCAILSKPLGNNGYLCTVTKECMPSCN 3232.9 3250.9 3268.9 3286.9 3304.9 3322.9 
ITLSTCAILSKPLGNNGYLCTVTKECMPSCN - 3149.8 3167.8 3185.8 3203.8 3221.8 
TLSTCAILSKPLGNNGYLCTVTKECMPSCN - 3036.7 3054.7 3072.7 3090.7 3108.7 
LSTCAILSKPLGNNGYLCTVTKECMPSCN - - 2953.6 2971.6 2989.6 3007.6 
STCAILSKPLGNNGYLCTVTKECMPSCN - - 2840.4 2858.4 2876.4 2894.4 
TCAILSKPLGNNGYLCTVTKECMPSCN - - - 2771.3 2789.3 2807.3 
CAILSKPLGNNGYLCTVTKECMPSCN - - - - 2688.2 2706.2 
AILSKPLGNNGYLCTVTKECMPSCN - - - - 2585.1 2603.1 
ILSKPLGNNGYLCTVTKECMPSCN - - - - 2514 2532 
LSKPLGNNGYLCTVTKECMPSCN - - - - 2400.8 2418.8 
SKPLGNNGYLCTVTKECMPSCN - - - - 2287.7 2305.7 
putative aa sequence of Licβ 
calculated MW [Da] of the Licβ-peptide 
depending on the dehydration state  
15 14 13 12 11 10 9 8 7 6 5 4 
NDVNPETTPATTSSWTCITAGVTVSASLCPTTKCTSRC 3635.3 3653.3 3671.3 3689.3 3707.3 3725.3 3743.3 3761.3 3779.3 3797.3 3815.3 3833.3 
DVNPETTPATTSSWTCITAGVTVSASLCPTTKCTSRC 3521.2 3539.2 3557.2 3575.2 3593.2 3611.2 3629.2 3647.2 3665.2 3683.2 3701.2 3719.2 
VNPETTPATTSSWTCITAGVTVSASLCPTTKCTSRC 3406.1 3424.1 3442.1 3460.1 3478.1 3496.1 3514.1 3532.1 3550.1 3568.1 3586.1 3604.1 
NPETTPATTSSWTCITAGVTVSASLCPTTKCTSRC 3307 3325 3343 3361 3379 3397 3415 3433 3451 3469 3487 3505 
PETTPATTSSWTCITAGVTVSASLCPTTKCTSRC 3192.9 3210.9 3228.9 3246.9 3264.9 3282.9 3300.9 3318.9 3336.9 3354.9 3372.9 3390.9 
ETTPATTSSWTCITAGVTVSASLCPTTKCTSRC 3095.8 3113.8 3131.8 3149.8 3167.8 3185.8 3203.8 3221.8 3239.8 3257.8 3275.8 3293.8 
TTPATTSSWTCITAGVTVSASLCPTTKCTSRC 2966.6 2984.6 3002.6 3020.6 3038.6 3056.6 3074.6 3092.6 3110.6 3128.6 3146.6 3164.6 
TPATTSSWTCITAGVTVSASLCPTTKCTSRC - 2883.5 2901.5 2919.5 2937.5 2955.5 2973.5 2991.5 3009.5 3027.5 3045.5 3063.5 
PATTSSWTCITAGVTVSASLCPTTKCTSRC - - 2800.4 2818.4 2836.4 2854.4 2872.4 2890.4 2908.4 2926.4 2944.4 2962.4 
ATTSSWTCITAGVTVSASLCPTTKCTSRC - - - 2721.3 2739.3 2757.3 2775.3 2793.3 2811.3 2829.3 2847.3 2865.3 
TTSSWTCITAGVTVSASLCPTTKCTSRC - - - 2650.2 2668.2 2686.2 2704.2 2722.2 2740.2 2758.2 2776.2 2794.2 
TSSWTCITAGVTVSASLCPTTKCTSRC - - - - 2567.1 2585.1 2603.1 2621.1 2639.1 2657.1 2675.1 2693.1 
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None of these signals clearly fit to calculated masses that might represent the active Licα-
peptide (figure 3.1.9 C; table 3.1.1). In contrast, two masses (2622 Da and 3520 Da) would 
matched calculated masses of the Licβ-peptide (figure 3.1.9 and table 3.1.1) representing 1. 
the LicA2 propeptide that has lost the first N-terminal aa and that harbors fifteen 
dehydrations and 2. a propeptide sequence with eight dehydrations that misses eleven aa at 
its N-terminus.   
Taken together, these MALDI-TOF results along with the results of agar well diffusion assays 
and stability testings, suggested the production of two different antimicrobials by B. 
licheniformis DSM 13. The antimicrobial substance of the cell wash extract most likely 
represented the lantibiotic lichenicidin, whereas the antimicrobial activity of the culture 
supernatant was predicted to reflect an additional, so far uncharacterized substance.  
 
Since B. licheniformis is known for its impressive production of seven different proteases, it 
was hypothesized that lantibiotic peptides might be inactivated within the culture 
supernatant by proteolytic degradation performed by at least one of these proteases. 
 
 
Figure 3.1.10: Co-incubation of cell wash extract and culture supernatant. In agar well diffusion 
assays, the cell wash extract showed an antimicrobial activity against S. aureus ATCC 33592 (blue 
bar) while the culture supernatant was inactive. Co-incubation of both extracts (blue-green bar), had 
no effect on activity of the extract, indicating that the antimicrobial substance was stable against 
proteases excreted by the producer strain.  
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Production of proteases under lantibiotic production condition was verified on skim milk 
agar plates by application of 50 µl per well of protease containing culture supernatant 
Subsequently, the cell wash extract (25 µl), after evaporation of isopropanol, was incubated 
with the culture supernatant (25 µl) in order to test protease stability of lichenicidin. After 2 
h of incubation, activity against S. aureus ATCC 33592 or S. gallinarum (data not shown) was 
not diminished, indicating that the lichenicidin peptides were indeed resistant against 
proteases excreted by the producer strain (figure 3.1.10). 
 
SDS-PAGE analysis of the pre-purified peptides of B. licheniformis cell wash extracts 
As indicated by MALDI-TOF analysis of cell wash extracts, B. licheniformis DSM 13 produces 
two most likely cell-surface associated peptides, that might represent the both lichenicidin 
peptides. For a first characterization of the substance associated with the inhibitory effect of 
the cell wash extract and in order to correlate the antimicrobial activity to these peptides, 
bacterial SDS-PAGE overlay assays were performed.  
 
 
 
Figure 3.1.11: SDS-PAGE analysis and in situ overlay assay of concentrated and pre-purified 
peptides of the cell wash extract. After evaporation of isopropanol, the cell wash extract was pre-
purified by RP-HPLC. Fractions that were characterized by an antimicrobial activity against M. luteus 
were pooled and concentrated by evaporation. A peptide band (A) of < 3.5 kDa was detected, that 
caused an activity against M. luteus in situ (B).  
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3.5 kDa
1 2A
B
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First peptide purifications by reversed phase HPLC (POROS II column, isopropanol-water 
gradient with 0.1% TFA) resulted in pre-purification of antimicrobial peptides (data not 
shown). Fractions, which had been eluted with 36-42% isopropanol were analyzed for their 
antimicrobial activity against the indicator strain M. luteus. To determine the size of the 
substance responsible for antimicrobial activity, active fractions were pooled, concentrated 
by evaporation and lyophilization and, finally, were assessed for their protein composition 
by SDS-PAGE (20%) analysis. Figure 3.1.11A showed presence of a band with a MW < 3.5 
kDa, that was correlated to the antimicrobial activity in situ by overlaying a corresponding 
unstained SDS-gel with the indicator strain M. luteus (figure 3.1.11 B). 
 
Inactivation of the putative lantibiotic modification enzymes LicM1 and LicM2 
In order to clearly link the observed antimicrobial activities and peptide masses of the cell 
wash extract to the putative lantibiotic gene cluster in B. licheniformis DSM 13, the 
biosynthetic enzymes LicM1 and LicM2 were genetically inactivated. Inactivation was 
performed by plasmid integration using derivatives of the thermo-sensitive shuttle vector 
pMAD (Arnaud et al,. 2004). The recombinant vector pMADDelLicM1AC carries 5′ and 3′ 
parts (each appr. 500 bp) of the gene bli04128 (licM1) and lacks start and stop codon of the 
gene. Insert fragments were generated via PCR using the oligonucleotide pair 
forΔLicM1fragmentA and revΔLicM1fragmentA for amplification of the 5′ part of licM1 and 
the primer pair forΔLicM1fragmentC and revΔLicM1fragmentC for the 3′ part. PCR products 
were digested by MluI, BglII and BamHI following the manufacturer’s instructions. Both 
fragments were ligated (T4 ligase, Fermentas) in tandem into corresponding restriction sites 
of pMAD. The resulting vector pMADDelLicM1AC was introduced into E. coli SCS110 as 
intermediate cloning host by electroporation.  
According to this protocol, a second derivative of pMAD, called pMADLicM2AC, was 
generated for inactivation of LicM2. 3′ and 5′ parts of the gene bli04126 were amplified 
using the primer pair forDelLicM2A and revDelLicM2A and forDelLicM2C and revDelLicM2C, 
respectively.  
Both recombinant vectors were introduced into B. licheniformis MW3 via protoplast 
transformation and transformants were selected at 30°C. Recombinants, that had inserted 
the plasmids into their genomes, were selected after overnight cultivation at a non-
permissive temperature (45°C) in TSB (25mg/l EM) and, subsequent, plating onto TSA agar 
plates (25 mg/l EM). Insertions of vectors into target genes were confirmed by PCR using 
primers that anneal within genomic sequences, which flank target genes (forhomRecLicM1, 
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Figure 3.1.12: Gene inactivation of licM1 and licM2 was performed by homologous recombination and plasmid integration using the recombinant plasmids 
pMADDelLicM1AC and pMADLicM2AC. Both integration mutants B. licheniformis LicM1INT (A) and LicM2INT (B) harbor two copies of the targeted lanM genes: 
a copy that is transcribed, but is truncated and a second copy that does not dispose of promoter, Shine Dalgarno sequence and start codon. Genes that derive 
from the plasmid pMADDelLicM1AC are marked in green and those deriving from pMADLicM2AC are marked in red.  
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revhomRecLicM1, forhomRecLicM2, revhomRecLicM2) and a primer that anneals within the 
vector sequence (pMADmcs2neu). Resulting strains were named B. licheniformis MW3 
LicM1INT and LicM2INT.  
Both integration mutants, harbor two copies of the LanM enzyme in their genome (figure 
3.1.12). The transcribed copy of licM1 which is located downstream of licA1 harbors an 
internal deletion that leads to loss of 718 aa. The second copy is located downstream of the 
bga gene on the opposite strand and does not dispose of promoter, Shine-Dalgarno 
sequence and start codon. The first copy of licM2 leads to transcription of a protein with a C-
terminal deletion of 873 aa and the second copy again cannot be transcribed.  
Furthermore, integration of the plasmid into BLi04126 was expected to exert a polar effect 
and to inhibit transcription of the downstream genes of the gene cluster i.e. of the 
transporter and peptidase, which might be involved in export and processing of both 
peptides (figure 3.1.12). After inactivating of the LicA1 modifying enzyme, the LicM1 
insertion mutant was characterized by loss of activity of the cell wash extract against M. 
luteus in agar well diffusion assays. In contrast, activity of the culture supernatant was not 
affected. MALDI-TOF mass spectrometry showed loss of a mass signal with 3251.7 Da 
(m+1H)1+ in the cell wash extract of this mutant (figure 3.1.13). After removal of the leader 
at the conserved GG cleavage site, the unmodified propeptide LicA1 possessed a calculated 
molecular mass of 3376.9 Da. The missing mass signal might correspond to the mature Licα 
where post-translational modification resulted in dehydration of seven (-126 Da) of eight 
possible sites. Furthermore, antibacterial activity of the cell wash extract was also lost in the 
LicM2 integration mutant. The antibacterial activity in the culture supernatant remained 
unaffected, indicating that this activity definitely is not related to the lantibiotic gene cluster. 
MALDI-TOF spectra of the cell wash extract lacked the mass signals [(m+1H)1+] at 3251.7 Da, 
at 3021.7 and a minor signal at 3039.6 Da that was present in some preparations indicating a 
correlation of all three masses to the lichenicidin gene cluster (figure 3.1.13). The calculated 
mass of the unmodified propeptide LicA2 amounts to 3905.3 Da. A mass of 3020.6 Da was 
predicted for a Licβ-peptide that has lost its six N-terminal aa by proteolytic processing and 
harbors twelve dehydrated residues and three hydroxy-aa. 
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Figure 3.1.13: MALDI-TOF mass spectra of B. licheniformis MW3 wild-type (A) and its insertion 
mutants LicM1INT (B) and LicM2INT (C). Isopropanol extracts of both insertion mutants were 
characterized by loss of activity against M. luteus. MALDI-TOF spectra of these cell wash extracts in 
comparison to the wild-type (A) showed loss of a mass signal at 3251 Da in the case of the LicM1 
insertion mutant (B) indicating that this mass represents the protonated form of the active Licα-
peptide. Plasmid insertion into licM2 inactivated this enzyme and most probably exerted a polar 
effect on the downstream genes, thus affecting production of both peptides. This mutant did not 
produce the Licα-peptide and is further characterized by the absence of a 3021 Da peak, which might 
represent the protonated form of the mature Licβ-peptide, harboring twelve dehydrated residues 
(C). In some cultivations a further mass signal of 3039 Da was observed, which might denote a Licβ-
peptide with only eleven dehydrations. 
 
HPLC purification of lichenicidin  
In order to show that the lost masses corresponded to the antibacterial activity, the cell 
wash extract was fractionated by HPLC and masses of active fractions were determined. 150 
ml isopropanol cell wash extract (10 cultivations) were evaporated resulting in approx.. 15 ml 
yellow peptide solution that was applied to a POROS II RP-HPLC column. Active fractions 
eluted in 36-42% of an isopropanol-water gradient (0.1% TFA), were pooled (22 ml), and 
lyophilized after evaporation of isopropanol. The resulting pellet was resuspended in 5 ml 
5% acetonitrile (0.1% TFA) and applied to a Nucleosil C18 RP-HPLC column.  
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Figure 3.1.14: HPLC chromatogram of the B. licheniformis cell extract. Pre-purified cell wash extract 
was applied to a RP-HPLC column (Nucleosil, C18) and eluted in a gradient of 20-55% acetronitrile 
(containing 0.1% TFA). MALDI-TOF analysis of active fractions [+ medium activity, ++ strong activity 
and (+) poor activity] showed presence of masses representing the Licα or the Licβ peptide. 
 
Active fractions eluted in a gradient of 20-55% acetronitrile (containing 0.1% TFA). As shown 
in figure 3.1.14 the masses for Licα (fraction 9) and Licβ (fraction 10-13) were associated 
with these active fractions confirming that these peptides represent the two-peptide 
lantibiotic lichenicidin. 
 
For other two-peptide lantibiotics a synergistic effect of α- and β-peptides has been 
described. This could also be shown for both lichenicidin peptides. 25 µl of above 
characterized fractions showed no antimicrobial activity in diffusion assays when tested 
separately. In contrast, a combination of these (each 25 µl) showed enhanced activity, 
indicating a synergistic action of both peptides (figure 3.1.15).  
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Figure 3.1.15: Synergistic effect of fractions containing Licα- or Licβ-peptides. 25 µl HPLC fractions 
that contained Licα or Licβ, as determined by mass spectrometry, were tested separately and in 
combination against M. luteus. Only combination of both peptides showed an antimicrobial activity 
indicating that both, Licα and Licβ, are required for an optimal effect.  
 
Antibiotic efficacy of lichenicidin against MRSA in comparison to other lantibiotics  
In order to compare the antibiotic efficacy of lichenicidin against MRSA strains to that of 
other lantibiotics, solutions containing lichenicidin, mersacidin, Pep5 and nisin were tested 
against S. aureus SG511 (methicillin sensitive strain, MSSA). S. aureus ATCC 33592 (methicillin 
resistant strain; MRSA) and S. aureus LT440/09 (community acquired MRSA). All lantibiotics 
had to be used at higher concentrations to inhibit growth of MRSA strains, compared to that 
resulting in growth inhibition of MSSA strains; the minimal inhibitory concentrations on agar 
plates were 2-fold (ATCC 33592) or 4-fold (LT440/09) higher for nisin. 6-fold (both strains) 
higher for mersacidin, 8-fold higher for lichenicidin (both strains) and 16- (LT440/09) or 32-
fold (ATCC 33592) higher for Pep5 than the MIC against S. aureus SG511. These results 
indicated, that the novel lantibiotic lichenicidin exhibits an antibiotic efficacy against MRSA 
strains that is comparable to that of other lantibiotics, like mersacidin.  
 
Analysis of lichenicidin production by other Bacilli strains 
An additional B. licheniformis strain (I5), which was isolated from the Lake Bogoria (Kenya), 
was tested under the above mentioned production conditions. Isopropanol wash extracts 
and culture supernatants were tested against M. luteus and analyzed by MALDI-TOF. This 
strain showed neither production of an antimicrobial substance nor presence of lichenicidin-
related masses in the MALDI-TOF spectra. In order to demonstrate presence of a lichenicidin 
gene cluster, PCRs employing primers that anneal within both biosynthetic enzymes were 
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performed. No PCR products were detected in agarose gel electrophoresis. Additionally, 
PCRs using LanM-specific degenerated primers, that were designed to screen for genes that 
code for lantibiotic modification enzymes of the LanM-type, failed (data not shown), 
indicating that this B. licheniformis strain does not harbor the lichenicidin cluster.  
Bacillus strains that were isolated from infested soil samples in this study showed the 
production of antimicrobially active substances in the cell wash extracts. MALDI-TOF analysis 
of one of these strains indicated production of two cell-envelope associated peptides with 
MWs of 3021 Da and 3251 Da (figure 3.1.16), that most probably represent the lantibiotic 
lichenicidin. In line with this, partial amplifications (500 bp) of the genes coding for the 
modification enzymes of lichenicidin were obtained by PCR and use of the primer pairs 
forΔLicM1fragmentA and revΔLicM1fragmentA as well as forΔLicM2fragmentA and 
revΔLicM2fragmentA (data not shown) thus indicating presence of a lichenicidin cluster in 
this strain.  
 
 
Figure 3.1.16: MALDI-TOF analysis of the isopropanol cell wash extract of a Bacillus strain isolated 
from an infested soil sample. The antimicrobially active cell wash extract was characterized by the 
presence of two mass signals, 3021 and 3251 Da, indicating the production of lichenicidin.  
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B: Novel lantibiotic-like gene clusters of Nostoc punctiforme ATCC 29133 and 
Caldicellulosiruptor bescii DSM 6725   
In addition to the gene cluster coding for lichenicidin, other lantibiotic-like clusters were 
identified by genomic data mining for novel lantibiotic modification enzymes. Two of those 
clusters, which were predicted to contain all genes necessary for lantibiotic production and 
were supposed to be complete clusters, were chosen for a detailed characterization in this 
thesis. The clusters were found within the genomes of the nitrogen-fixing cyanobacterial 
strain Nostoc punctiforme ATCC 29133 and the Gram-positive clostridial strain Anaerocellum 
thermophilum DSM 6725, that has recently been renamed Caldicellulosiruptor bescii sp. nov. 
DSM 6725 (Yang et al., 2010). 
Of note, cyanobacteria like Nostoc are referred to as Gram-negative bacteria, which had not 
been considered potential lantibiotic producers until identification of the cyanobacterial 
lantipeptide prochlorosin in 2010 (Li et al., 2010). All other known producers of lantibiotics 
and lantipeptides are Gram-positive bacteria.  
The aim of the present study was the heterologous expression of the HIS-tagged 
biosynthetic enzymes and their corresponding prepeptides by Escherichia coli for 
subsequent in vitro modification assays.  
 
In silico analysis of lantibiotic-like biosynthesis genes found in Nostoc punctiforme  
Genome sequence annotation identified four LanM-like proteins (Npun_F5047, NpunR3312, 
Npun_AF076, Npun_R3205) in the genome of N. punctiforme ATCC 29133 (Meeks et al., 
2001). A more detailed analysis of neighboring genes revealed a lantibiotic-like gene cluster 
(14892 bp; Npun_F5043-Npun_F5052) in vicinity of the LanM-coding gene Npun_F5047 
(figure 3.2.2). In agreement with the classical lantibiotic designation scheme, the name 
puncticin (Pun) was proposed for this gene cluster.  
The LanM homolog Npun_F5047 (PunM) showed the highest sequence similarity (app. 70%) 
to three other LanM proteins identified in the genome of N. punctiforme ATCC 29133, and 
had an aa sequence similarity of 27% to MrsM. Contrary to other LanM, the conserved third 
zinc binding motif (CHG; Li et al., 2006; Zhu et al., 2003) of PunM appeared to be altered to 
CCG (figure 3.2.1). A similar aa exchange is present in the sequence of the LanM protein, that 
modifies the cyanobacterial lantipeptide prochlorosin (ProcM; Li et al., 2010). Interestingly, 
this sequence alteration was found in all LanM-like proteins present in N. punctiforme. 
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MrsM            RYKEEQILNLITKCGNRLIQNINVMEKGVGWKVPANPTPASGFAHGASGIIWALYEIYAI 882 
LicM1           QLDDPVFLKLAEKCAGHLLQHKTNIENGAAWKDPHTQNYYTGFAHGTSGIAAALSRFNKV 866 
PunM            VTKDATVLEKAIACGQHLLSRQVSYKGAPKAWQTLGEQPLTGFSHGTAGISYALLRLYTV 925 
Npun_R3312      ATGNENILLKAIACGQHLLAYRYSETGATRAWQTLGKIPLAGFSHGAAGIAYALLRLYTV 928 
Npun_AF076      EQ--PMVLKQAIACGQHLLKYCNEVFG-----KTSNLKGLIGFSHGAAGIAYALLRLYAV 938 
Npun_R3205      VTQESDTLEQAIAWGNYLLDRRVTTDTGYKIWTNAEGEPLTGFSQGIAGIAYALLQLYAI 970 
AnaM            KTAEEKIREELLSICTKILYAINEKSNKCKEGITWGEEGYVGYSHGNAGVTSQLIRLFYI 870 
ProcM           ES----ALQLALRAGDHLIAQQ---NEEGAWSSSSSQPGLLGFSHGTAGYAAALAHLHAF 874 
LicM2           IKQHPAVLDSIRQVLSRLNDRIGRLLDS----IEQDAVSLTGFSHGLTGIAFSIAKAAKV 865 
LctM            YLEYRDEIDILLKSLSNKIKLK---------------ESIASYAHGNSGIATAFVHGYKV 740 
                                                         .:::* :*    : .   . 
 
MrsM            TKQTVFKEVAEKALEFERTLFIPEKNNWADI---KLENGQFRNDNFVAWCNGAAGIGLSR 939 
LicM1           FDSQSLKKIISQCLAFEKQLYIASEKNWGSK---GREQ------LSVAWCHGAAGILLSR 917 
PunM            TQNQDYYEAALAGIEYERSVFCESQGNWPDFR--SAEMNQ-PPGFPVRWCHGATGIGLGR 982 
Npun_R3312      TQDQSYLAAAQEGIEYERTVFSESRGNWPVSH--KAERTGGKVTFPSQWCHGAAGIGLAR 986 
Npun_AF076      TQDTDYLDAARMAIAYENALFYPSVGNWREIT--PVYDPASLPVFWSTWCHGAPGIALGR 996 
Npun_R3205      AKNSDFLSAAKEAIAYEQSCS----------------IAADKLSPLANWCHGLPGIILAR 1014 
AnaM            NHNSNIIDLIRLSLTYERNMFDKRNNNWRRS--------LLEDGFSFGWCHGAPGILLSR 922 
ProcM           SADERYRTAAAAALAYERARFNKDAGNWPDYRSIGRDSDSDEPSFMASWCHGAPGIALGR 934 
LicM2           IHDDSCKELVLKLVEEEDRYFQKDHLNWLDLR------NDSHTLSPSYWCHGAPGILLGR 919 
LctM            TKNEKYLKIFHELWNLENSSKLRRGWTDSR---------KVDSSYSSQWCHGASGQAIAR 791 
                  .             *                               **:* .*  :.* 
 
MrsM            ILILPHNQNE-LIKDEAHVAINTTL---------KYGFEHDQSLCHGDLGNLDILMYA-- 987 
LicM1           SILRENGVNDPGLHTDILNALETTV---------KHGLGNNRSFCHGDFGQLEILRGF-- 966 
PunM            LGSLGVIDSP-EIEQEIEIALQTTQ---------NYSLQDSDHLCCGNLGRIEVLLVG-- 1030 
Npun_R3312      LGSLEILNTA-EIQQEIEIALRTTE---------NFGLEAIDHLCCGNMGRVEVLLVG-- 1034 
Npun_AF076      LGSLSIDRSE-QILTDIEVALKTTQ---------NTALQTIDHLCCGNLGRCEVMLVA-- 1044 
Npun_R3205      LASLSILNTE-EIRQEIETSLPKIQ---------QPSLKALDNLCCGNFADVEVLLVA-- 1062 
AnaM            INLIEKGYHDDYCFEEIKKAIEITK---------KYAFGKDYCLCHGDIGNLRILYYT-- 971 
ProcM           ACLWGTALWDEECTKEIGIGLQTTA---------AVSSVSTDHLCCGSLGLMVLLEMLSA 985 
LicM2           AHIQAFIPELTTRTLKLQEALQSSL---------NLADCQNHSLCHGLIGNLNILLDIK- 969 
LctM            MEWITVNKTARFLSNSELIKVKKELGELIDILKKEGMYTDNFCLCHGILGNLLILNTY-- 849 
                               .    :                      :* * :.   ::      
 
Figure 3.2.1: Partial alignment of  aa sequences of (putative) LanM proteins.  
AA sequences of lantibiotic modification enzymes of mersacidin (MrsM), lichenicidin (LicM1; LicM2), 
lacticin 481 (LctM) and of the lantipeptide prochlorosin (ProcM) were compared to those of the 
LanM-like proteins that were identified within the genomes of C. bescii (AnaM) and N. punctiforme 
(PunM, Npun_R3312, Npun_R3205, Npun_AF076). Conserved zinc binding motifs (Paul et al., 2007; Li 
et al., 2006; Zhu et al., 2003) are marked in violet, red and green. In all putative LanM found in N. 
punctiforme, aa alterations (orange) within the third motif were observed. A similar aa alteration was 
also found in the sequence of ProcM.  
 
Npun_F5045 and Npun_F5046, both coding for hypothetical peptides with a length of 91 aa, 
appeared to be the corresponding lantibiotic structural genes, punA1 and punA2. They are 
characterized by a high amount of Cys, Thr and Ser residues, that are predominantly located 
in their C-terminal sequences. With exception of a putative conserved GG cleavage site, 
which apparently separates the precursors into extremely long leaders (73 aa) and short 
propeptide sequences (18 aa), their aa sequence was not similar to that of other lantibiotics. 
Both peptides have almost similar sequences and only differ in three aa; two of which are 
within the predicted leaders and one is found within the propeptide sequences. The latter is 
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located at the far end of the propeptide and results in replacement of the C-terminal Lys 
(PunA2) by an Arg (PunA1) which is also positively charged. As these aa exchanges are 
caused by single point mutations in almost all cases, structural genes might have evolved by 
gene duplication. This hypothesis is supported by the highly similar intergenic regions, that 
directly flank punA1 and punA2 (upstream flanking region: 44 bp 80.4% sequence similarity; 
downstream flanking region: 120 bp 77%). Three Cys and four hydroxy-aa were found within 
both predicted peptides and, therefore, formation of up to three thioether-bridges is likely.  
Npun_F5050 and Npun_F5052 resemble typical lantibiotic exporters (29-38% sequence 
similarity). As only Npun_F5050 possesses an N-terminal protease domain, it was believed to 
be responsible for export and processing of the lantibiotic peptides.  
A regulatory function was predicted for proteins encoded by Npun_F5044 and Npun_F5043, 
due to aa similarity to histidine kinases and transcriptional regulators, respectively.  
Npun_F5048, Npun_F5049 and Npun_F5051 had no significant sequence similarity to 
proteins associated with lantibiotic production. Blast analysis suggested a relation of 
Npun_F5048 to membrane fusion proteins of the superfamily of HylD-like secretion proteins. 
Npun_F5049 codes for a hypothetical protein of 116 aa that contains a conserved motif with 
unknown function, that is discussed to be associated with membrane proteins. An additional 
membrane fusion protein is encoded by Npun_F5051 that appeared to be homologous to a 
periplasmatic subunit (ErmA) of an ABC transporter involved in antibiotic efflux. Therefore, 
these proteins might have a function in immunity or in the export of puncticin.  
 
 
Figure 3.2.2: Predicted lantibiotic-like gene cluster of N. punctiforme ATCC 29133 (puncticin) 
The putative lantibiotic-like gene cluster covers bp 6247825-6262716 (locus tags Npun_F5043 to 
Npun_F5052). Genes of the prepeptides (punA1; punA2) are light blue; the gene of the modification 
enzyme (PunM) is dark blue. Other genes are marked as follows: transporter with protease domain, 
kinase, transcriptional regulator, subunits of ABC transporters and membrane proteins are 
highlighted in green-blue and turquoise colors. Numbers give the last two digits of the gene 
annotations.  
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The cluster is flanked by Npun_R5042 and Npun_R5053, both of which are on the opposite 
DNA strand. Npun_R5042 encodes a protein of the cupin 2 barrel superfamily that includes 
proteins with diverse actions and functions, such as proteins associated with secondary 
metabolism or non-ribosomal antibiotic biosynthesis machineries. NpunR_5053 is a protein 
with unknown function. Neither these two, nor other loci in vicinity to the proposed 
puncticin cluster resemble loci known to be associated with lantibiotic production and, thus, 
they were not believed to be part of the biosynthesis cluster.  
A GC content of 42% was calculated for the cluster, that slightly differs from the GC content 
of the N. punctiforme genome (45.7%). The gene cluster did not appear to be associated 
with any genetic mobile element, like transposons or IS-elements.  
In addition to the PunM of the puncticin gene cluster, three further LanM-like proteins 
(NpunR3312, Npun_AF076 (plasmid associated), Npun_R3205) were identified in the 
genome of N. punctiforme (table 3.2.1). These lanM genes are often flanked by short 
hypothetical genes that are annotated as Nif11-like peptides. Interestingly, the N-termini of 
some of these short genes and the leader sequences of both puncticin precursors are similar 
(up to 65% sequence similarity on aa level; table 3.2.1). Although all peptides contain a 
putative GG cleavage site, Cys residues are not present in any of the peptides (figure 3.2.3). 
Therefore, Npun_F3224-26 and Npun_F6115 cannot represent lantibiotic prepeptides and 
the status of Npun_R3313 and Npun_AF077 is unclear.  
 
Table 3.2.1: Lantibiotic-like biosynthesis and structural genes found in the genome of Nostoc 
punctiforme ATCC 29133. 
 
Protein ID Similarity to 
PunA1 leader 
lanM in vicinity Nif11 
annotation  
Length 
(aa) 
Npun_F5045 (PunA1) 100%  Npun_F5047 - 91 
Npun_F5046 (PunA2) 97%  Npun_F5047 - 91 
Npun_R3313 65%  Npun_R3312 + 93 
Npun_AF077 33% Npun_AF076 + 103 
Npun_F3224 47% ? (Npun_R3205) + 95 
Npun_F3225 44% ? (Npun_R3205) + 95 
Npun_F3226 42% ? (Npun_R3205) + 97 
Npun_F6115 43%  ? + 77 
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Npun_F3224       ---MSKEAVIKLIEVAESNPTLLKQLHNAQGP-ETVLAIGAERGFQFSEAELIAVMQEKQ 56 
Npun_F3225       ---MSKESVIKLIEAAESNPTLLKQLHNAQGP-ETVLAIGAERGFQFSEAELVAVMQEKQ 56 
Npun_F3226       ---MSRESVIKLIESAENDQNLLKQLYSAQGP-ESILAIASTRGYKFSEEELLSVMQERQ 56 
Npun_F5045_PunA1_----MLHQIKELLQNAQLQQQVKAAANQAEAI-KVLAIASAEKGYNFTVEAISQMLAELT 55 
Npun_F5046_PunA2_----MLHQIKELLQNAQLQQQVKTAANQAEAI-KVLAIASADKGYNFTVEAISQMLAELT 55 
Npun_R3313       ----MLSQIKELLSNAQLQQKIEEATNLAESI-KLIMAAGAEKGYNFTTEAISQILTDLN 55 
Npun_AF077       MSQENLEQFYVLVQNSEQLQELLGATENTDSFNELAVRLGQDNGYNFTIQEVDAFVTENL 60 
Npun_F6115       ---MTQQNATRLFQAVKKDQALQQKLKATADP-EAFIKIAKERGYDFTTDELENEIN--- 53 
                            *..  :    :      :    :     .  .*:.*:   :   :     
 
Npun_F3224             LSFASQELSEEQLEAIV-GGKG-KKTTNNDYSKNIQ-YGIQP--- 95 
Npun_F3225             LSFASQELSQEQLEAVV-GGKG-KKTTNNDYSKNIQ-YGLQP--- 95 
Npun_F3226             LSFSTDVLSGEELEAIA-GGKGDVKATYNDASKTLY-FPQKKK-- 97 
Npun_F5045_PunA1_      -SVASDELSEEELLSVS-GGAVSESHVHMSCCNDCP-TR------ 91 
Npun_F5046_PunA2_      -SVASDELSEEELLSVS-GGAVSESHVHMSCCNDCP-TK------ 91 
Npun_R3313             -SVESYELSEEELLSVS-GAMMSANHTNKDIDWHCT-AGCA---- 93 
Npun_AF077             -QNVNAELRDEELELVA-GGKGKSCPLDTQFTACFLRSGCWGSKC 103 
Npun_F6115             ------KLSEEDLAAIVNPGWGTRRHILPR--------------- 77 
                              *  *:*  :   .                          
 
Figure 3.2.3: AA sequence alignment of peptides that share aa sequence similarity to leader 
sequences of the putative PunA prepeptides. In blast analyses employing leader sequences of 
PunA1/PunA2, six short, hypothetical peptides were identified in N. punctiforme. Some of these 
peptides appeared to be located next to putative lanM genes. Putative leader cleavage sites are 
marked in red, Cys residues are highlighted in pink and Ser/ Thr in blue.  
 
In silico analysis of lantibiotic-like gene cluster of C. bescii DSM 6725 
A putative lantibiotic modification enzyme of the LanM-type was identified in the genome of 
the completely sequenced strain C. bescii DSM 6725 (Athe_1107; Kataeva et al., 2009). The 
corresponding aa sequence harbored LanM-typical active sites and zinc binding motifs 
(figure 3.2.1) and showed up to 33% aa identity to the lantibiotic modification enzymes 
HalM1 (haloduracin), LicM1 (lichenicidin) and MrsM (mersacidin).  
In vicinity to this predicted LanM, additional ORFs were located, that shared significant aa 
sequence similarity with proteins or functions involved in production of lantibiotics. 
Together, these genes (Athe_1106-1112; bp 1199478-1208568) may form a gene cluster 
coding for a novel lantibiotic named besciin. In the following, the designation Ana is used for 
genes associated with this cluster.  
A putative anaA structural gene (265 bp) is encoded by the ORF Athe_1106. The prepeptide 
consists of 95 aa and contains three Gly residues (41-43 bp) that might include the typical GG 
cleavage site. The predicted AnaA sequence exhibited an aa similarity of about 40% to the 
LanA1 precursor of lichenicidin (LicA1) and to the predicted precursor of ruminococcin B 
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(figure 3.2.4 B). This similarity was mainly restricted to the leader sequences. Besides, the 
precursor and both lantibiotics had only low aa similarity. Interestingly, conserved residues 
included three Cys, three hydroxy-aa and a conserved Glu residue, that resembles the typical 
lipid II binding motif of class II lantibiotics. This similarity raised the question, whether the C-
terminus of the active besciin peptide might have a thioether bridging pattern similar to the 
conserved bridging patterns of LanA1 and mersacidin-like peptides. Since AnaA contains 
additional hydroxy-aa in this region, the bridging pattern could not be predicted clearly. 
The putative propeptide (53/52 aa) is extremely long compared to other lantibiotics. The 
presence of three Cys residues and a total of twelve hydroxy-aa (six Ser and six Thr) allows 
introduction of up to three thioether-aa and twelve dehydrations (figure 3.2.4 A). A net 
positive charge of 1.88 was calculated at pH7. 
 
A 
MKESTIIKNPVLRNKVNAKIYNPAGDIVKEIQEQNLPEQAGGGTPTVVVGVISAVTAVTNLAFSIDQA
ITKYYACSLVYTYSAECRSDGRSCRMR 
 
B 
LicA1           MSKKEMILSWKNPMYR---TESSYHPAGNILKELQEEEQ-HSIAGGTITLSTCAILSKP- 55 
RumB            MKKN-----YRNPMTR---PENFMNPAGNVMKEIKEADL-NNFSAG---------AGEPR 42 
AnaA            MKES---TIIKNPVLRNKVNAKIYNPAGDIVKEIQEQNLPEQAGGGTPTVVVGVISAVTA 57 
                *.:.      :**: *     .  :***:::**::* :  .. ..*          . .  
 
LicA1           LGNNGY----------LC----TVTKEC-----MPSCN-- 74 
RumB            VSDGSQ----------FC----TSTKECNWGTIMFVCC-- 66 
AnaA            VTNLAFSIDQAITKYYACSLVYTYSAECR--SDGRSCRMR 95 
                : : .            *    * : **        *    
 
Figure 3.2.4: AA sequence of the predicted AnaA precursor (A) and alignment (B) with the 
lantibiotic prepeptides of lichenicidin (LicA1) and ruminococcin B (RumB). (Putative) leader 
cleavage sites are marked in red. For the AnaA precursor, Cys residues are highlighted in pink and 
Ser/ Thr in blue. For LicA1, residues involved in (Me)Lan bridge formation are highlighted in colored 
boxes, whereas subsidiary residues of one thioether aa are marked in the same color. Hydroxy-aa 
that are dehydrated to Dha and Dhb in the active peptide Licα are marked in orange.  
 
Athe_1109-11 code for ATPase (Athe_1109) and permease (Athe_1110 + ATHE_1111) 
subunits of ABC-transporters and, thus, might possibly play a role in assembly of a LanEFG 
immunity transporter. The gene product of athe_1112 (737 aa) resembles a typical class II 
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lantibiotic exporter containing an internal protease domain. A blast analysis, demonstrated 
up to 41% sequence identity to exporters of the lantibiotics haloduracin and lichenicidin.  
Athe_1108 is annotated as FMN-reductase and was predicted to be an NADPH-dependent 
dehydrogenase. It had no sequence similarity to proteins involved in biosynthesis of 
lantibiotics. Enzymes of the FMN-reductases superfamily are associated with production and 
modification of another class of ribosomally synthesized peptides, the TOMMs. Some TOMM 
gene clusters had been shown to hold similarity to lantibiotics regarding 1. the presence of 
LanM-like modifications enzymes and 2. the leader structures of the precursors (Haft et al., 
2010). Therefore, the aa sequence of Athe_1108 was compared to FMN dehydrogenases 
present in gene clusters of typical TOMM peptides (e.g. microcin B17, streptolysin S, 
thiopeptides TP-1161, heterocycloanthracin, plantazolicin, trunkamide), but no significant aa 
similarity was found. In addition, no other modification enzymes usually found in TOMM-like 
gene clusters, scaffold proteins or cyclodehydratases involved in class specific peptide 
modifications, were detected in the genome of C. bescii.  
Mersacidin is modified by an FMN-dependent decarboxylase (MrsD), which catalyzes the 
introduction of the C-terminal AviMeCys residue. The sequence of Athe_1108 is dissimilar to 
that of MrsD and the corresponding propeptide sequence of AnaA does not contain a C-
terminal Cys residue, thus raising the question, whether this enzyme might represent a new 
type of lantibiotic biosynthesis enzyme. In line with these findings, a blast analysis with the 
ORF Athe_1108 identified as yet uncharacterized LanM- and LanA-like proteins in vicinity of 
homologous FMN-reductases in Bacillus cereus AH621 (38%), Clostridium botulinum H04402 
065  (35%), B. cereus SJ1 (34%) and Clostridium beijerinckii NCIMB 8052 (34%). The same 
blast analysis did not find a homologous FMN-reductase in any known lantibiotic producer.  
At both ends, the predicted besciin gene cluster is flanked by two almost identical GCN5-
related N-acetyltransferase coding genes (91% DNA, 98% aa sequence identity) that both are 
located on the opposite DNA strand. Proteins of this N-acetyltransferase family perform 
diverse functions such as promotion of antibiotic resistance, but no correlation of these 
enzymes and lantibiotic production has been reported up to now. Therefore, these genes 
probably do not belong to the besciin gene cluster. This notion is supported by presence of 
quite similar genes in other Caldicellulosiruptor strains with up to 94% aa sequence similarity 
- a feature that is uncommon for genes involved in production of lantibiotics. Additionally, in 
these strains GCN5-related N-acetyltransferase coding genes are not co-localized with LanM-
like enzymes or other genes associated with lantibiotic production.  
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Taken together, the besciin gene cluster (figure 3.2.5) comprises the structural gene anaA, 
along with one modification enzyme of the LanM-type (AnaM;), an additional gene with an 
unknown function, ABC transporter subunits with similarity to lantibiotic immunity-
transporters and an exporter containing a protease domain (AnaT(P)).  
The GC content of the putative lantibiotic cluster was calculated to be 28.7% and differed 
significantly from the average GC content (35.2 %) of the whole genome suggesting an 
uptake by horizontal gene transfer. Presence of two nearly identical flanking regions and 
absence of associated mobile elements might indicate integration by homologous 
recombination.  
 
 
 
Figure 3.2.5: The lantibiotic-like gene cluster of C. bescii DSM 6725 (besciin) 
The lantibiotic-like gene cluster covers bp 1199478-1208568 (locus Athe_1106 to Athe_1112). The 
gene of the predicted prepeptide AnaA is light blue; the gene of the modification enzyme (AnaM) is 
dark blue. Other genes are marked as follows: transporter with protease domain, subunits of ABC 
transporters and membrane proteins are highlighted in green colors. A gene with an unknown 
function is marked in grey. Numbers give the last two digits of the locus tags.  
 
Introduction of a XA-factor cleavage site into lantibiotic-like precursors  
In order to facilitate removal of the leader sequence subsequently to in vitro modification 
and processing assays, an engineered XA-factor protease cleavage site was introduced into 
the structural genes found in N. punctiforme and C. bescii.  
The putative structural genes coding for puncticin (punA1) and besciin (anaA) were 
introduced into pUC19 (2686 bp). PCR employing the primer combination forAnaApUC19 
and revAnaApUC19 resulted in amplification of a fragment including anaA (285 bp) and 
downstream (53 bp) and upstream (40 bp) flanking sequences. Using primers 
forPunA1pUC19 and revPunA1pUC19, punA1 itself (276 bp) and flanking regions (68 bp at 
the 5’end; 25 bp at the 3’end) were amplified. The PCR products were digested by EcoR1 and 
HindIII. Vector and insert were ligated using T4 ligase (Fermentas) and were directly 
AnaA AnaM AnaT(P)
06 07 08 09 10 11 12
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transferred in E. coli JM109. Plasmid integrity of pUC19AnaA and pUC19PunA1 was 
confirmed by sequencing of both inserts.  
Finally, these recombinant plasmids were used as templates in a site directed mutagenesis 
approach using the QuickChangeTM Site-Directed-Mutagenesis Kit (Agilent). For introduction 
of cleavage sites specific for XA-factor proteases, the natural GG protease cleavage sites and 
two aa upstream were replaced by the site specific recognition sequence (IEGR) of the XA-
factor protease according to the protocol for in vitro modification and processing of the 
heterologous expressed haloduracin peptides (McClerren et al., 2007; table 2.5).  
Corresponding mutations were introduced by mutagenic primers, AnaA_XA_Muta_sense 
and AnaA_XA_Muta_antisense for the anaA gene, or PunA1_XA_Muta_sense and 
PunA1_XA_Muta_antisense for mutagenesis of PunA1. The resulting plasmids harboring the 
desired mutations were confirmed by sequencing of the inserts and were named pUC19 
AnaA_XA and pUC19PunA1_XA.  
 
Table 3.2.2: Introduction of XA-factor cleavages sites into PunA1 and AnaA by primer mutagenesis.  
 
AnaA  
aa sequence within AnaA Q A G G 
DNA sequence C A A G C T G G T G G T 
position in anaA  115 116 117 118 119 120 121 122 123 124 125 126 
position in pUC19AnaA 405 406 407 408 409 410 411 412 413 414 415 416 
desired aa sequence I E G R 
mutated DNA sequence  A T A G A A G G T A G A 
PunA1 
aa sequence within PunA V S G G 
DNA sequence G T T A G T G G A G G A 
position in punA1  208 209 210 211 212 213 214 215 216 217 218 219 
position in pUC19PunA1 677 678 679 680 681 682 683 684 685 686 687 688 
desired aa sequence I E G R 
mutated DNA sequence  A T T G A G G G A A G A 
 
Construction of recombinant pET vectors for heterologous expression of lantibiotic-like 
biosynthesis genes of C. bescii and N. punctiforme in E. coli 
For heterologous expression of the putative lanM and lanA genes of N. punctiforme and C. 
bescii, the putative structural genes (anaA; punA1) and both LanM-coding sequences (anaM; 
punM) were cloned into the expression vectors pET28b and pET22b, respectively.   
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(A) Cloning of the structural genes anaA and punA1 and their mutated variants into pET28 
In order to obtain N-terminally HIS-tagged prepeptides by heterologous expression in E. coli, 
punA1 and anaA and their mutated variants, were cloned into pET28b. PunA1 and PunA1_XA 
were amplified by the primer pair forPunApET28 und revPunA1pET28. For amplification of 
the AnaA coding ORF, the primers forAnaApET28 and revAnaApET28 were employed. PCR 
fragments lacking the original start codon were subsequently digested by NdeI and XhoI and 
ligated into corresponding restriction site of pET28. The resulting expression vectors were 
named pET28AnaA, pET28AnaA_XA, pET28PunA1 and pET28PunA1_XA and were confirmed 
by sequencing. Finally, recombinant vectors were introduced into the expression strains E. 
coli Bl21 and E. coli C43.   
 
(B) Cloning of PunM and AnaM into pET22 
Genes coding for modification enzymes of the lantibiotic-like gene clusters of N. punctiforme 
(PunM) and C. bescii (AnaM) were introduced into pET22b. Complete amplification of the 
PunM coding ORF was achieved using primers forpET22HisPunM and revpET22HisPunM. The 
resulting PCR fragment was 3318 bp long and lacked a terminal stop codon. In a 
complimentary approach, the target gene was cloned stepwise, by insertion of two 
fragments (4-2150 bp; 2150-3466 bp), into pET22b. To this end, the primer pair 
forpET22HisPunM and revPunMBamHIMUT was used to amplify the N-terminal part of the 
gene (4-2150 bp). The C-terminal punM sequence (2150-3466 bp) was amplified by PCR 
employing the primers forPunMBamHIMUT and revpET22HisPunM. An additional restriction 
site for BamHI (2148-2153 bp) was introduced into punM by primer mutagenesis that 
generated a silent mutation at position bp 2148 (CG; table 3.2.3).   
 
Table 3.2.3: Introduction of an additional BamH1 restriction site into punM. 
  
aa sequence 
within PunM  
L D P 
DNA sequence 
within punM 
C T C G A T C C T 
position (bp) 2146 2147 2148 2149 2150 2151 2152 2153 2154 
mutated 
sequence 
C T G G A T C C T 
BamH1 site    G G A T C C  
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Cloning of anaM was performed likewise. The complete AnaM coding sequence without the 
stop codon was amplified with the primers forAtheMHispET22 and revAtheMHispET22. In a 
complimentary approach, the target gene was cloned stepwise, by insertion of two 
fragments (4-1157 bp; 1157-3306 bp) into pET22b. An N-terminal fragment of anaM was 
generated with the primer combination forAtheMHispET22 and revAnaMEcoR1. PCR using 
primers forAnaMEcoR1 and revAtheMHispET22 generated a C-terminal fragment. A “G to A” 
exchange at position 1155 bp by primer mediated mutagenesis, introduced an additional 
EcoR1 restriction site into anaM (bp 1153-1158; table 3.2.4). 
 
Table 3.2.4: Introduction of an additional EcoR1 restriction site into anaM.  
 
aa sequence 
within AnaM  
R I L 
DNA sequence 
within anaM 
A G G A T T C T C 
position (bp) 1153 1154 1155 1156 1157 1158 1159 1160 1161 
mut. sequence A G A A T T C T C 
EcoR1 site   G A A T T C   
 
Successful ligations were performed using T4 Ligase (Roche) overnight. Dephosphorylated 
vector backbones and inserts were incubated in an 1:5 ratio. Subsequently, E. coli JM109 or 
JM83 were transformed with these ligation samples.  
Recombinant vectors carrying the coding sequences for PunM or AnaM could be generated 
by two-step cloning of two lanM fragments only and the resulting vectors were named 
pET22PunMAB and pET22AnaMAB. After confirmation of plasmid integrity by sequencing, 
recombinant plasmids were finally transferred into the expression hosts E. coli Bl21 or E. coli 
C43 for overexpression. 
 
First attempts to purify of heterologous expressed, HIS-tagged lantibiotic precursors and 
biosynthetic enzymes by NI-NTA affinity chromatography  
Heterologous expression of LanM-like proteins and LanA-like peptides was attempted 
according to the expression and Ni-NTA purification protocols published by McClerren et al. 
(2006). As positive control, the N-terminally HIS-tagged mersacidin modification enzyme was 
expressed by the expression host E. coli Bl21 pET28MrsM.   
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Successful purification of HIS-tagged MrsM was achieved with the LanM expression and 
purification protocol of McClerren et al. (2006). Eluates were analyzed by SDS-PAGE gel 
electrophoresis (figure 3.2.6) and showed expression and purification of a protein with app. 
120 kDa that matched with the calculated mass for HIS-tagged MrsM protein (123 kDa; 
appendix page 167).  
 
 
 
Figure 3.2.6: SDS-PAGE analysis of HIS-tagged MrsM purified by Ni-NTA affinity chromatography.  
HIS-tagged MrsM protein was expressed in E. coli Bl21 pET28MrsM (1 l LB, 1 mM IPTG, 20 h, 18°C) 
and purified according to the LanM purification protocol of McClerren et al., 2006. Purified proteins 
were analyzed by SDS-PAGE gel (10%) electrophoresis and stained with PageBlueTM protein staining 
solution (Fermentas). Lane M1 = prestained protein marker (kDa), lane W4 = wash fraction 4, lanes 
E1-E7 = eluates, lane M2 = unstained protein marker (kDa).  
 
HIS-tagged PunM and AnaM could not be purified under the previously established 
expression and purification conditions employing E. coli Bl21 as expression host. Growth 
curves of PunM or AnaM expressing E. coli Bl21 strains were compared to that of E. coli Bl21 
pET28MrsM (figure 3.2.7). For the latter strain, a final optical density of 2.5 was obtained in 
expression cultures, whereas significantly lower OD600 values of 1.9 and 1.4, respectively, 
were observed for PunM and AnaM expression strains 20 h after induction. Additionally, a 
slower growth rate indicated a cell lytic effect, as did a decrease in cell density of the E. coli 
Bl21 pET22AnaMAB expression culture 4 h after induction of protein expression.  
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Figure 3.2.7: Growth curves of LanM expressing cultures. Growth of E. coli Bl21 and E. coli C43 
cultures harboring the recombinant vectors pET22AnaMAB and pET22PunM were monitored in 
comparison to the MrsM expressing strain E. coli Bl21 pET28MrsM after induction of protein 
expression. In contrast to E. coli Bl21 expressing MrsM and all tested E. coli C43 strains, expression of 
the recombinant PunM and AnaM proteins apparently caused cell lysis of E. coli Bl21 due to protein 
toxicity of overexpressed proteins as indicated by slower growth rates and lower cell densities.  
 
Based on these results, it was suggested that the recombinant AnaM and PunM proteins 
might be toxic to E. coli Bl21 when overexpressed. Therefore, pET22AnaMAB und 
pET22PunMAB were transferred into E. coli C43, which is optimized for overexpression of 
toxic proteins.  
HIS-tagged AnaM and PunM proteins were expressed in these hosts and the bacterial 
growth of corresponding expression cultures was compared under different induction and 
expression conditions (figure 3.2.7). E. coli C43 clones were grown in 1 l LB in presence of the 
selection marker ampicillin (40 mg/l) and under following conditions: 1. overexpression was 
induced at OD600 0.5 with a final concentration of 1 mM IPTG. Cells were cultivated for 
additional 20 h at 18°C (according to McClerren et al., 2006); 2. cultures were induced at 
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OD600 0.5 and subsequently grown for 16 h at 30°C (according to Türck and Bierbaum, 2012); 
3. protein expression was induced with 0.15 mM IPTG at OD600 0.6-0.8 and cells were grown 
for 48 h at 12°C (Müller et al., 2011). Under these tested conditions, all E. coli C43 mutant 
strains reached a final OD of 3-3.5 (figure 3.2.7) indicating that toxicity of overexpressed 
AnaM and PunM might be overcome in these expression strains proteins.  
The resulting cell pellets were purified by Ni-NTA affinity chromatography under native 
conditions (LanM purification protocol of McClerren et al., 2006), denaturative conditions 
(LanA purification protocol of McClerren et al., 2006) or using a purification protocol for 
membrane proteins according to Türck and Bierbaum (2012). Unfortunately, purification of 
HIS-tagged AnaM and PunM was not successful.  
Following the same expression and purification strategies, overexpression of both 
lantibiotic-like precursors, AnaA and PunA1, and their mutated variants, AnaA_XA and 
PunA1_XA, was aimed in E. coli Bl21. No toxic effect could be observed after induction of 
protein overexpression in E. coli Bl21 mutants. Finally, successful heterologous production of 
HIS-tagged PunA1_XA and AnaA_XA was achieved in 500 ml cultivation of E. coli Bl21 in 
presence of the selection marker kanamycin (25 mg/l). Overexpression was induced by 1 
mM IPTG and followed by incubation at 37°C for 3 h. Ni-NTA purification was performed 
according to McClerren et al., 2006. Eluates were analyzed by Nu-PAGE gel electrophoresis 
(4-12% Bis-Tris gradient gel, MES buffer, Invitrogen; figure 3.2.7 (A) and (B)) and showed for 
both batches expression and purification of peptides with a mass <15 kDa that matched with 
the calculated masses of the HIS-tagged PunA1_XA (12.077 kDa; appendix page 165) and 
AnaA_XA (12.633 kDa; appendix page 166) peptides. Additionally, in both gels bands with 
app. 24 kDa were observed that might represent dimers of the HIS-tagged precursors.   
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Figure 3.2.7: Nu-PAGE analysis of heterologous expressed and N-terminally HIS-tagged PunA1_XA 
(A) and AnaA_XA peptides (B) purified by Ni-NTA affinity chromatography.  
HIS-tagged precursors were expressed in E. coli Bl21 pET28PunA1_XA and pET28AnaA_XA (0.5 l LB, 1 
mM IPTG, 3 h, 37°C) and purified according to the LanA purification protocol of McClerren et al., 
2006. Purified proteins were analyzed by Nu-PAGE gel (Bis-Tris 4-12% gradient gel) electrophoresis 
and stained with PageBlueTM protein staining solution (Fermentas). Lane 1 = protein marker SM0661 
(Fermentas; kDa), lane 2 = cell lysat; lane 3 = supernatant after first sonification step; lane 4 = 
supernatant after second sonification; lane 5 = pellet after third sonification; lane 6 = pellet after 
centrifugation of combined supernatants; lane 7 = flow through; lane 8 = wash step 1; lane 9 = wash 
step 2; lane 10 = combined eluates 1-4; lane 11 = combined eluates 5-8; lane 12 = protein marker 
SM1881 (Fermentas; kDa).  
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PART 2: Mersacidin production by Bacillus amyloliquefaciens FZB42  
Introduction and aim of the project 
Mersacidin, a class II lantibiotic, is one of the best characterized lantibiotic peptides. It 
consists of 20 aa, of which nine are subjected to post-translational modifications that result 
in four intramolecular rings and a globular structure (figure 3.3.1; Chatterjee et al., 1992). 
The active lantibiotic peptide has a MW of 1825 Da.  
 
 
Figure 3.3.1: Structure of mersacidin  
Mersacidin consists of 20 aa and has four intramolecular rings including three methyllanthionines 
and a C-terminal aminovinyl-methyl-D-cysteine.  
 
Mersacidin is produced by a not yet closer characterized Bacillus strain called B. sp. HIL Y-
85,54728 which is not naturally competent (Chatterjee et al., 1992). In order to enable 
genetic manipulation of the mersacidin gene cluster, this project mainly focused on the 
transfer of the mersacidin biosynthetic gene cluster (figure 3.3.2 A) to an easily 
transformable Bacillus strain.  
Total genome sequencing identified a partial mersacidin cluster in the genome of the 
naturally competent B. amyloliquefaciens FZB42 (Chen et al., 2009). This partial cluster 
contains the genes mrsE;F;G;R2;K2 that are involved in producer self-protection (figure 3.3.2 
B). MrsFGE encode an ABC transporter that inhibits binding of mersacidin to producer cells 
(Guder et al., 2002), and mrsK2R2 is a two-component regulatory system that induces 
expression of mrsFGE in presence of mersacidin (Schmitz et al., 2006). The biosynthesis part 
of the mersacidin gene cluster (mrsA;M;D;R1;T) was transferred into B. amyloliquefaciens, 
resulting in strain B. amyloliquefaciens mrs1 (figure 3.3.2 C; A.M. Herzner, diploma thesis, 
2008). This mutant harbors a complete mersacidin gene cluster with exception of the 
structural gene mrsA, which is replaced by an erythromycin resistance cassette (ermB) that 
served as selection marker.  
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Comparison of DNA sequences, including 16S rRNA genes, and biochemical testings of B. 
amyloliquefaciens FZB42 and B. sp. HIL Y-85,54728 indicated that the latter might be a 
member of the species B. amyloliquefaciens (A.M. Herzner, diploma thesis, 2008).  
The study presented hereafter aimed a complete reconstitution of the mersacidin gene 
cluster in B. amyloliquefaciens mrs1 to allow production of mersacidin by this mutant. 
Furthermore, the relatedness of the mersacidin wild-type producer and the 
amyloliquefaciens group were evaluated more in detail. 
 
 
 
 
 
Figure 3.3.2: (Partial) mersacidin gene clusters of B. sp. HIL Y-85,54728 (A; wild-type producer), B. 
amyloliquefaciens FZB42 (B) and the mutant B. amyloliquefaciens mrs1 (C). 
(A) The mersacidin gene cluster (12.3 kb; Altena et al., 2000) consists of immunity genes mrsFGE 
(green), the structural gene mrsA (light blue), modification enzymes mrsD;M (dark blue), an exporter 
containing a protease domain mrsT (purple) and regulatory genes mrsR1;R2;K2 (yellow and orange).  
(B) B. amyloliquefaciens FZB42 harbors a partial mersacidin gene cluster consisting of immunity 
genes mrsFGE and regulatory genes mrsK2;R2 that are found at the same site as in the original 
producer strain. 
(C) In B. amyloliquefaciens mrs1, competence transformation using genomic DNA of a mersacidin 
deletion mutant (B. sp. HIL Y-85,54728 Rec1; Schmitz et al., 2006) resulted in a partial completion of 
the mersacidin gene cluster. The gene mrsA is replaced by ermB. MrsR1, most probably, is not 
transcribed due to a polar effect.  
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Bioinformatic analysis of the partial mersacidin gene cluster present in Bacillus 
amyloliquefaciens FZB42  
In a bioinformatic analysis the partial mersacidin gene cluster, identified in B. 
amyloliquefaciens FZB42, was compared to corresponding sequences of the wild-type 
producer. Coding sequences showed up to 99.6% aa identity. MrsE and MrsF proteins of 
both strains differ in two aa, whereas regulators representing MrsR2 differ at one position 
only. Four exchanges were found in both MrsK2 coding sequences. None of these exchanges 
were found within active sites or domains. For MrsG, a lower level of identity was obvious 
and both annotations mainly differ at their N-termini. A detailed analysis of both mrsG DNA 
sequences indicated, that a thymidine residue was missing in position 980 of the original 
sequence, resulting in definition of a false stop codon and, thus, in annotation of a 
shortened MrsG (R. Reinartz, diploma thesis, 2005). After sequence correction, both mrsG 
sequences were identical.  
Additionally, corresponding non-coding sequences were compared and were found to have a 
high degree of sequence similarity, with exception of an intergenic region that is located 
between mrsE and fbaB (figure 3.3.3). Here, a short sequence of 147 bp is inserted in the 
genome of B. amyloliquefaciens FZB42 (bp 3774591-3774738) that is not present in the wild-
type producer strain and did not yield any hits in databases. This sequence is flanked by two 
distinct regions that are similar to intergenic regions found within the mersacidin gene 
cluster. The upstream 38 bp region is similar to the sequence found downstream of mrsE, i.e. 
the sequence upstream of the putative mrsA operator. The 89 bp region downstream of the 
147 bp insertion is homologous to the sequence downstream of mrsT and upstream of fbaB 
and contains the inverted repeat that is thought to delimit the mersacidin gene cluster (G. 
Bierbaum, personal communication). FbaB, which encodes a fructose-bi-phosphate aldolase, 
reflects the 3’ flanking ORF of the mersacidin gene cluster in the wild-type producer. 
In conclusion, a partial mersacidin gene cluster was identified in B. amyloliquefaciens FZB42 
that is highly similar to the corresponding genes of the mersacidin wild-type producer and 
reflects the complete mersacidin immunity operon. Even DNA sequences, including 
intergenic and non-coding sequences, have a high degree of similarity. These results might 
indicate that the biosynthetic part of the mersacidin cluster was lost from B. 
amyloliquefaciens FZB42 during evolution. Therefore, this organism was chosen as amenable 
to mersacidin production and reconstitution of the cluster was performed by transferring 
the biosynthetic part into B. amyloliquefaciens FZB42.   
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Figure 3.3.3: Intergenic region between mrsE and fbaB in B. amyloliquefaciens FZB42. The 
intergenic region contains 5’ and 3’ sequences that are homologous to corresponding sites in the 
mersacidin gene cluster. In between, there is an insertion of 147 bp that was found neither in other 
B. amyloliquefaciens strains nor in the mersacidin wild-type producer.  
 
Determination of the minimum inhibitory concentration of mersacidin against Bacillus 
amyloliquefaciens  
Producer self-protection of strains producing class II lantibiotics is mediated by an ABC-
transporter whose subunits are encoded by lanEFG genes. Comparison of MIC values of the 
wild-type mersacidin producer and its mrsK2R2 knockout clone, which does not express the 
mersacidin immunity genes mrsFGE, had demonstrated that expression of mrsK2R2FGE 
increased resistance to mersacidin about threefold (Guder et al., 2002). Identification of the 
complete mersacidin immunity operon in B. amyloliquefaciens raised the question, whether 
this strain would be immune to mersacidin. Therefore, MIC values of B. amyloliquefaciens 
FZB42 and its mrs1 mutant, which only harbors a partially reconstituted gene cluster, were 
determined in comparison to the mersacidin wild-type producer. All three strains exhibited 
MICs in the same range (25 µg/ml) indicating that B. amyloliquefaciens FZB42 and its 
mutants were at least as resistant to mersacidin as the producer strain and, therefore, 
amenable to heterologous mersacidin production. 
 
Generation of mersacidin producing B. amyloliquefaciens mutants 
In order to facilitate generation of a mersacidin producing B. amyloliquefaciens mutant, the 
pCU1 based, recombinant plasmids pPAR1/1 and pOPAR1 (Schmitz et al. 2006), both 
harboring the structural gene of mersacidin (mrsA) were introduced into B. 
amyloliquefaciens mrs1. This mutant harbors a partially reconstituted mersacidin gene 
cluster in which the structural gene and its promoter are replaced by an erythromycin 
mrsT fbaB
mrsE fbaB
mrsE mrsA
B. amyloliquefaciens FZB42
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resistance cassette (A.M. Herzner, diploma thesis, 2008). The regulator MrsR1 is essential for 
mersacidin biosynthesis (Guder et al., 2002) and is transcribed from the mrsA promoter 
(Bierbaum, unpublished results). Due to insertion of ermB, transcription of this regulator is 
likely to be affected by a polar effect in this mutant strain.  
Successful generation of B. amyloliquefaciens mersacidin-producing mutants was achieved 
by in trans completion of mrsA and mrsR1 using the recombinant plasmids pOPAR1 and 
pPAR1. Both plasmids harbor a fragment of the gene cluster that encodes mrsA and mrsR1, 
and those are arranged in the same orientation as in the chromosomal context (Schmitz et 
al., 2006). The vectors pOPAR1 and pPAR1, that differ in the presence of an operator 
sequence upstream of mrsA (figure 3.3.4), were prepared from E.coli strains, that served as 
intermediate hosts, and were directly transferred by competence transformation into B. 
amyloliquefaciens mrs1. Transformants were selected on TSA (containing 5 µg/ml 
chloramphenicol) and were subsequently cultured on TSA agar plates (25 µg/ml CM). The in 
trans completed gene cluster harboring strains were named B. amyloliquefaciens mrs1 
pPAR1/1 or B. amyloliquefaciens pOPAR1 (figure 3.3.5). For control purposes a mutant strain 
that carries the empty pCU1 vector also was transformed and this strain was named B. 
amyloliquefaciens mrs1 pCU1. Successful transformation was confirmed by plasmid 
preparation and gel electrophoresis.   
 
 
 
Figure 3.3.4: Inserts of the pCU1-based, recombinant vectors pOPAR1 and pPAR1/1. O = putative 
operator structure, P = promotor; mrsA = structural gene coding for the lantibiotic prepeptide of 
mersacidin; mrsR1= gene coding for a transcription factor of the mersacidin gene cluster (A.M. 
Herzner, diploma thesis, 2008 and Schmitz et al., 2006).  
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Figure 3.3.5: In trans completed mersacidin gene clusters of B. amyloliquefaciens mrs1 pPAR1 (D) 
and pOPAR1 (E). Successful generation of mersacidin-producing mutants was achieved by in trans 
completion of mrsA and mrsR1 using pOPAR1 and pPAR1.  
 
Production of mersacidin by B. amyloliquefaciens mrs1 pPAR1 and pOPAR1 
In order to prove heterologous expression of mersacidin, B. amyloliquefaciens FZB42 and its 
mutant strains were grown for 24 h in 2xBPM. Sterile culture supernatants were analyzed for 
production of mersacidin by MALDI-TOF and assayed for antimicrobial activity after sterile 
filtration. 
MALDI-TOF spectra of culture supernatants of B. amyloliquefaciens mrs1 pPAR1 and pOPAR1 
were compared to those of B. amyloliquefaciens FZB42 and the mrs1 strain (figure 3.3.6) and 
to purified mersacidin. The latter showed three characteristic signals, with 1826 Da being the 
protonated lantibiotic peptide itself, 1848 Da and 1864 Da respectively representing sodium 
and potassium adducts of mersacidin. These characteristic mersacidin masses were also 
detected in culture supernatants of the mutant strains harbouring pPAR1 or pOPAR1, 
indicating expression of fully modified mersacidin. In contrast, spectra of B. 
amyloliquefaciens FZB42 and B. amyloliquefaciens mrs1 did not show any mersacidin-related 
mass signals.  
Besides, the spectra of mersacidin-producing cultures showed additional mass signals (e.g. 
1965 Da and 1981 Da) that were not detected in supernatants of the FZB42 wild-type and 
the mrs1 mutant. Therefore, these peptides were thought to correlate with mersacidin 
production and their MWs (3 Da differences in mass) are in line with calculated masses of 
different incompletely modified or partially processed mersacidin variants and the 
corresponding potassium and sodium adducts thereof (table 3.1)  
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Figure 3.3.6: Comparative MALDI-TOF analysis of culture supernatants of B. amyloliquefaciens FZB42 (B), mrs1 (C) and the isogenic mrs35 mutant (D), mrs1 
pOPAR1 (E, F) and pPAR1 (G, H) in comparison to purified mersacidin (A). In contrast to culture supernatants of B. amyloliquefaciens FZB42 and the mrs1 
mutant, substances with MWs corresponding to mersacidin-derived masses could be detected in both strains that harbor in trans completed gene clusters 
when cultivated in presence of chloramphenicol (F, H). In the absence of chloramphenicol, mersacidin production was detected in supernatant of pPAR1 
mutant only (H).  
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Table 3.1: Calculated masses of mersacidin variants that differ in their (incomplete) modification 
and processing states. Calculated MWs that matched, considering 3 Da in difference, with mass 
signals that were detected in MALDI_TOF spectra of the culture supernatant of mersacidin-
expressing mutants, are highlighted in red.  
 
Mersacidin peptide/ variant Calculated MW [Da] 
CTFTLPGGGGVCTLTSECIC mersacidin K 
adduct 
Na 
adduct 
lacking 
AviMeCys 
K 
adduct 
Na 
adduct 
0 dehydration 1914.3 1953.3 1937.3 1962.3 2001.3 1985.3 
1 dehydration 1896.3 1935.3 1919.3 1944.3 1983.3 1967.3 
2 dehydrations 1878.3 1917.3 1901.3 1926.3 1965.3 1949.3 
3 dehydrations 1860.3 1899.3 1883.3 1908.3 1947.3 1931.3 
4 dehydrations 1842.3 1881.3 1865.3 1890.3 1929.3 1913.3 
5 dehydrations 1824.3 1863.3 1847.3 1872.3 1911.3 1895.3 
A CTFTLPGGGGVCTLTSECIC       
0 dehydration 1937.4 1976.4 1960.4 1985.4 2024.4 2008.4 
1 dehydration 1919.4 1958.4 1942.4 1967.4 2006.4 1990.4 
2 dehydrations 1901.4 1940.4 1924.4 1949.4 1988.4 1972.4 
3 dehydrations 1883.4 1922.4 1906.4 1931.4 1970.4 1954.4 
4 dehydrations 1865.4 1904.4 1888.4 1913.4 1952.4 1936.4 
5 dehydrations 1847.4 1886.4 1870.4 1895.4 1934.4 1918.4 
AA CTFTLPGGGGVCTLTSECIC       
0 dehydration 2056.4 2095.4 2079.4 2104.4 2143.4 2127.4 
1 dehydration 2038.4 2077.4 2061.4 2086.4 2125.4 2109.4 
2 dehydrations 2020.4 2059.4 2043.4 2068.4 2107.4 2091.4 
3 dehydrations 2002.4 2041.4 2025.4 2050.4 2089.4 2073.4 
4 dehydrations 1984.4 2023.4 2007.4 2032.4 2071.4 2055.4 
5 dehydrations 1966.4 2005.4 1989.4 2014.4 2053.4 2037.4 
EAA CTFTLPGGGGVCTLTSECIC       
0 dehydration 2185.6 2224.6 2208.6 2233.6 2272.6 2256.6 
1 dehydration 2167.6 2206.6 2190.6 2215.6 2254.6 2238.6 
2 dehydrations 2149.6 2188.6 2172.6 2197.6 2236.6 2220.6 
3 dehydrations 2131.6 2170.6 2154.6 2179.6 2218.6 2202.6 
4 dehydrations 2113.6 2152.6 2136.6 2161.6 2200.6 2184.6 
5 dehydrations 2095.6 2134.6 2118.6 2143.6 2182.6 2166.6 
 
However, a clear assignment of these mass signals to specific mersacidin-variants was 
impossible, as the latter often showed nearly identical MWs and, thus, cannot be 
distinguished based on mass spectra only.  
Chloramphenicol was used in routine cultures of B. amyloliquefaciens pPAR1 and pOPAR1. 
Since the antimicrobial activity of chloramphenicol in culture supernatants interferes with 
the antimicrobial activity of heterologous expressed mersacidin in agar diffusion assays, 
cultivations were additionally investigated in absence of chloramphenicol. The resulting 
supernatants were analyzed by MALDI-TOF. Here, mersacidin-derived masses were only 
detected in culture supernatant of the pPAR1 mutant (figure 3.3.6). Additionally, plasmid 
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maintenance was analyzed by plasmid preparation and gel electrophoresis. In concert with 
the mass spectrometry results, the plasmid pOPAR1 was lost in cultivations that were grown 
in absence of its selection marker chloramphenicol, whereas pPAR1 was still detectable after 
24 h of cultivation.  
Although mersacidin production was detected in supernatants of the pPAR1 mutant by 
MALDI-TOF analysis, inhibition zones against M. luteus, S. simulans and B. megaterium in 
agar well diffusion assays were not significantly larger than those of the non-mersacidin-
producing strains B. amyloliquefaciens FZB42 or B. amyloliquefaciens mrs1 (figure 3.3.7).  
It might be possible, that this was due to production of another antibiotic substance. B. 
amyloliquefaciens FZB42 is known to produce various antimicrobial and antifungal 
substances, as seen in table 3.1, including polyketides (bacillaene, difficidin, macrolactin), 
lipopeptides (surfactin, fengycin, bacillomycin D), antimicrobial and antifungal dipeptides 
chloroetaine and bacilysin and the TOMM peptide plantazolicin (Rückert et al., 2011; Idriss 
et al., 2002 and Arguelles-Arias et al., 2009).  
 
 
 
Figure 3.3.7: Inhibition zones of culture supernatant of B. amyloliquefaciens mrs1 pPAR1 / pOPAR1 
in comparison to B. amyloliquefaciens wild-type (WT) and the mrs1 strain. For all three B. 
amyloliquefaciens strains inhibition zones (wells with a diameter of 0.7 cm) of comparable size were 
detected against the indicator strains M. luteus, B. megaterium and S. simulans.  
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Table 3.1: Overview over antimicrobial and antifungal substances produced by B. 
amyloliquefaciens strains (according to Arguelles-Arias et al., 2009)  
 
Type of antibiotic Name Masses [Da] 
+H +Na +K 
polyketides bacillaene A 583.5  - - 
bacillaene B 583.5 605.5  - 
difficidin 559.2 - - 
macrolactin A28 403.4 425.4  - 
macrolactin A 7-o-malonyl 489.4 511.4  - 
macrolactin A 7-o-succinyl 503.4 525.4  - 
macrolactin D 629.3 - - 
lipopeptides surfactin C13 1008.8  1030.8   1046.8  
surfactin C14 1022.8 1044.8 1060.8 
surfactin C15 1036.8 1058.8 1074.8 
fengycin Ala6 C15 1449.9 1471.9 1487.9  
fengycin Val6 C16 1491.9 1513.9 1529,9 
fengycin Ala6 C16 1463.9 1485.9    1501.9 
fengycin Ala6 C17 1477.9 1499.9 1515.9 
fengycin Val6 C17 1505.8 1527.8 1543.8 
bacillomycin D 1044.1 1066.1 - 
iturins C15 A 1057.1 1079.1 - 
non-ribosomally 
expressed di-
peptides 
chlorotetaine 289.2 - - 
bacilysin 270  - - 
TOMM plantazolicin 1335 - - 
 
Comparative MALDI-TOF spectra of B. amyloliquefaciens FZB42 and its mutant strains were 
recorded in order to identify production of these antibiotic substances under conditions 
permitting lantibiotic production. Mass spectrometric analysis of culture supernatants of B. 
amyloliquefaciens and its mutant strains revealed the presence of signals with masses of 
approximately 1500 Da and 1050 Da, indicating production of the lipopeptide surfactin and 
the antifungal compounds fengycin and bacillomycin D (figure 3.3.8). This notion was 
supported by the finding that surfactin activity could be detected in hemolysis assays on 
Columbia blood agar plates (figure 3.3.9). Thus, antimicrobial activity of mersacidin was most 
probably masked by the activity of surfactin in the agar well diffusion assays.  
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Figure 3.3.8: Comparative MALDI-TOF analysis of the culture supernatants (24 h incubation, in 
presence (+CM) or absence (-CM) of chloramphenicol) of B. amyloliquefaciens FZB42, B. 
amyloliquefaciens mrs1 and the isogenic mrs35 strain, B. amyloliquefaciens mrs1 pOPAR1 and B. 
amyloliquefaciens pPAR1 indicated production of the lipopeptide surfactin and the antifungal 
compounds fengycin and bacillimycin D.   
 
 
 
Figure 3.3.9: Detection of a haemolytic activity of culture supernatants (-CM) of B. amyloliquefaciens 
FZB42 (WT), B. amyloliquefaciens mrs1, B. amyloliquefaciens mrs1 pOPAR1 and B. amyloliquefaciens 
pPAR1 on Columbia agar plates also indicated production of a surfactant.  
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HPLC purification of mersacidin produced by B. amyloliquefaciens mrs1 pPAR1 and 
determination of antimicrobial activity of the purified peptide  
Since determination of the effective antimicrobial activity of heterologous expressed 
mersacidin failed in agar diffusion assays employing crude supernatants, HPLC-purified 
mersacidin was used in subsequent assays.  
In order to verify that mersacidin produced by B. amyloliquefaciens mrs1 pPAR1 is correctly 
modified and active, mersacidin was purified by two consecutive HPLC runs. Notably, HPLC 
peaks containing mersacidin were significantly larger when supernatants of 
chloramphenicol-containing cultures were analyzed compared to that of chloramphenicol-
free cultures. In addition, mersacidin containing HPLC fractions were more active against M. 
luteus. A control run with 2xBPM containing 20 mg/ml chloramphenicol resulted in an active 
fraction (3.2 cm against M. luteus) that was eluted at min 4-6. Thus, the enhanced 
antimicrobial activity observed on mersacidin-containing fractions of chloramphenicol-
containing cultures (eluted at min 17-18) can be attributed to mersacidin itself and is not an 
effect of chloramphenicol.  
In the first purifications (figure 3.3.10), culture supernatant of B. amyloliquefaciens mrs1 
pPAR1 was applied to a POROS II RP-HPLC column and an active substance was eluted in a 
gradient of 30-42% acetonitrile (containing 0.1% TFA). HPLC-fractions that eluted between 
min 17-18 (36.5- 38% acetonitrile) were active against M. luteus (1.9 cm) and corresponding 
MALDI-TOF spectra showed mersacidin-related masses. However, these fractions also 
showed a hemolytic activity on Columbia agar plates and masses assigned to surfactin. 
Likewise, corresponding HPLC fractions of the mrs1 mutant supernatant (negative control) 
contained surfactin-related masses and hemolytic activity, but exhibited no or only a weak 
(0.9 cm) antimicrobial activity against M. luteus (data not shown). These results indicated 
that mersacidin is responsible for the antimicrobial effect of the active fraction of the 
mersacidin producing mutant.  
For these first HPLC purification runs, 85 ml supernatant were used and resulted in 17 active 
fractions. A total volume of approx. 30 ml was subsequently lyophilized and yielded in 500 
mg white powder. Lyophilized pellets were resuspended in 15 ml 5% acetonitrile containing 
0.1% TFA, but complete dissolution, as proved by centrifugation, was impossible, even after 
addition of 50 µl, 100 µl or 150 µl chloroform. The latter treatment still resulted in an 
insoluble yellow-orange pellet that was finally removed by centrifugation. The resulting 
solutions (5% acetonitrile) showed antimicrobial activity with an inhibition zone of 2.3 cm 
against M. luteus. MALDI-TOF analysis confirmed the presence of mersacidin and surfactin. 
The sample was further analyzed by a second HPLC run (figure 3.3.10).  
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Figure 3.3.10: HPLC pre-purification of mersacidin from culture supernatant of B. amyloliquefaciens 
mrs1 pPAR1 (A). Fractions were assayed for antimicrobial activity in agar well diffusion tests against 
M. luteus (B) and analyzed by MALDI-TOF (C-E). Active fractions eluted after 17-18 min in a gradient 
of 50-65% acetonitrile (0.1% TFA) and were characterized by the presence of an 1847 Da mass signal 
representing the sodium adduct of mersacidin (E) and surfactin (1055 Da) (C) and fengycin-derived 
(D) mass signals (1488 Da).  
 
In order to prove that mersacidin produced by B. amyloliquefaciens exhibits antimicrobial 
activity, the sample was further purified by applying to a Nucleosil C18 column. Active 
fractions were eluted after 20-21 min in a gradient of 50-65% acetonitrile (0.1% TFA) and 
showed the typical adsorption spectrum of mersacidin (3.3.12 A). Antimicrobial activity of 
these fractions was demonstrated in agar diffusion assays against M. luteus, in which they 
caused inhibition zones with diameters up to 3.2 cm (figure 3.3.12 C). Furthermore, MALDI-
TOF spectra displayed mass signals characteristic of mersacidin and typical surfactin-derived 
mass signals were not present (figure 3.3.12 B). In line with this, no hemolytic activity was 
detected on blood agar plates (figure 3.3.12 C). 
In conclusion, these results indicated, that the mutant B. amyloliquefaciens mrs1 pPAR1 had 
produced mersacidin which is active and fully modified.  
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Figure 3.3.12: Purification of mersacidin. (A). Active fractions were assayed for antimicrobial activity 
in agar well diffusion tests against M. luteus (C) and analyzed by MALDI-TOF (B). Active fractions 
eluted after 20-21 min in a gradient of 50-65% acetonitrile (0.1% TFA) and were characterized by 
presence of a mersacidin signal (1826 Da). Surfactin could neither be detected in mass spectra nor in 
hemolysis assays.  
 
Phylogenetic classification of the mersacidin producer within the species B. 
amyloliquefaciens  
In previous experiments A.M. Herzner had demonstrated, that the mersacidin producer 
most likely belongs to the species B. amyloliquefaciens and postulated that this strain might 
rather be related to B. amyloliquefaciens FZB42 than to the DSM7 type strain. Very recently, 
these two strains have been reported to be typical representatives of two amyloliquefaciens 
subspecies (Borriss et al., 2010): 1. the subgroup of plant associated B. amyloliquefaciens 
subspec. plantarum and 2. the non-plant associated subgroup B. amyloliquefaciens subspec. 
amyloliquefaciens.   
In order to further clarify the degree of relatedness between the mersacidin producer B. sp. 
HIL Y-85,54728 and other bacilli of the amyloliquefaciens group, a phylogenetic tree based 
on the gyrA sequence, which codes for the gyrase subunit A, was calculated. To this end, 
parts of the gyrA gene of the mersacidin producer were amplified by PCR using previously 
published primers (Reva et al., 2004). The resulting products were sequenced. Subsequently, 
the obtained DNA sequences were compared in an alignment based taxonomic tree 
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calculation to previously annotated gyrA sequences of different members of the plantarum 
and amyloliquefaciens subspecies, as well as to other Bacillus strains of the cereus, subtilis 
and licheniformis groups.   
 
Figure 3.3.13: Phylogenetic tree based on the partial nucleotide sequence of the gyrA gene. The 
tree was calculated based on the gyrA nucleotide sequences of the mersacidin producer (BHILY, 
marked by a red box) and different members of the genus Bacillus (NCBI accession numbers in 
brackets) [B. amyloliquefaciens = BAMY strains: FZB42 (CP000560), CAUB946 (FN652789), S23 
(FN652780), ATCC 15841 (FN662838), DSM 7 (FN597644), NAUB3 (FN652783), NAUB55 (FN652801), 
UCMB5113 (AY212974); B. licheniformis = BLIC strains: MY75 (EU073420), DSM13 (BLi00007), 
CICC10085 (GQ355995); B. subtilis = BSUB strains: 168 (BSU00070), DV1-B1 (EF134416) and B. cereus 
= BCER strain: ATCC14579 (BC0006)]. The mersacidin wild-type producer is placed among members 
of the subspecies B. amyloliquefaciens subsp. plantarum forming a cluster that is strictly separated 
from all other bacilli strains.   
 
In this taxonomic tree (figure 3.3.13), the mersacidin producer strain is found in a cluster 
formed by members of B. amyloliquefaciens. In detail, the strain clustered with strains that 
belong to the plantarum subspecies and was clearly distinct from strains related to B. 
amyloliquefaciens type strain DSM7 and to the other bacilli.  
These results verified the high degree of relatedness of the wild-type mersacidin producer to 
B. amyloliquefaciens FZB42. Most likely this strain itself is a member of the genus B. 
amyloliquefaciens and appeared to belong to the plant-associated B. amyloliquefaciens 
plantarum subgroup.  
B. amyloliquefaciens subsp. amyloliquefaciens
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Discussion  
 
Emergence and spread of resistance to widely used antimicrobial therapeutics among clinical 
relevant bacteria has become one of the most challenging tasks in treatment of infectious 
diseases. Over the past decades, many resistance mechanisms have been emerged in 
pathogens (Wright, 2012). At the same time, only few new antibiotics have reached the 
pharmaceutical market, thus resulting in a dramatic shortage in the availability of potent 
therapeutics in future (Bassetti et al., 2011). Infections caused by resistant pathogens such 
as methicillin-resistant Staphylococcus aureus strains, lead to prolonged hospitalizations, 
increased costs and lethality, thus representing a significant burden of the health care sector 
worldwide. This necessitates search for and development of new antimicrobial compounds 
with new modes of action and targets to overcome the growing problem of antibiotic 
resistance (Wright, 2012).  
Advances in various high-throughput techniques, such as next generation sequencing, 
resulted in an explosion of genomic data and new bioinformatic tools are revolutionizing 
biology (Lee et al., 2010; Wecke and Mascher, 2011). In this context, the mining of bacterial 
genomes for potential antibiotic substances has opened the door to a new era in natural 
product drug discovery (Haney et al., 2002; Gross, 2009) and has already resulted in the 
identification of various new antibiotics and antibiotic classes (de Jong et al., 2010; Taylor 
and Wright, 2008).  
Lantibiotics are among the most promising candidates for future antimicrobials due to their 
capacity to inhibit the growth of clinically relevant pathogenic bacteria, even of multidrug 
resistant strains, by mechanisms of action not shared by other antibiotics in use (v. Heel et 
al., 2011). Enzymes involved in the introduction of class specific modifications of lantibiotics 
share conserved aa sequences and structures and, therefore, are amenable to in silico 
identification of homologous proteins (de Jong et al., 2010), thus leading to the prediction of 
novel lantibiotic gene clusters.  
This thesis aimed at the identification of novel lantibiotic producers employing in silico 
screening for as yet unknown lantibiotic modification enzymes in publicly available bacterial 
genome sequences. This bioinformatic approach resulted in prediction of lantibiotic-like 
gene clusters in B. licheniformis DSM 13, N. punctiforme ATCC 29133 and C. bescii DSM 6527.  
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The novel two-peptide lantibiotic lichenicidin is produced by Bacillus licheniformis DSM 13  
A closer bioinformatic inspection of the predicted lantibiotic gene cluster of B. licheniformis 
DSM 13 indicated that this cluster encodes a two-peptide lantibiotic, lichenicidin, with 
structural and sequence similarity to known two-peptide lantibiotics such as haloduracin. So 
far, nine two-peptide lantibiotics have been described, eight of which are closely related 
with regard to their structures and aa sequences. Interestingly, lichenicidin and haloduracin, 
both produced by two different Bacillus strains, share the highest similarity and their clusters 
have a similar organization e.g. corresponding gene arrangement.  
MALDI-TOF analyses of whole cells and isopropanol cell wash extracts identified two cell-
surface-associated peptides with size of 3251 and 3021 Da that were suggested to represent 
the fully modified and active lichenicidin peptides. In a comparable genome mining 
approach, Begley et al. (2009) identified the same lichenicidin gene cluster in the isogenic B. 
licheniformis ATCC 14580 strain. The same MWs were predicted for both lichenicidin 
peptides based on results of colony mass spectrometry. 
In this thesis, mass prediction for both lichenicidin peptides was verified by disruption of the 
lichenicidin modification enzymes (LicM1; LicM2) via integration mutagenesis. In subtractive 
MALDI-TOF analyses, the antimicrobial activity of the cell wash extracts could be attributed 
to production of a lantibiotic encoded by the predicted gene cluster and a mass of 3251 Da 
for active Licα and a mass of 3021 Da for the active Licβ-peptide was confirmed.  
LicA1 exhibits aa sequence similarity to LanA1 peptides of other two-peptide lantibiotics. 
With exception of a Lys residue, that probably is located within a third thioether ring 
(position +25 which is taken by His in some other peptides), all aa found in Licα are present 
in at least one other peptide of the LanA1 group. A mass of 3251 Da is consistent with seven 
dehydrations and indicated that one residue of LicA1 escapes dehydration. This unmodified 
hydroxy-aa most likely is the Ser residue at position 30, especially since analogous Ser 
residues in the α-peptides of haloduracin and plantaricin W escape dehydration (McClerren 
et al., 2006; Holo et al., 2001).  
In addition, the location of the typical LanA1 motif (Cotter et al., 2006) responsible for 
formation of the conserved C-terminal three rings, indicated that the C-terminal thioether 
bridging pattern of Licα might be identical to that of other α-peptides with a solved structure 
(lacticin 3147 and haloduracin). This close similarity does not extend to the N-terminus, 
where, just as in mersacidin, a fourth (Me)Lan might be formed, since a Cys and several 
hydroxy-aa are present additionally.  
In 2010, Shenkarev et al., demonstrated that lichenicidin is also produced by B. licheniformis 
VK21. Caetano et al. (2011) additionally identified a lichenicidin gene cluster in the strain B. 
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licheniformis I89. Prepeptides of these two lichenicidin producers are, with regard to their aa 
sequences, identical to lichenicidin produced by the DSM 13 strain. Partial sequencing of the 
lichenicidin gene cluster of B. licheniformis VK21 revealed identical DNA sequences for both 
structural genes and the structural genes found in the DSM 13 strain, whereas aa sequences 
coding for the LicA1 modifying enzyme (LicM1) differ in five aa (Shenkarev et al., 2010).  
In both studies, structures of fully modified lichenicidin peptides (figure 4.1 and 4.2) were 
elucidated by NMR (Shenkarev et al., 2010), site directed mutagenesis and MS/MS 
fragmentation (Caetano et al., 2011).  
 
 
 
Figure 4.1: Structure of the lichenicidin α-peptide according to (A) Caetano et al. (2011) and (B) 
Shenkarev et al. (2010). Four thioether aa are present in active Licα-peptides. The most N-terminal 
Thr residue is modified to an oxobutyryl residue. C-terminal rings are formed as in haloduracin. An 
additional, N-terminal MeLan ring is present. For this ring, two different structures have been 
published: (A) a three aa spanning ring (Thr5-Cys7) by Caetano et al. (2011) and (B) a five aa spanning 
ring (Thr3-Cys7) by Shenkarev et al. (2010). 
 
As predicted, the Ser at position +30 is not dehydrated in the active LicA1 peptide. 
Additionally, these structure resolutions confirmed the herein predicted C-terminal 
thioether bridging pattern of Licα and formation of an additional, N-terminal MeLan ring 
structure. According to Shenkarev et al. (2010) this N-terminal MeLan is formed by Thr at 
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position +3 and Cys at position +7. In contrast, the structure published by Caetano et al. 
(2011) contains a shorter MeLan ring, which is formed by a thioether linkage between Thr 
(+5) to Cys (+7). 
The mass of 3251 Da indicated that leader cleavage occurs after the anticipated proteolytic 
cleavage sequence (GG; aa 41/42, position -1; -2) in LicA1, resulting in an N-terminal Dhb 
residue (+1), which was demonstrated to be modified to oxobutyryl in both studies. N-
terminal Dhb residues are instable in aqueous solutions and undergo spontaneous and rapid 
hydrolysis that results in a 2-oxobutyryl residue by desamination (Kellner et al., 1989). Such a 
modification has previously been demonstrated for N-terminal Dhb residues found in the α-
peptide of lacticin 3147 and in the single-peptide lantibiotic Pep5 (Ryan et al., 1996; 
Bierbaum et al., 1996).  
As seen for LicA1, a conserved two-peptide lantibiotic motif, the LanA2 motif (Cotter et al., 
2006), was observed in LicA2, strongly supporting formation of the three conserved C-
terminal rings. Its N-terminus deviates from other lantibiotic peptides and contains several 
additional hydroxy-aa. Furthermore, Licβ-peptides are characterized by masses consistent 
with eleven or twelve of fifteen possible dehydrations and an additional N-terminal 
processing of six aa. Such a second processing has also been demonstrated for Halβ and the 
β-peptide of plantaricin W (Holo et al., 2001; McClerren et al., 2006). This step occurs 
extracellularly after the proteolytic leader cleavage site by an additional protease and results 
in the removal of the N-terminal six aa of the propeptide sequence. In all three cases, the 
mature peptides gain a positive net charge by removal of two negatively charged aa. The 
protease encoded by BLi4124 contains a secretion signal and might well be involved in this 
second extracellular processing reaction.  
The N-terminus of LicA2 contains a further Cys and seven hydroxy-aa, suggesting formation 
of a fourth ring. The insensitivity of the antibacterial activity in the cell wash extract to 
treatment with chymotrypsin strongly indicates presence of such a fourth, N-terminal ring 
structure, since a chymotrypsin cleavage site (TTPATTSSW↓TC) is located in this area.  
The predicted thioether ring pattern suggest an elongated peptide structure for the mature 
Licβ-peptide, resembling peptide structures of pore-forming class I lantibiotics. Nisin, the 
prototype of class I lantibiotics, harbors an internal linear region, the so called flexible hinge 
region, that is involved in transmembrane orientation of the C-terminus of the peptides 
during pore formation (Wiedemann et al., 2001). Based on the predicted ring pattern of 
LicA2, a linear region may be located between aa I12 - V18. A proteinase K cleavage site 
within this linear region (ITA↓GVTV) might account for loss of activity seen upon treatment 
with this protease, thereby strongly supporting a linear peptide structure in this region. 
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Indeed, Caetano et al. (2011) and Shenkarev et al. (2011) found such an elongated structure 
for the mature LicA2, that is, in large parts, consistent with the structure proposed here. As 
predicted, both studies revealed a C-terminal lanthionine bridging pattern corresponding to 
haloduracin and plantaricin W and confirmed presence of a fourth Lan ring in the N-
terminus, which involves Ser at position 7 and Cys at position 11. After processing, the 
resulting peptide retains a free Dhb at its N-terminus, that is spontaneously hydrolyzed and 
desaminated to 2-oxobutyryl. 
 
 
 
Figure 4.2: Structure of the mature LicA2 peptide of the lantibiotic lichenicidin according to 
Shenkarev et al. (2010) and Caetano et al., 2011.  
Licβ contains two MeLan and one Lan ring in its C-terminus with the same connectivity as confirmed 
for haloduracin. An additional N-terminal Lan ring is formed between Ser (7) and Cys (11). A second 
proteolytic cleavage removes six N-terminal aa resulting in an N-terminal Dhb residue, which is 
subsequently modified to a 2-oxobutyryl residue.  
 
With the exception of cytolysin, all two-peptide lantibiotic gene clusters harbor two LanM 
modification enzymes, which display little sequence similarity. McClerren et al. (2000; 2006) 
demonstrated that each lacticin 3147 and haloduracin peptide is modified separately by one 
of these LanM enzymes and it has been proposed that this is a common feature in the 
modification of two-peptide lantibiotics. A similar modification strategy was observed for 
both lichenicidin peptides here. Inactivation of the LicA1 modifying enzyme LicM1 resulted in 
loss of Licα expression, whereas expression of the fully modified Licβ-peptides was not 
affected. As previously reported for mature lacticin 3147 peptides (McClerren et al., 2000), 
export and processing of mature Licβ-peptide was even observed in absence of Licα 
indicating that transport and leader cleavage of both structural peptides occurs 
independently of each other.  
Remarkably, the antimicrobial activity of lichenicidin targeted a broad range of MRSA strains 
that cause problematic infections in the hospital setting. The test panel included clinical 
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isolates of epidemic strains, which are currently widespread in Germany. For the two-
peptide lantibiotics haloduracin and lacticin 3147 a dual mode of action principle has been 
described that combines inhibition of peptidoglycan biosynthesis by binding and dislocation 
of lipid II with pore formation in bacterial membranes (Wiedemann et al. 2006; Oman et al., 
2011). Both functions are assigned to two distinct lantibiotic peptides. The globular α-
peptide with homology to mersacidin binds to lipid II. As previously shown for nisin, Halα 
binds lipid II in a 2:1 ratio and, thereby, inhibits cell wall biosynthesis at the stage of 
transglycosylation catalyzed by the penicillin binding protein PBP1 (Oman et al., 2011). 
Elongated β-peptides bind to the Lanα-lipid II complexes and subsequently results in pore 
formation in bacterial membranes that finally leads to cell death.  
Structural and sequence data of lichenicidin suggested, that it might act by a similar lipid II-
involving mechanism. The Licα-peptide harbors the lipid II binding motif, which is believed to 
be important for lipid II binding of mersacidin-like peptides (Sahl and Bierbaum, 2009; 
Böttiger et al., 2009). Such a MeLan ring is also found in other LanA1 peptides and in the N-
terminus of one-peptide lantibiotics of the lacticin 481 subgroup. Based on NMR data, 
Shenkarev et al. (2010) proposed an N-terminal ring structure in Licα, that resembles a part 
of the lipid II binding motif of nisin-like lantibiotics (Hsu et al., 2004), which is absent in other 
LanA1 peptides. Formation of three H-bridges between amides of the Licα-peptide backbone 
and oxygen atoms of the pyrophosphate moiety of lipid II was predicted. To this end, the 
authors suggested that Licα might bind lipid II via two motifs, the N-terminal nisin-like and 
the C-terminal mersacidin-like motif.  
It is worth mentioning, that a recent publication reporting the identification of the new two-
peptide lantibiotic enterocin, suggested a synergistic effect of two membrane active 
peptides (Sawa et al., 2011). This is in clear contrast to the above described MoA, that was 
thought to hold true for two-peptide lantibiotics in general. Although both enterocin 
peptides harbor typical Lanα- and Lanβ- motifs, including the lipid II binding site of class II 
lantibiotics, and are highly similar to plantaricin W, both were demonstrated to act on model 
membranes without docking molecules in nanomolare concentrations. A membrane-
targeting effect of enterocin was determined by tryptophan fluorescence spectroscopy, light 
scattering and calcein leakage tests using egg yolk liposomes, which mimic gram-positive cell 
membranes. Activity of either peptide alone was barely detected and an optimal efficacy 
required addition first of α-peptide and then enterocin Wβ, suggesting that the order of 
peptide binding to membranes might be important for antimicrobial activity.  
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In this thesis, it was clearly demonstrated, that both lichenicidin peptides are necessary for 
an optimal antimicrobial activity, indicating a synergistic effect of Licα and Licβ. This 
observation was also described by Shenkarev et al. (2010) and, in addition, the authors 
demonstrated a maximal synergistic effect at a 1:1 ratio of both lichenicidin peptides.  
For some two-peptide lantibiotics, an activity of the single Lanα- and Lanβ-peptides was 
demonstrated. The alpha-peptides of plantaricin W and lacticin 3147 and β-peptides of 
haloduracin and lacticin 3147 exhibit low level of activity, but this is only observed in higher 
concentrations (µM) (McClerren et al., 2006; Holo et al., 2001; Wiedemann et al., 2006). This 
effect is most likely due to a lipid II binding-mediated inhibition of the cell wall biosynthesis. 
LicA1is likely to have a certain degree of activity on its own, as HPLC fractions that only 
contain Licα were active against M. luteus. Similarly, an activity was also observed in HPLC 
fractions containing Licβ, which probably was due to formation of ion-conducting pores. µM 
concentrations of nisin in lipid II free liposomes indicated, that pore formation occurs also in 
absence of the target molecule and might be due to binding of cationic peptides to anionic 
lipids within the membrane (Wiedemann et al., 2001 and 2004).  
Starón et al. (2011) and Burkhard and Stein (2008) established four B. subtilis whole cell 
biosensors that test the interference of peptide antibiotics with the lipid II cycle which is 
essential for peptidoglycan biosynthesis. Promotor-lacZ fusion mutants were generated in 
order to monitor induction of detoxification systems by different cell-wall-acting antibiotics 
such as the single-peptide lantibiotics mersacidin, actagardine, duramycin, gallidermin, nisin 
and subtilin. Each of these peptides was sensed by at least one of these indicator strains. It 
was observed that sensing was specific for each detoxification system and specificity did not 
appear to be correlated to the MoA or the structure of tested peptides. Thus, closely related 
lantibiotics, like mersacidin and actagardine, are not sensed by the same system (Starón et 
al., 2011).  
An inhibition of all envelope biosyntheses by the lichenicidin peptides could not be verified 
using these biosensors and, therefore, it was hypothesized that none of the indicator strains 
is able to sense two peptide-lantibiotics. This notion was supported by results of the 
bioassays with culture supernatant of the haloduracin producer B. halodurans C-125. This 
two-peptide lantibiotic showed no induction in the four biosensors as well, although it has 
been demonstrated to act by lipid II binding and pore formation (Oman et al., 2011).  
Taken together, a MoA similar to that of lacticin 3147 and haloduracin, with exception of the 
2:1 lipid II binding stoichiometry, is likely for lichenicidin. Further MoA studies will focus on 
the lipid II binding and the pore formation capacity of the lichenicidin peptides.  
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The question, why lichenicidin is exclusively present in cell wash extract, remains open, but 
an explanation might be an attachment of these peptides to the cell-surface of the producer 
strain. A location in the cell wall has also been described for haloduracin and lacticin 3147 
(Lawton et al., 2007; Cotter et al., 2006). For the lacticin peptides, studies with various 
mutants indicated that the LtnA2 peptides might be tethered to the cell wall of producing 
cells via the LtnA1 peptides (Cotter et al., 2006). Such a tethering effect was not observed for 
Licα, since Licβ is still located on the cell-surface in absence of Licα, as indicated by MALDI-
TOF analysis of culture supernatants and cell wash extracts of the LicM1 insertion mutant 
(figure 5.1, appendix, page 168).  
Proteolytic degradation of lichenicidin was supposed to be an alternative explanation for the 
absence of active lichenicidin peptides in the culture supernatant, but this notion was 
disproven by the observation that lichenicidin was stable against the proteases excreted by 
the producer strain. An attachment of the lichenicidin peptides to cell surfaces might 
alternatively be mediated by a cell capsule. B. licheniformis is able to produce a glutamyl 
polypeptide capsule (Troy, 1973). Diffusion of the positively charged lichenicidin peptides 
(Licα +1, Licβ +2) might be restricted by capsule formation, especially as incubation of 
another strain of this species, B. licheniformis DSM 641, on nisin containing agar plates 
selected nisin resistant mutants with increased capsule formation (Bierbaum, unpublished 
results). These results suggested that capsules indeed inhibit diffusion of, or can bind, 
cationic lantibiotics.  
On the whole, such a cell-surface location seems inappropriate, considering that the 
overwhelming majority of lantibiotics is regarded as bacteriocins. These molecules function 
in defense of producer strains and, thus, the peptides need to be present in the surrounding 
medium. On the other hand, some morphogenetic peptides, e.g. SapB and SapT of 
Streptomyces strains are lanthionine-containing peptides, too, and possess only very low 
antimicrobial activity (Kodani et al., 2004 and 2005). In recent years, other lantibiotic 
peptides that do not exert antimicrobial effects have been identified, e.g. the 
labyrinthopeptins and prochlorosin (Müller et al., 2010; Li et al., 2011). These peptides form 
a new class of lantibiotics, called lantipeptides, comprising lanthionine-containing peptides 
with functions other than antimicrobial activity (Willey and v. d. Donk, 2007).  
Interestingly, the majority of lantipeptides was identified in filamentous bacteria, e.g. 
strepto- and actinomycetes (Kodani et al., 2005; Kodani et al., 2006; Li et al., 2011; Müller et 
al., 2010; Goto et al., 2010). Some of these peptides were supposed to fulfill intracellular as 
well as intercellular signalling functions. A signalling function has also been described for 
antimicrobially active lantibiotics like nisin and mersacidin: these peptides are autoinducers 
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of their own biosynthesis in quorum sensing systems (Schmitz et al., 2006; Kuipers et al., 
1995). Thinking of the cell surface association of lichenicidin, it is intriguing to speculate 
about further functions and roles played by antimicrobially active lantibiotics, too, e.g. 
signalling functions involved in cell morphogenesis such as sporulation. 
In contrast to the DSM 13 producer strain, lichenicidin produced by B. licheniformis VK21 
and I89 was additionally detected in culture supernatants (Shenkarev et al. 2010; Caetano et 
al., 2011). Furthermore, neither publication mentions production of an additional, 
lichenicidin-independent antimicrobial activity, which might be due to different cultivation 
conditions or variations in the genomic background of these B. licheniformis strains.  
For lantibiotic producers, it is obvious that production of a lantibiotic is nearly always 
restricted to specific strains and not a common feature of the species. This is supported by 
the observation that lantibiotic gene clusters often appear to be gained by horizontal gene 
transfer. In agreement with this notion, neither presence of a lichenicidin coding gene 
cluster nor production of an antimicrobial substance was found in the B. licheniformis strain 
I5 in this study. Lichenicidin is produced by at least four different B. licheniformis strains e.g. 
B. licheniformis DSM 13/ATCC 14580, I89 and VK21 and a Bacillus strain that was isolated 
from infested soil in this study. Previous studies reported that due to the ability to form 
endospores, B. licheniformis strains can be isolated from soils and plant material all over the 
world (Sneath et al., 1986). In line with this, the lichenicidin producers were isolated from 
different sources and ecological niches: the isogenic B. licheniformis DSM 13 and ATCC 
14580 strains were isolated from soil samples (Rey et al., 2004); whereas the I89 and VK21 
strains are isolates from hot springs in the Azores (Portugal) or of the Kamchatka Peninsula 
(Russia), respectively (Mendo et al., 2004; Temirov et al., 2003). These findings indicate that 
lichenicidin producing Bacillus strains are widely distributed in nature and are found in 
different ecological niches. In contrast, the morphogenetic prochlorosin lantipeptides are 
widely distributed in strains of the same or related species found in the same ecological 
niche and appeared to fulfill more general intra- or extracellular functions (Li et al., 2010). 
Complete genome sequences of B. licheniformis I89 and VK21, that would give more insights 
into relatedness of all three lichenicidin producers, are not yet available.  
 
Potential applications for lantibiotics are food conservation and novel therapeutics. An 
obstacle that has hampered medical application of many lantibiotics is their missing 
resistance to proteases; this is especially characteristic for elongated pore-forming peptides 
like nisin, epidermin and Pep5. These peptides possess a linear hinge region, that is essential 
for pore-formation and which is susceptible to proteolytic degradation by, for example, 
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chymotrypsin or trypsin. Stabilization of Pep5 by a further ring structure prevented its 
digestion by chymotrypsin; however, the antibacterial activity was also decreased (Bierbaum 
et al., 1996). In contrast, peptides that are characterized by formation of intertwined 
thioether rings and do not have elongated linear stretches, e.g. mersacidin, show higher 
protease resistance. One reason that B. licheniformis DSM 13 was chosen for further 
investigations is, that it is most prominent in protease production. Seven protease genes are 
annotated in the genome of this strain (BLi00340, BLi04019; BLi01123; BLi02863; BLi02862, 
BLi01109, BLi01909). Among those are alkaline serine proteases (subtilisins) e.g. Subtilisin 
Carlsberg, a protease that is employed in detergents. Therefore, the antibacterial activity 
excreted by the DSM 13 strain was expected to show higher protease resistance than 
lantibiotics produced by members of the genera Staphylococcus and Lactococcus. Indeed, 
the protease treatments confirmed, that lichenicidin is resistant against trypsin, 
chymotrypsin and proteases excreted by the producer making lichenicidin a potential 
antibiotic for medical applications.  
 
In conclusion, the data presented here, establish that B. licheniformis DSM 13 produces a 
novel two-component lantibiotic that was attributed to the presence of a lantibiotic gene 
cluster, that was found in a bioinformatic approach. This novel, cell surface associated two-
peptide lantibiotic lichenicidin displays interesting features for medical applications such as 
protease resistance and activity against (multiresistant) human-pathogenic strains.  
 
Bacillus licheniformis DSM 13 produces an additional bacteriocin  
In the course of this thesis, B. licheniformis DSM 13 was shown to produce two antibiotic 
substances, one present in cell wash extract and an additional in the culture supernatant. 
Performing agar well diffusion assays showed that both exhibit antimicrobial activities 
against Gram-positive clinical isolates and were inactive against Gram-negatives. 
Interestingly, both suspensions displayed a slightly different spectrum of activity indicating 
that two independent antibiotic substances were produced under chosen conditions. This 
suggestion was underlined by results of peptide stability assays showing that the substance 
in the culture supernatant is less stable to heat treatment than the lantibiotic lichenicidin, 
the substance in the cell wash extract. Furthermore, differences in growth assays with M. 
luteus and B. subtilis based whole cell biosensor assays (Staron et al., 2011) were observed. 
The latter suggested that the substance present in culture supernatant causes a cell 
envelope stress, whereas lichenicidin does not activate the pLIA reporter system. Finally, 
studies with lichenicidin knock out mutants, demonstrated that the antimicrobial activity in 
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the B. licheniformis culture supernatant is not associated to the lichenicidin gene cluster and, 
instead, is caused by an independent, unknown substance.  
Bacillus species are known to produce a large number of peptide antibiotics with various 
chemical structures and their genomes very often harbor more than one gene cluster coding 
for biosynthesis of antibiotic substances (von Doehren et al., 1995). In B. subtilis 168, 
different polyketide synthetases exist, that cover almost 4% of its genome. Interestingly, 
these genes were not identified in the genome of the close relative B. licheniformis DSM 13, 
although it exhibits a marked co-linearity with the genome of B. subtilis (Veith et al., 2004; 
Lapidus et al., 2002). In contrast to other B. licheniformis strains, e.g. B. licheniformis ATCC 
10716, genes coding for biosynthesis machinery of the cyclic polypeptide bacitracin are 
absent in the DSM 13 strain (Flickinger and Perlman, 1979; Rey et al., 2004).  
Besides the gene cluster coding for lichenicidin, four genes (BLi00401- BLi00404) encoding 
subunits of non-ribosomal peptide synthesis complexes involved in biosynthesis of lichenysin 
were identified during annotation of the genome (Veith et al., 2004). Lichenysin is a cyclic 
anionic lipopeptide resembling surfactin, an amphipathic biosurfactant, which is produced 
by B. subtilis strains (Yakimov et al., 1995; Grangemard et al., 2001). Based on its membrane-
disruptive effect, surfactin exhibits an antimicrobial activity against Gram-positive bacteria 
and causes hemolysis of erythrocytes (Arima et al., 1968; Nakano et al., 1988). Analog 
activities were also reported for lichenysin (Yakimov et al., 1995) and production of at least 
six slightly different lichenysin variants (lichenysin A, B, C, D, G and BL86) with a MW 
between 979-1091 Da, has been observed for B. licheniformis strains (Nerukar, 2010).  
B. licheniformis DSM 13, is not thought to produce lichenysin itself, although it harbors the 
corresponding biosynthesis genes. Transcription of the lichenysin biosynthesis machinery is 
activated by the phosphorylated form of the competence factor ComA (Yakimov et al., 
1997). However, in B. licheniformis DSM 13, the gene of the kinase ComP, that is necessary 
for activation of the factor ComA, has suffered insertion of an IS element (IS3Bli1) (Lapidus et 
al., 2002; Rey et al., 2004) and this gene inactivation might account for the failure to produce 
lichenysin. In line with this and contrary to the surfactin producer B. subtilis 168, no 
hemolytic activity could be detected for B. licheniformis DSM 13 when streaked on Columbia 
agar plates. In addition, the antimicrobially active substance in the culture supernatant lacks 
a hemolytic activity indicating that this substance does not represent lichenysin. 
In 2009, D. Haft identified, based on bioinformatic studies, existence of a new subfamily of 
thiazole- and oxazole-modified microcins (TOMMs), the heterocycloanthracins. An 
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analogous, not yet annotated, structural gene was found in the genome of B. licheniformis 
ATCC 14580, which is isogenic to the DSM 13 strain (figure 4.3 (A)).  
TOMM peptides are highly modified bacteriocins, that undergo extensive post-translational 
modifications resulting in introduction of class specific heterocyclic oxazole and thiazole 
rings. In a first step, the aa side chains of Cys, Ser and Thr residues are joined to the carbonyl 
group contributed by the peptide bond with the immediately N-terminally located residue, 
which often is glycine. The reaction eliminates a water molecule from the amide backbone, 
thereby, introducing the heterocyclic rings, thiazolines and oxazolines, and is catalyzed by an 
ATP-dependent cyclodehydratase. An FMN-dependent dehydrogenase removes two 
electrons and protons to form the class specific aromatic rings, thiazoles and oxazoles. Both 
modification enzymes are co-organized and form a trimeric modifying protein complex with 
an additional scaffold protein (Ghilarov et al., 2011; Melby et al., 2010).  
The heterocycloanthracin precursor of B. licheniformis is characterized by twelve repetitive 
cysteine-rich motifs in its C-terminal sequence (figure 4.3). Eight of these repeats are 
tripeptides characterized by a CXS motif and five of them share the related “CWS” sequence. 
A similar tetrapeptide “CWSC” repeat is present in the class IIa bacteriocin thuricin S 
produced by B. thuringiensis (Haft, 2009; Chehimi et al., 2007). In this cationic and 
hydrophobic peptide, the CWSC motif also occurs within a repetitive CXX sequence. Based 
on the aa sequences of the precursor, introduction of up to thirteen thiazoline/thiazoles and 
ten oxazolines/oxazoles would be possible  
 
MQPFHDELQSLEMDHFQADDMTHWDPDRHHANVKH CAS CWS CGS CAS CWS C HS AG
CWS C HS MG CWS C H AG CC S W C GGM WH
  
Figure 4.3: AA sequence of the predicted heterocycloanthracin precursor identified in the genome 
of B. licheniformis DSM 13. The putative heterolycloanthracin precursor of B. licheniformis DSM 13 is 
characterized by repetitive CXX motifs ( ).  orange
 
In vicinity of the putative bacteriocin precursor, Haft identified two ORFs (BLi01044 and 
BLi01045) that are similar to enzymes and proteins involved in post-translational 
modifications of TOMM peptides. Although this arrangement is commonly found in gene 
clusters coding for bacteriocins, a co-localization of precursor and corresponding 
modification enzymes was not found universally in genomes of predicted producers of 
heterocycloanthracins (figure 4.3 (B)).  
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Figure 4.4: Genomic regions in B. anthracis Ames and B. licheniformis ATCC 14580 predicted to 
encode bacteriocin precursors of the heterocycloanthracin group. Putative structural genes are 
black and other genes are marked as follows: cyclodehydratases, putative docking scaffold proteins, 
dehydrogenases and protein with unknown function (Haft, 2009).  
 
ORF BLi01044 codes for a cyclodehydratase and BLi01045 is a scaffold-like protein. In 
contrast to other TOMMs, even to other putative heterocycloanthracin producers, a 
thiazole/oxazole-producing dehydrogenase was not identified in the genome of B. 
licheniformis (Haft, 2009), a finding that has previously been described for producers of the 
TOMM peptides of the cyanobactin subfamily, too. Absence of modification enzymes 
resembling FMN-dependent dehydrogenases in these producers results in synthesis of 
peptides with thiazoline and oxazoline rings. Subsequently, these residues are partially 
converted into their aromatic heterocycles by so far uncharacterized cellular enzymes 
(McIntosh and Schmidt, 2010; Ghilarov et al., 2011). However, some of these oxazolines and 
thiazolines still remain unmodified in the otherwise completely modified peptides, e.g. 
patellamides A and trunkamide (Irland et al., 1982; Wipf et al., 2000). Interestingly, for 
members of other TOMM peptide subfamilies, e.g. microcin B17 and streptolysin S, variants 
containing unoxidized thiazolines or oxazolines were not detected (Ghilarov et al., 2011). 
These findings open the following questions regarding the structure of the putative 
heterocycloanthracin peptide found in B. licheniformis DSM 13:  
1. Does this bacteriocin contain the unoxidized oxazoline and thiazoline residues instead of 
oxazole and thiazole rings? 
2. Are these residues (partially) converted into oxazoles and thiazoles by an unknown, 
additional modification enzyme?  
3. Is this gene cluster a complete heterocycloanthracin gene cluster that confers ability to 
produce the fully modified peptide?  
The antimicrobial substance in the B. licheniformis DSM 13 culture supernatant might 
represent this new TOMM-like bacteriocin. As demonstrated in B. subtilis whole cell 
biosensor assays, the substance in the supernatant most likely targets the bacterial cell 
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surface. Interestingly, such an effect has not been described for any antimicrobially active 
peptide of the TOMM family so far. Nevertheless, a cell membrane affecting MoA has been 
described for thuricin S, which possesses only little aa similarity to the putative B. 
licheniformis heterocycloanthracin and apparently belongs to another class of bacteriocins 
(Chimini et al., 2007; 2010; Haft, 2009).  
No bacteriocin of the predicted heterocycloanthracin subfamily has been purified or 
experimentally characterized up to now. Therefore, putative molecular weights, 
modification states or MoA could not be predicted for these new bacteriocins based on in 
silico analysis.  
However, MALDI-TOF analysis of the culture supernatant revealed different mass signals 
within the TOMM relevant range (2-10 kDa, see appendix page 168). At least one of these 
signals might represent the modified bacteriocin. This hypothesis awaits experimental 
confirmation. To this end, cyclodehydratase knock out mutants will be generated in order to 
correlate antimicrobial activity of B. licheniformis DSM 13 culture supernatant to the 
predicted bacteriocin-coding gene cluster. Additionally, future studies will focus on 
purification, structural characterization and MoA analysis of this promising substance.  
 
Caldicellulosiruptor bescii DSM 6752 and Nostoc punctiforme ATCC 29133 are putative 
producers of lanthionine-containing peptides 
Detailed bioinformatic analysis identified complete lantibiotic-like gene clusters in N. 
punctiforme and C. bescii. However, both strains display features uncommon for producers 
of lantibiotics and lantibiotic peptides: 
(A) Caldicellulosiruptor bescii DSM 6752 (besciin) 
The genes of the lantibiotic-like gene cluster of C. bescii are highly similar to corresponding 
genes of the lichenicidin gene cluster. This sequence similarity extends to the C-terminal part 
of the besciin propeptide and led, together with the presence of a mersacidin-like binding 
motif, to the assumption that the encoded lantibiotic peptide might 1. hold a conserved 
lanthionine-bridging pattern as seen in LanA1 peptides of two-peptide lantibiotics and 2. be 
antimicrobially active due to lipid II binding and inhibition of the cell wall biosynthesis.  
On the other hand, the propeptide sequence is extremely long, compared to other 
lantibiotics, and leader cleavage at the conserved processing site would lead to the largest 
lantibiotic peptide identified so far (52 aa). Similar to other predicted lantibiotic gene 
clusters, this cluster contains a gene coding for an FMN-depended reductase that might 
exert a so far unknown role in modification of the lantibiotic besciin.   
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(B) Nostoc punctiforme ATCC 29133 (puncticin) 
The predicted lantibiotic gene cluster of N. punctiforme ATCC 29133 contains two almost 
identical putative lantibiotic structural genes (PunA1; PunA2), a modification enzyme of the 
LanM-type (PunM), an exporter (PunT(P)) typical for class II lantibiotics in addition to a 
second exporter lacking an internal protease domain and genes coding for membrane 
proteins. The genome additionally harbors three further LanM-like proteins and six ORFs 
coding for short peptides that exhibit sequence similarity to the leaders of PunA1 and 
PunA2. Three of those putative LanA coding ORFs (Npun_F3224 – 26) are clustered and two 
share almost identical aa sequences. A lanM-gene was not found in direct vicinity of these, 
but ~20 kb upstream. The other LanAs are widely distributed within the genome and two of 
them (Npun_R3313; Npun_AF077) are flanked by a LanM-like protein. The sixth ORF is not 
co-localized with a LanM and apparently is no lantipeptide precursor, since Cys are absent in 
its C-terminus.  
Irrespective of the culture conditions chosen, no production of an antimicrobial activity 
could be detected for Nostoc punctiforme (diploma thesis, J. Dischinger, 2008). MALDI-TOF 
analysis of supernatants and isopropanol cell wash extracts did not identify expression of 
peptides attributable to the predicted puncticin precursors. For this reason, this study aimed 
at the establishment of expression systems for heterologous expression of the predicted 
precursors and modification enzymes with focus on the lanA and lanM genes found in the 
puncticin cluster.  
Of note, cyanobacteria like Nostoc are referred to as Gram-negatives, which had not been 
considered as potential lantibiotic producers until characterization of the cyanobacterial 
lantipeptide prochlorosin (Li et al., 2010) that was described during preparation of this 
study. Prochlorosin is produced by the single-cell, planktonic, marine cyanobacterium 
Prochlorococcus MIT9313. A total of 29 different structural genes was identified, all have 
leader sequences that include GG or GA cleavage sites. Seven structural genes are found 
clustered with the gene coding for ProcM. The other 22 procA genes are found elsewhere in 
the genome, 20 of which also cluster in three further regions. Propeptide sequences of these 
precursors are diverse in regard to their length and aa composition. Even the aa precursors 
for lanthionine and methyllanthionine, Ser, Thr and Cys, are unevenly distributed in these 
peptides (Li et al., 2010).  
In contrast to the leaders of prochlorosin peptides which are highly conserved with almost 
identical aa sequences, the putative structural genes identified in N. punctiforme have 
similar (33-65%) leader sequences. Exceptions are PunA1 and PunA2: both sequences are 
only almost identical, since their leaders differ in two positions and 1 aa exchange is found in 
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their propeptides. To this end, an evolution of these peptides by gene duplication is likely, 
especially since the intergenetic regions flanking both genes are highly similar, as well. 
Evolution by gene duplication of two almost identical lantibiotic precursors has been 
described for the lantibiotic gene cluster coding for streptococcin AM49 (Hynes et al. 1994).  
In in vitro enzyme assays, 17 prochlorosin peptides were modified by a single, promiscuous 
LanM enzyme (ProcM) (Li et al., 2010). In addition, production of at least three prochlorosins 
was demonstrated in vivo and occurred in late-exponential growth stage. Resulting 
lantipeptides are polycyclic, conformationally constrained products with highly diverse ring 
topologies. None of the analyzed peptides had aa sequence similarity or an analogous 
thioether ring pattern to known lantibiotics or lantipeptides. The peptides are believed to 
play habitat- and/or community-specific roles and were assigned to exert intracellular 
functions. Genomic data mining for similar lantipeptides in metagenomic databases of ocean 
samples showed that corresponding sequences occur in variable amounts across the oceans, 
with a hot spot in a Galapagos hypersaline lagoon (Li et al., 2010). First data suggest an 
involvement of cyanobacterial lantipeptides in nitrogen metabolism. Whole genome 
expression studies showed that transcription of procA genes is down-regulated by nitrogen 
starvation, but does not respond to phosphate or iron starvation (Li et al., 2010).  
Wang et al. (2011) showed, using genome mining, that filamentous heterocyst-forming 
cyanobacterial strains, such as Nostoc strains with larger genomes, tend to possess more 
bacteriocin gene clusters than unicellular marine strains. N. punctiforme is able to 
differentiate into different cell forms: nitrogen-fixing heterocysts, spore-like akinetes, and 
motile hormogonium filaments. Identification of global gene expression patterns in 
heterocyst-containing cultures and at specific time points during differentiation of akinetes 
and hormogonia (Campbell et al., 2007), showed that nitrogen-fixing conditions upregulate 
expression of a histidine kinase and its corresponding transcriptional regulator, that both 
were thought to be part of the puncticin gene cluster. This might indicate an involvement of 
puncticin in heterocyst differentiation and nitrogen assimilation.  
Sequence similarity of predicted leader sequences found in N. punctiforme and Nif11 
proteins, which code for nitrogen fixing proteins provide an additional link of cyanobacterial 
lantipeptides to nitrogen metabolism. In agreement with these data, certain prochlorosin 
precursors resemble Nif11 proteins, too (Li et al., 2010). Existence of bacteriocins containing 
Nif11-like leader sequences in cyanobacteria was discovered by Haft et al. (2010) and Wong 
et al. (2011) additionally identified different classes of bacteriocins in cyanobacteria by 
genomic data mining. Some of these predicted bacteriocin gene clusters include typical 
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lantibiotic modification enzymes of the LanM-type, others are co-localized with genes coding 
for enzymes involved in modification of TOMM-like bacteriocins.  
Fourteen bacteriocin-coding gene clusters have been predicted for N. punctiforme ATCC 
29133 (Wang et al. 2011. The authors reported four lantipeptide-like gene clusters in this 
organism, indicating that beside the putative precursors identified in this thesis, other 
putative lantibiotic-like precursors exist, which share no sequence similarity with PunA1 and 
PunA2. 
Based on the data presented, it is assumed that the predicted structural genes of N. 
punctiforme code for lantipeptides without antimicrobial activity, too. Existence of different 
LanM enzymes and structural genes suggests that more than one lantipeptide is expressed in 
this organism, forming a complex lantipeptide-mediated signal network. Future studies will 
further explore heterologous expression of these lanM and lanA genes. In vitro 
reconstitution of lantibiotic modifications will be performed to confirm their lanthionine-
containing structure.  
 
(C) heterologous expression  
For both putative producers, N. punctiforme and C. bescii, expression of biosynthesis 
enzymes and structural genes in a heterologous system to subsequently assess in vitro 
reconstitution of lantibiotic biosynthesis was tested. Recombinant vectors coding for N-
terminally HIS-tagged precursors and C-terminally HIS-tagged modification enzymes were 
generated successfully. By site directed mutagenesis, engineered factor XA protease 
cleavage sites were introduced into the precursors to enable site specific in vitro processing. 
Heterologous expression of the precursors PunA1_XA and AnaA_XA was successfully 
achieved in E. coli Bl21 following the LanA NI-NTA purification protocol published by 
McClerren et al. (2006). Heterologous expression of PunM and AnaM was not successful so 
far and, thus, remains in the focus of ongoing studies. Using complementary approaches, 
overproduction of N-terminally HIS-tagged MrsM, the modification enzyme of mersacidin, 
was achieved successfully. First experiments in which PunM and AnaM were expressed in E. 
coli indicated overexpression of these proteins, but resulted in cell lysis due to a toxic effect. 
This challenge will be tackled by co-expression of chaperones in E. coli strains optimized for 
expression of toxic proteins.  
Successful heterologous production and in vitro modification have previously been shown 
for other lantibiotics and lantipeptides, e. g. haloduracin, prochlorosin, nisin (McClerren et 
al., 2006; Li et al. 2010; Chen et al., 2007). In vitro modification systems hold certain 
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advantages in discovery and characterization of new lantibiotics and also in bioengineering 
of lantibiotic peptides. Thus, these systems allow rapid production and characterization of 
highly modified lantibiotic variants. In vivo, expression of engineered peptide variants often 
fails, since these peptides are not recognized by innate immunity, regulatory or transporter 
systems of producers and, hence, cannot be secreted or are toxic for producing strains. 
Moreover, these systems are promising tools for utilizing lantibiotic modification enzymes 
for incorporation of thioether rings into other medical peptides in order to increase their 
chemical and proteolytic stability (Kuipers et al., 2005; Bosma et al., 2011). Additionally, in 
vitro reconstitution of lantibiotic biosynthesis opens the door for a detailed investigation of 
new lantibiotics that were identified in silent or incomplete gene clusters or in metagenomic 
sequences.  
 
The genome of B. amyloliquefaciens FZB42 harbors the mersacidin immunity genes that 
confers resistance against the lantibiotic mersacidin  
Genome sequence annotations indicated that lantibiotic immunity operons are widely 
distributed in bacterial genomes. Typically, lantibiotic immunity operons are co-located with 
other genes involved in lantibiotic production and together they form lantibiotic gene 
clusters (Siezen et al., 1996). In bacteria producing lantibiotics, immunity proteins confer 
resistance against the lantibiotic produced, a phenomenon which is commonly referred to as 
immunity or producer self-protection. Mining of bacterial genomes revealed orphan 
immunity operons that did not appear to be associated with production of a corresponding 
lantibiotic in these hosts. Some of these immunity proteins have a high aa sequence 
similarity to previously described immunity systems and, thus, they might offer protection 
against the same lantibiotic or closely related peptides by homologous protein functions. 
This suggestion is supported by results obtained by transfer of immunity providing proteins 
to sensitive indicator strains. Expression of epidermin immunity transporters in 
Staphylococcus carnosus resulted in a 6-fold higher resistance to gallidermin, an epidermin 
analog (Otto et al., 1998).  
Annotation of the B. amyloliquefaciens FZB42 genome revealed presence of the two 
mersacidin immunity operons (Chen et al., 2007). These include the subunits of the 
mersacidin immunity transporter, MrsEFG, and a two-component regulatory system 
comprising the transcriptional regulator MrsR2 and the histidine kinase MrsK (Altena et al., 
2000). The latter is involved in transcriptional regulation of the immunity operon in the wild-
type producer and induces expression of MrsEFG in presence of mersacidin (Schmitz et al., 
2006; Guder et al., 2002). Involvement of the ABC-transporter subunits MrsEFG in resistance 
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against mersacidin was clearly demonstrated by heterologous expression of these proteins 
in Staphylococcus carnosus TM 300 (R. Reinartz, diploma thesis, 2005).  
In silico analysis showed, that immunity proteins and their intergenic regions found in the 
FZB42 strain are highly similar to corresponding sites in the mersacidin gene cluster. 
Additionally, this cluster is located in the same genetic context as in the mersacidin producer 
B. sp. HIL Y-85,54728. These findings support the idea that B. amyloliquefaciens FZB42 might 
have lost the biosynthetic part of the mersacidin cluster during evolution.  
In this study, the mersacidin immunity system in B. amyloliquefaciens FZB42 was 
demonstrated to confer resistance against mersacidin. In MIC determinations this strain was 
at least as resistant to mersacidin as the wild-type producer. B. amyloliquefaciens FZB42 
produces a vast array of antibacterial and antifungal compounds that are thought to provide 
competitive advantage in its natural habitat, the rhizosphere. Presence of genes, which are 
almost identical to the immunity genes of mersacidin provides additional protection against 
competing strains that excrete this lantibiotic.  
Recently, a gene locus spiEFG, resembling the subunits of the immunity ABC transporter 
(NsuEFG) of nisin U, was identified in Streptococcus infantarius (Draper et al., 2012). As seen 
for B. amyloliquefaciens FZB42, this gene locus also contains genes coding for the two-
component regulatory system which is involved in regulation of nisin U biosynthesis and 
expression of the dedicated immunity system in the wild-type producer Streptococcus 
uberis. Heterologous expression of SpiEFG in Lactococcus lactis conferred resistance against 
nisin U and its variants as well, and verified a correlation of this transporter to nisin U 
resistance (Draper et al., 2012).  
In agreement with this, “immune mimicry” has been described for proteins homologous to 
LanI referring resistance to lantibiotics due to natural presence or acquisition of homologs of 
lantibiotic immunity proteins (Draper et al., 2009). The authors demonstrated presence of 
orphan LanI peptides, that have sequence similarity to the LtnI peptide, which is associated 
with immunity to the two-component lantibiotic lacticin 3147. Orphan LanI peptides were 
identified in non-lantibiotic producers such as E. faecium DO and heterologous expression of 
these peptides resulted in development of resistance against lacticin 3147 in sensitive strains 
(Draper et al., 2009). 
Presence of such immunity protein homologs, that confer innate resistance in pathogenic 
bacteria, might become an immense problem when lantibiotics are developed for clinical 
application. Additionally, transfer of these immunity systems by horizontal gene transfer 
among pathogenic strains might facilitate emergence of lantibiotic-resistant strains.  
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However, the lantibiotic nisin has been used as food preservative for more than 50 years and 
development of resistance has rarely been observed. If it occurs, the resistance generally 
relies on target modification such as changes in membrane composition (Kaur et al., 2011). 
On the other hand, lantibiotic immunity proteins are highly specific and cross immunity is a 
rare phenomenon, even among producers of structurally highly similar lantibiotics. Thus, 
possession of lantibiotic immunity proteins might confer resistance to only one lantibiotic or 
closely related variants thereof. This implies, that immune mimicry is not a general 
mechanism of resistance to lantibiotics.  
 
Mersacidin is heterologous expressed in B.amyloliquefaciens FZB42  
The mersacidin wild-type producer B. sp. HIL Y-85,54728 is not naturally competent. This 
means, that genetic manipulation of the lantibiotic gene cluster could only be achieved by 
protoplast transformation, which is time consuming and yielded only low transformation 
frequencies. This study, aimed at transferring the complete mersacidin gene cluster into a 
naturally competent Bacillus strain and the subsequent heterologous expression of 
mersacidin by this host.  
Successful heterologous production has previously been shown for several lantibiotics, e. g. 
for subtilin (Liu et al., 1991) and nisin (Yuksel et al., 2007) by B. subtilis 168, for lacticin 3147 
by Enterococcus faecalis (Ryan et al., 2001), or for epicidin 280 by Staphylococcus carnosus 
(Heidrich et al., 1998). Very recently, production of active lichenicidin has even been 
achieved in E. coli (Caetano et al., 2011). However, heterologous production of a lantibiotic 
cannot be taken for granted and remains difficult. For example, epicidin 280 and Pep5 are 
two closely related lantibiotics, but Pep5 shows a higher antibacterial activity than epicidin 
280. In contrast to epicidin 280, Pep5 cannot be expressed in S. carnosus, which is 
susceptible to this agent in a nanomolar range, indicating that toxicity of the product may be 
a problem here (G. Bierbaum, unpublished data).  
Lantibiotics generally target essential and conserved cell structures such as bacterial cell 
membranes or the cell wall precursor lipid II, structures that are present in producing strains, 
as well. This necessitates, that these targets have to be protected by dedicated producer-
self-protection systems to inhibit self-destruction of the producers. This common feature has 
to be considered when production of lantibiotics is aimed to be transferred into a 
heterologous expression host. Thus, for successful and high-level expression of mersacidin in 
a heterologous host, two hurdles have to be overcome: functional producer self-protection 
and transfer of the biosynthetic gene cluster to the new host. 
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Here, it was demonstrated that B. amyloliquefaciens FZB42 is resistant to mersacidin due to 
existence of homologous mersacidin immunity genes. Therefore, this strain was chosen as 
amenable to heterologous production of mersacidin. After transfer of the biosynthetic part 
of the gene cluster, successful expression of mersacidin was obtained from plasmids in trans. 
As demonstrated by MALDI-TOF analysis, HPLC based peptide purification and agar well 
diffusion assays, the expressed mersacidin was antimicrobially active and fully modified.  
In conclusion, it could be shown here, that it is possible to produce mersacidin in B. 
amyloliquefaciens FZB42. The successful production of fully modified and active mersacidin 
by this strain provides an appropriate in vivo expression system for the construction and 
expression of mersacidin analogs and modified variants, as previously demonstrated for the 
in vivo expression system for nisin (Kuipers et al., 2005; Bosma et al., 2011). Production of 
mersacidin in this strain additionally allows genetic manipulation and downstream 
modification of the whole biosynthesis gene cluster.  
 
The Mersacidin producer B. sp. HIL Y-85,54728 belongs to the species B. amyloliquefaciens  
Presence of the mersacidin immunity operon in B. amyloliquefaciens FZB42 raised the 
question whether the natural, so far uncharacterized, mersacidin producer might also 
belong to the species B. amyloliquefaciens.  
In previous studies of our research group, various gene sequences obtained from the 
mersacidin producer were compared to those of the publicly available genome sequences of 
B. amyloliquefaciens FZB42, DSM 7 and B. subtilis 168 (A.M. Herzner, diploma thesis, 2008). 
In these in silico analyses, a high similarity between B. amyloliquefaciens FZB42 and the 
producer strain of mersacidin was obvious. All analyzed sequences, including the intergenic 
regions, showed about 98.5% nucleotide sequence identity to the FZB42 strain, whereas 
these sequences had about 93.5% and 77.4% identity to B. amyloliquefaciens DSM 7 and B. 
subtilis 168, respectively. Existence of a gene cluster coding for the non-ribosomal peptide 
antibiotic bacillaene was described for both amyloliquefaciens strains (Chen et al., 2007; 
Rueckert et al., 2011) and presence of the gene baeD, coding for a malonyl-CoA-
transacylase/oxidoreductase involved in bacillaene synthesis, was also demonstrated in B. 
sp. HIL Y-85,54728. These findings indicated that the mersacidin producing strain at least 
carries parts of the bacillaene cluster.  
Additionally, biochemical identification tests demonstrated that in contrast to B. subtilis 168, 
B. amyloliquefaciens FZB42 and B. sp. HIL Y-85,54728 were able to metabolize xylose, lactose 
and starch. Both strains neither grew at 50°C nor in presence of 10% sodium chloride. 
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Furthermore, both strains did not produce acid from trehalose and mannitol, but differed in 
their ability to metabolize gelatin. To clearly classify B. sp. HIL Y-85,54728, 16S rRNA coding 
genes were sequenced. NCBI BLAST searches employing the obtained sequences indicated a 
close similarity to B. amyloliquefaciens FZB42 (A.M. Herzner, diploma thesis, 2008).  
 
B. amyloliquefaciens FZB42 was isolated from the plant rhizosphere and has recently been 
defined as the type strain of a group of growth-promoting and plant-associated B. 
amyloliquefaciens strains. Members of this group form a distinct cluster within the 
amyloliquefaciens species, the subspecies B. amyloliquefaciens subspec. plantarum. In 
addition to their ability to colonize plant roots, members of the plantarum subspecies are 
discriminated from the subspecies B. amyloliquefaciens subspec. amyloliquefaciens by 
differences in gyrA and cheA nucleotide sequences, hydrolysis of cellulose and an increased 
ability to produce non-ribosomal secondary metabolites like fengycin and difficin (Borriss et 
al., 2010; Chen et al., 2009; Chen et al., 2007; Rueckert et al., 2011). 
Here, the gyrA gene of the mersacidin wild-type producer, which codes for the subunit A of 
the gyrase, was sequenced. A blast analysis in the NCBI database verified a close similarity of 
B. sp. HIL Y-85,54728, to B. amyloliquefaciens species. In a taxonomic tree, that was 
calculated based on gyrA sequences of the mersacidin producer and different members of 
the genus Bacillus, the producer strain is located in the cluster formed by members of the 
plantarum subspecies, suggesting a close association between the mersacidin wild-type 
producer and plant-associated strains. This similarity was not confined to the gyrA sequence, 
but was also reflected in the generally higher nucleotide sequence identity of B. sp. HIL Y-
85,54728 and B. amyloliquefaciens subspec. plantarum FZB42 in comparison to the values 
reached by the DSM 7 type strain of the B. amyloliquefaciens subspec. amyloliquefaciens 
group. 
A distinguishing feature of the subspecies B. amyloliquefaciens subsp. plantarum is the 
ability to colonize Arabidopsis roots (Borriss et al., 2010). In fact, nearly all members of this 
subspecies were isolated from plants, plant roots or, like B. amyloliquefaciens FZB42, from 
infested soil. The only exception is represented by the strain UCMB5113 that was isolated 
from soil. In contrast, the producer strain of mersacidin originates from soil of a salt pan in 
Mulund, India, and unfortunately association of the original isolate with plants was not 
mentioned in the first report (Chatterjee et al., 1992). However, the strain did not grow in 
presence of 10 % salt in the laboratory, indicating that the salt pan might not be its natural 
biotope and that its presence in the sample might rather be due to its ability to form long-
lived spores.  
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In conclusion, the mersacidin wild-type producer was clearly demonstrated to belong to the 
species B. amyloliquefaciens and apparently is closely related to the plant-associated 
subspecies plantarum. Therefore, B. sp. HIL Y-85,54728 should be renamed Bacillus 
amyloliquefaciens HIL Y-85,54728.  
 
General conclusion and comments 
The data presented here, demonstrated the advantage of genomic data mining and 
bioinformatic analysis in the discovery of new antibiotic substances over classical antibiotic 
identification methods. The gene cluster encoding lichenicidin was identified by 
bioinformatics and its identification is an additional example of how publicly available 
bacterial genome sequences support discovery of new lantibiotics. On the other hand, 
structure elucidation of lichenicidin peptides showed, that prediction of lanthionine bridging 
pattern based on aa sequence similarity is not always correct and has to be verified 
experimentally.  
Besides identification of new lantibiotic producers, genomic data mining of lantibiotic 
immunity proteins resulted in identification of a Bacillus strain immune to mersacidin. The 
strategy employed here, i.e. use of an organism that already possesses immunity genes of a 
lantibiotic, for production of the same substance, was successful and allowed production of 
active and fully modified mersacidin in an in vivo expression system using the naturally 
competent B. amyloliquefaciens FZB 42.  
Bioinformatic prediction of new lantibiotic producers revealed that lanthionine-containing 
peptides are more widely distributed among bacteria than assumed. This finding is in line 
with recent publications reporting the identification and prediction of new bacteriocin 
producers, including bacterial taxa that were not assigned to be putative lantibiotic 
producers (Li et al., 2010). Characterization of antimicrobially inactive lanthionine-containing 
peptides and their distribution in nature suggested other than antimicrobial functions, like 
morphogenetic or signalling activity. This indicates that we are just starting to learn why 
bacteria produce these fascinating peptides. 
 
 
 
 
| 136 | 
 
Summary 
Lantibiotics are microbial peptide antibiotics that are characterized by presence of the 
thioether aa (methyl-)lanthionine. Lantibiotics possess structural genes which encode 
inactive prepeptides. During maturation, the prepeptides undergo post-translational 
modifications including 1. introduction of rare aa such as (methyl-)lanthionine; and 2. 
proteolytic removal of the leader. The structural gene (lanA) and the other genes involved in 
modification of lantibiotics (lanM, lanBC, lanP), regulation (lanR, lanK), export (lanT(P)) and 
immunity (lanEFG) are organized in gene clusters.  
The focus of the present studies was the identification of novel lantibiotic producers by 
genomic data mining. Lantibiotic modification enzymes share conserved structures and 
sequences. To this end, they are useful blueprints for bioinformatic identification and 
prediction of novel lantibiotic gene clusters.  
Here, BlastP searches identified three putative lantibiotic producers, Bacillus licheniformis 
DSM 13, Nostoc punctiforme ATCC 29133 and Caldicellulosiruptor bescii DSM 6725, that 
were chosen for detailed analyses in this thesis.  
For B. licheniformis DSM 13 a two-peptide lantibiotic cluster was predicted. Here, production 
of two antimicrobial substances was demonstrated for this strain, one present in the culture-
supernatant and the other in the cell wash extract. Both exhibited differences in the activity 
spectra and displayed different biochemical properties.  
By site-directed mutagenesis the antimicrobial activity of the cell extract could be attributed 
to production of a two-peptide lantibiotic, lichenicidin, encoded by the predicted gene 
cluster. Subtractive MALDI-TOF analysis of mutants confirmed masses of 3020.6 and 3250.6 
Da for active lichenicidin. Both peptides were shown to exhibit activity, but antimicrobial 
action was enhanced when both were combined indicating a synergistic effect. Lichenicidin 
showed interesting activities against Gram-positives including multi-resistant Staphylococcus 
aureus strains. Its efficacy was comparable to that of other lantibiotics, some of which are 
promising candidates for medical application.  
Antimicrobial activity of the culture supernatants was unaffected in these knock out mutants 
and apparently is not based on the lichenicidin cluster. During preparation of this study, the 
existence of a structural gene coding for a bacteriocin of a new family of thiazole-oxazole-
microcin B17-like peptides (TOMM) was predicted (Haft, 2009) and this gene product might 
represent the uncharacterized antimicrobial substance of the supernatant. Future work will 
focus on characterization of this substance.  
For the lantibiotic-like gene clusters found in N. punctiforme and C. bescii, features 
uncommon for lantibiotic producers are evident: 1. cyanobacteria like Nostoc are referred to 
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as Gram-negatives, which had not been considered lantibiotic producers until identification 
of the cyanobacterial lantipeptide prochlorosin (Li et al., 2010), and 2. the predicted 
lantibiotic precursor of C. bescii shares similarity to known lantibiotics, but is extremely long 
compared to other lantibiotic propeptides and its gene cluster might harbor a new 
modification enzyme. Furthermore, the active besciin peptide would be the largest 
lantibiotic known.   
In this thesis, heterologous expression of biosynthesis enzymes and structural genes of both 
producers was aimed for the subsequent in vitro reconstitution of lantibiotic biosynthesis. 
Recombinant vectors coding for N-terminally HIS-tagged precursors and C-terminally HIS-
tagged modification enzymes were successfully generated. Site directed mutagenesis 
introduced an engineered factor XA protease cleavage site into the precursors to enable site- 
specific in vitro processing. Heterologous expression of the HIS-tagged puncticin and besciin 
precursors was successfully achieved, whereas expression of the corresponding modification 
enzymes was not successful so far and this challenge is the subject of ongoing studies. 
The second project aimed at constructing an in vivo lantibiotic expression system to produce 
mersacidin in a naturally competent Bacillus strain. B. amyloliquefaciens FZB42 harbors the 
mersacidin immunity genes and could be shown to be resistant to mersacidin. Therefore, B. 
amyloliquefaciens FZB42 was chosen for heterologous expression. After transfer of the 
biosynthetic part of the cluster, production of fully modified and antimicrobially active 
mersacidin was achieved in trans. The new mersacidin producer allowed genetic 
manipulation of the lantibiotic cluster. Furthermore, the mersacidin wild-type producer was 
demonstrated to be a member of the species B. amyloliquefaciens and, therefore, it was 
renamed B. amyloliquefaciens HIL Y-85,54728.  
Both projects support the usefulness of genomic data mining and bioinformatics in 
identification of genes associated with lantibiotic production or immunity and enabled the 
discovery and characterization of the new two-peptide lantibiotic lichenicidin and the 
establishment of an in vivo mersacidin expression system in B. amyloliquefaciens FZB42.  
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Appendix 
 
AA sequence of the N-terminally HIS-tagged PunA1 
• 11.922 kDa 
• present in pET28PunA1 
• additional aa that are not present in the original PunA1 sequence are highlighted in bold  
• putative cleavage sites are underlined  
MGSSHHHHHHSSGLVPRGSHMLHQIKELLQNAQLQQQVKAAANQAEAIKVLAIASAEKGYNFTVEAIS
QMLAELTSVASDELSEEELLSVSGGAVSESHVHMSCCNDCPTR* 
 
AA sequence of the N-terminally HIS-tagged PunA1_XA 
• 12.077 kDa 
• present in pET28PunA1-XA 
• additional aa that are not present in the original PunA1 sequence are highlighted in bold 
• the XA-factor cleavage site is underlined  
MGSSHHHHHHSSGLVPRGSHMLHQIKELLQNAQLQQQVKAAANQAEAIKVLAIASAEKGYNFTVEAIS
QMLAELTSVASDELSEEELLSIEGRAVSESHVHMSCCNDCPTR* 
 
AA sequence of C-terminally HIS-tagged PunM 
• 124.828 kDa 
• present in pET22bPunMAB  
• additional aa that are not present in the original AnaM sequence are highlighted in bold 
MSQLFVQSSQQIPLSDLATIVTKASFLWERLNTKQFAIAAGLLNEQKIDHRLERWCQVVAQGNWNTLQ
KRLEWEGLDFDTIRPQLGTVEFNAGQPLPKWAETLQKIIQTATEFQPELETFLPTDSENPIPFEDIFL
PIIKVARLELRTRLEEHLPQLLLTETAYRNLERSLLQRLATFCTKTLHFEFSQARPFGQNLLNLLGLE
TESEKTKTHYNKFVNQLLQDGLMAFFCKYPVLGRLVATVVNFWVDFTAEFLQRLAEDKADIQQIFGEF
GSEQPDYLGKVAEIKTSLSDPHKQGRTVILLTFESGLKLVYKPKDLGLEVSFNQFLDWCNQHSHLLDF
KVIQVLNRNNYGWVEYVEHQACIDEAAAERFYQRAGMLLCVLYTLRGTDCHHENLIASGEHLVLIDTE
TLLHHEANLIENSPDMQGSEANAEQQLGNSVLRSGLLPRWDFSSDRRVAYDVSGLGSTDPQQAPQKVP
RWGLVNTDEMHLGYEFITLPIQKNVPYIGEIGLSPNDYQAQIAAGFEQMYRFLMDNKDMLFQPKSPLT
VMGKQQVRFVFRPTRVYSVILQKIWASDYLKDGIDYSIELERLSCAFLVAQEKPNAWHILSAELRAME
QLDIPFFTANAASDELSVSDDLSIPHYFKQPSYHHVLRQLQAMSKTDLARQIAIIQGSFHAKLAQTSS
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EESEQWDVESAPLLSSAQLIEEAGAIANALEKTAILDPDGSINWIGLNYVPEAERFRLQVLGSGLYDG
RSGVALFLAALNKVAGEPRLRDLALRTLQPLRRQIQTFDLESQQRMSRLMGIGGGAGLGSLIYAFVKV
RQFLNDETLLADAQALAEWMTPELIAADKKLDIMSGAAGAILGLLSLYEVTKDATVLEKAIACGQHLL
SRQVSYKGAPKAWQTLGEQPLTGFSHGTAGISYALLRLYTVTQNQDYYEAALAGIEYERSVFCESQGN
WPDFRSAEMNQPPGFPVRWCHGATGIGLGRLGSLGVIDSPEIEQEIEIALQTTQNYSLQDSDHLCCGN
LGRIEVLLVGAQRCSRSDWHQIALQNAANVVAKAKQTGAYQMFTNLPSSVFHPSLFRGTAGIGYELLR
LATDDLPSVLLWELEHHHHHH* 
 
AA sequence of the N-terminally HIS-tagged AnaA 
• 12.491 kDa 
• present in pET28AnaA 
• additional aa that are not present in the original AnaA sequence are highlighted in bold 
• putative cleavage sites are underlined  
MGSSHHHHHHSSGLVPRGSHMKESTIIKNPVLRNKVNAKIYNPAGDIVKEIQEQNLPEQAGGGTPTVV
VGVISAVTAVTNLAFSIDQAITKYYACSLVYTYSAECRSDGRSCRMR* 
 
AA sequence of N-terminally HIS-tagged AnaA_XA 
• 12.633 kDa 
• present in pET28AnaA_XA 
• additional aa that are not present in the original AnaA sequence are highlighted in bold 
• the XA-factor cleavage site is underlined  
MGSSHHHHHHSSGLVPRGSHMKESTIIKNPVLRNKVNAKIYNPAGDIVKEIQEQNLPEIEGRGTPTVV
VGVISAVTAVTNLAFSIDQAITKYYACSLVYTYSAECRSDGRSCRMR* 
 
AA sequence of C-terminally HIS-tagged AnaM  
• 122.567 kDa 
• present in pET22bAnaMAB  
• additional aa that are not present in the original AnaM sequence are highlighted in bold 
MMKQDNNWLIYNLSTDKEFTFDDVINYWLTLFPEIKKKEELEKLLQEISNTNFEKIREYYYSTEKHGE
KFLGKYCNNIELVLELERLLAIIHNEYKWVYFFKPIIRTYFEYIYELTQRSEFIHDKNEFMIQILKLA
IENLYKIAYRVLILELNIARIESKLVGETPEQRANYFSNILLRNDDYIEKLYMEYNELTRLMDLCMRN
FCNYLREIIENTEREEKQLSKKLLDGKHLGKLKSIEFGAGDMHNGGRSVAVLYFDSGVKLIYKPRALD
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LEVKFGEFIEWLNNQCIPNFYSLKTCRTYTIESAGWVEFIEYKECCEIDEIKRFYYRAGEILCILYTL
NARDMHFENIIAEGENPVLIDLETLFHPDLFDINRTETFASTEVLRILNNSVRGIGLLPTQIVNFKSG
KVFEIGGLCAEDEQEAPFHSLFVNNYNTDEIKIEYDYAIIKPKSNNPIMKGKRIKSSEYVNEIINGFV
NTYKWILKNKNEYIKKVREKFQNCKCRVIFKPTSIYAQLLATSYHPDLLRNSIDRKVFLHRIGLVPYE
EEKRIVLSEIEDMLNGDVPYFTTFLNCNSIINSKGEKIEPCYKQTPLDYVIKKIESMNEKDLERQVAL
INMSYLNKVTYDMGYHTNIRFKTCNNIKKFDKQKFLDIAKKIGDLILEKSIMGKRNGKNERSWIGSIG
IDDKFYFITDVGYDLYSGNSGIALFLAFLGAITGSKKYKLAAIEAMVPVISYIENLGKVSNSKINRIG
AFSGVCGYFYALFHIGKCLDIKEFLDIVYGKIGILSKAELITENHDIISGLSGTLGVLLSIYDKTAEE
KIREELLSICTKILYAINEKSNKCKEGITWGEEGYVGYSHGNAGVTSQLIRLFYINHNSNIIDLIRLS
LTYERNMFDKRNNNWRRSLLEDGFSFGWCHGAPGILLSRINLIEKGYHDDYCFEEIKKAIEITKKYAF
GKDYCLCHGDIGNLRILYYTAKVLKDEELKISCLATLNEFLDRYFMGRWCNGEFNKIENYGLMTGLSG
VGYAFLQFCEYVQMPEILCLELEHHHHHH* 
 
AA sequence of N-terminally HIS-tagged MrsM 
• 123. 23 kDa 
• present in pET28MrsM   
• additional aa that are not present in the original MrsM sequence are highlighted in bold 
MGSSHHHHHHSSGLVPRGSHMHTKFKRNSVWNRSSSISERKVRRSLNTNWDELTNRRFERWKSLVESD
EGIRIEDVLATQNIDEETLKHTINAKEVEFINEGDHQGWLEIIQLVDEQSYKNVNIEVRKDILFFSFI
KPFLKIARGKLEEVLYSHSTKSLIKEELSPSVIDDLLNNLGETLSAISSRILILELNVARVSGKLRGE
TSEERASYFNQALLNDPAYVRSIREEYIVLTRLLATKTMYWIQNTSDLLVRFHQDKGILESEFSNGQK
LGKIISIDTGSGVSDTHNKGKTVAILNFETGIKIVYKPRSLEIDVKFNKFVNYLNGKNLSFDLKTVHT
LNKKSYGWTQFISYKECQEELQIGKFYWRIGSYLAILYAMNAVDFHMQNLIADGEYPILVDLESLFHN
NSTYTDTSAFSRAQEHIERSVLRIGLLPRKINSKAGFEGIDLSALGAQEGQVSPHKTSTIVDRDKDTV
RIEEKNFPIPVSQHRPMLHGQIINTVAYEGNIIKGFEETYFLFMKYKQDMLEQIDSFKGVTVRQILRG
TSRYANLLKISLHPDFMRDGLDREMILDKLWLDTKLNPRLNQVVNSEKEGLFLGDIPYFTSKPESTNM
WDSSGRKINNFFKTSALNETKEKINEMNESDCHEQVSFIKTAILVIKDSYRKHKVFDINPRLHVFNPK
DFFQEAIKIGDFLASRAIEGEQLDGQEDVSWIGSFVDNQREDQFKISAANSSLYEGVGGISLFLAYLG
RLSNNEKYTKLSKKALVAVHKNMSASSDLGAFGGIASYLYLLDHLSKLWNDEQLLKNELYSALNKLDS
LIERDENNDILTGVAGTAVILINLFKRYKEEQILNLITKCGNRLIQNINVMEKGVGWKVPANPTPASG
FAHGASGIIWALYEIYAITKQTVFKEVAEKALEFERTLFIPEKNNWADIKLENGQFRNDNFVAWCNGA
AGIGLSRILILPHNQNELIKDEAHVAINTTLKYGFEHDQSLCHGDLGNLDILMYAAENFNKKLSVNVT
ELSHKILNDIKLRGWLTGFEKNNESPSLMMGYAGIGLGLLKIFAPVEVPSVLRLQSPLELKL 
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Figure 5.1: MALDI-TOF spectra of culture supernatant of (A) B. licheniformis MW3 and (B) its LicM2 insertion mutant. Both spectra showed existence of 
similar mass signals, which are not associated to the lichenicidin gene cluster. In conclusion none of these peaks represent active Licα- or Licβ-peptides. Both 
samples showed antimicrobial activity in agar diffusion assays, that was hypothesizes to be due to expression of a predicted novel TOMM-like bacteriocin, 
heterocycloanthracin, which might be supposed to be represented by at least one of observed mass signals shown in A and B. Validation of this notion will be 
focused in future experiments.   
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